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Abstract 
 
 
Changes in DNA methylation patterns are a hallmark of both cancer and ageing, and 
may underlie susceptibility to developing age-related diseases such as cancer. To 
uncover the impact that such variation has on health and ageing, we assessed DNA 
methylation patterns in the peripheral blood leukocytes (PBL) of 480 participants in the 
Newcastle 85+ study to determine the levels, and degree of inter-individual variation, of 
DNA methylation in the promoter region of a panel of genes by Pyrosequencing. 
We found considerable inter-individual variation in promoter CpG methylation in 
several genes and a remarkable similarity to leukaemic patterns of aberrant methylation. 
This included specific methylation of the same sets of genes, strong correlations 
between methylation of the genes (in a pattern reminiscent of the CpG island methylator 
phenotype observed in cancer) and the presence of densely methylated alleles in highly 
methylated individuals, identical to patterns observed in cancer cells. This suggests that 
ageing and cancer related methylation may be closely linked. 
Further analysis of PBL DNA methylation levels in Newcastle 85+ study participants 
with a previous history of cancer (n=113) versus cancer-free individuals (n=113) found 
significantly higher methylation in those with a cancer history (10.71% vs. 10.21%, 
p=0.04). Further, a separate group of 72 individuals diagnosed with cancer within the 3 
year duration of the study had similarly increased methylation levels  (10.96% vs. 
10.36%, p=0.03), suggesting that pre-existing methylation in normal cells may increase 
risk of cancer and may be evident prior to clinically detectable disease. In addition, 
individuals with increased DNA methylation were more likely to be categorised as frail 
(as defined by Fried) than those with lower DNA methylation measures, indicating that 
disrupted methylation patterns are associated with detrimental effects on healthy ageing. 
Subsequently, a GWAS analysis found that SNPs in two genes, DSCAM and 
DSCAML1, appeared to be associated with determining DNA methylation levels in the 
Newcastle 85+ study participants. 
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Chapter 1 – Introduction 
 
 
1. Epigenetics 
 
Epigenetics refers to the heritable DNA modifications and gene expression changes 
which occur independently of any alterations to the underlying DNA sequence (Bird, 
2007). The term heritable in this definition refers to the transmission through mitotic 
division, but not necessarily heritable through the germline. Driven by advances in 
technology, the interest in studying gene regulation by epigenetics mechanisms such as 
DNA methylation, histone modifications and non-coding RNA has grown exponentially 
over recent years.  
 
DNA methylation marks are the mostly widely studied of the epigenetic modifications 
and are characterised by the addition of a methyl group (CH3) to the carbon at position 5 
of cytosine nucleotides, forming 5’methyl cytosine (Figure 1.1). This typically occurs 
when cytosine is followed by guanine in the nucleotide sequence, referred to as CpG 
sites. 
 
The primary role of DNA methylation is to restrict gene expression. Methylation of 
CpG sites surrounding the transcriptional start site of a gene is typically, but not 
exclusively, associated with silenced expression, whereas the promoter region of 
actively transcribed genes is usually free of methylation. However, this is not always the 
case, and it is clear that the interaction between DNA methylation and histone 
modifications are important for determining gene activity levels which will be discussed 
more thoroughly in subsequent sections (illustrated in Figure 1.2). 
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Figure 1.1: Methylation of cytosine forming 5’methylcytosine 
S-adenosylmethionine (SAM) acts as a methyl donor for the methylation reaction at the 
carbon 5 position of cytosine, catalysed by DNA methyltransferase enzymes (DNMTs). 
Figure from (Strathdee and Brown, 2002). 
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Figure 1.2: Interaction between DNA methylation and histone modification for 
transcriptional repression 
(a) Chromatin in its active form is associated with acetylated histone tails and bound by 
RNA polymerase II. (b) Methylation at CpG sites is catalysed by DNA 
methyltransferase (DNMT) and (c) 5’ methylcytosine is targeted by methyl binding 
proteins including MeCP2, MBD2 and MBD3, and large complexes (such as NuRD and 
Sin3a) containing histone deacetylases (HDAC) and other chromatin remodelling 
factors are recruited, leading to altered chromatin structure and deacetylation of histone 
tails. Figure from (Strathdee and Brown, 2002). 
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1.1 DNA methylation 
 
As described earlier, DNA methylation occurs almost exclusively symmetrically at CpG 
dinucleotides in the mammalian somatic genome, as the CpG sequence is a signal for 
the DNA methyltransferase enzymes which catalyse the addition of the methyl group to 
cytosine nucleotides (McKay et al., 2004).  
 
1.1.1 Non CpG methylation 
 
Although the primary site of DNA methylation is at CpG sites, in certain instances 
methylation can occur in a Non-CpG context. This can often be non-symmetrical and 
appears to be largely restricted to embryonic stem cells (ESC) or induced pluripotent 
stem cells (iPSC), and is very rare in differentiated or somatic cells (Lister et al., 2009). 
A comparison of ESCs and somatic cells found that levels of CpG methylation are 
mostly similar between ESCs and somatic cells, however CpA methylation levels were 
around 15% of the total methylated cytosines, CpT around 3% and CpC approximately 
1% in ESCs, which was far more frequent than in somatic cells (Ramsahoye et al., 
2000). The presence of non-CpG methylation appears to be independent of DNMT1, 
since its knockdown in ESCs had no effect on non-CpG methylation levels; however it 
may be that DNMT3A and DNMT3B are able to compensate for a lack of DNMT1. The 
authors were able to induce small amounts of CpG, CpA and CpT in Drosophila (which 
has no endogenous methylation) by expressing DNMT3a, suggesting a role for this 
particular DNA methyltransferase enzyme in directing non-CpG methylation. This was 
corroborated by another study which found partial knockdown of DNMT3a in ESC line 
reduced levels of CpA, CpT and CpC methylation, with little effect on CpG methylation 
(Ziller et al., 2011). Non-CpG methylation does not appear to be a stable modification, 
with a large degree of variation in amount of CpA methylation between different ESC 
lines and the same cell lines at different passage numbers suggesting it is not well 
conserved (Ziller et al., 2011). The function of non-CpG methylation is unclear; 
however the fact that it is lost upon differentiation, but recurs after reprogramming to 
form iPSCs suggests that it may be important for controlling expression of genes 
associated with differentiation, in order to sustain pluripotency.  
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1.1.2 DNA methylation patterns across the genome 
 
The incidence of CpG sites is vastly underrepresented in the genome. Cytosine is the 
most unstable of the four nucleotide bases, susceptible to a deamination reaction 
forming uracil (Duncan and Miller, 1980). The uracil DNA glycosylase (UDG) 
enzymes function to cleave uracil bases from the DNA strand, triggering base excision 
repair (BER) at that site and subsequent replacement with cytosine (Nilsen et al., 2001). 
However, failure of repair mechanisms can lead to the base pairing of adenine with 
uracil, and replacement with thymine (Duncan and Miller, 1980). In addition, 
methylated cytosine is subjected to an increased rate of spontaneous deamination 
compared with cytosine (Shen et al., 1994) and the direct deamination product of 
5’methylcytosine is thymine, which is more difficult to recognise and repair compared 
to uracil this nucleotide is not foreign to DNA. This results in a number of cytosine to 
thymine mutations, replacing CpG sites with TpG sites (Coulondre et al., 1978). The 
consequence of this is that CpG sites are typically infrequent throughout the bulk of 
DNA. 
 
Mutations involving methylated cytosine are estimated to be responsible for as much as 
30% of all mutations occurring in both germline and somatic cells (Shen et al., 1994). 
For example, p53 is frequently mutated in a multitude of cancer types, and the 
frequency of G:CA:T transitions at methylated CpG sites suggests that deamination 
of 5’methylcytosine may be responsible for a large proportion of these. In fact, around 
50% of germline mutations observed in Li-Fraumeni syndrome correspond to mutation 
of CpG sites (Greenblatt et al., 1994).  
 
Regions of the genome exist where the frequency of CpG dinucleotides is close to the 
expected level. These are known as CpG islands, and are often located at the 5’ end of 
annotated genes, in the promoter region or first exon (Saxonov et al., 2006) The 
functional consequences of DNA methylation, both within and outside CpG islands, are 
greatly dependent on the genomic location of the modification, which will be discussed 
more thoroughly in subsequent sections. 
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1.1.3 CpG Island methylation 
 
A CpG island was originally defined as being larger than 200bp in length, having a CG 
content greater than 50% and an observed/expected CG ratio of more than 0.6 
(Gardiner-Garden and Frommer, 1987). In recent years though, more stringent criteria 
for defining CpG islands have generally been utilised. One such definition was 
proposed by Takai and Jones (2002) and stated a CpG island should have a minimum 
length of 500bp, CG content greater than 55% and observed/expected CG ratio of 0.65 
(Takai and Jones, 2002). Numerous other threshold values have been used to predict the 
number of CpG islands in the genome, which leads to variation in the number reported 
(Illingworth and Bird, 2009). Repetitive regions of the genome, such as Alu elements, 
often have a high CG content and observed/expected CG ratio but a more stringent 
threshold for defining CpG islands has led to the exclusion of many repetitive regions 
from CpG island analysis (Takai and Jones, 2002). 
 
Studies have suggested that approximately 70% of human gene promoters have a high 
CpG content (Saxonov et al., 2006), and approximately 50-55% of genes have a defined 
CpG island crossing the transcriptional start site (Wang and Leung, 2004; Illingworth et 
al., 2008). 
 
Promoter associated CpG islands are typically free of methylation regardless of 
expression status (Weber et al., 2007), suggesting that mechanisms exist to prevent 
aberrant methylation of these regions. The unmethylated status of gene promoters may 
partly explain why such a large proportion of CpG islands are maintained in these 
regions, as cytosine which is unmethylated are not subjected to as high a rate of 
deamination and mutagenesis as methylated cytosine, so maintain higher 
observed/expected CG ratios (Saxonov et al., 2006). 
 
Housekeeping genes are constitutively active, have a methylation free promoter region 
and are frequently associated with Sp1 elements, suggesting a possible role for Sp1 in 
maintaining active transcription and unmethylated promoters (Holler et al., 1988). 
Subsequently, it has been shown that Sp1 does appear to protect CpG island associated 
sites from acquiring methylation and may play an important role in establishing correct 
methylation patterns in early development (Brandeis et al., 1994). There are examples 
of genes such as E-cadherin (CDH1) and von Hippel-Lindau (VHL) which contain a 
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normally unmethylated CpG island surrounded by heavily methylated Alu rich repeat 
sequences. At the border separating the methylated/unmethylated region there is 
enrichment for Sp1 binding sites, again implicating a role for Sp1 in controlling against 
spreading methylation, although protection could be overridden by overexpressing 
DNMTs (Graff et al., 1997). 
 
Disruption of gene expression levels can induce methylation changes and affect long 
term expression of target genes. For example, siRNA knockdown of ESR1 led to 
decreased ESR1 binding, and the initial recruitment of histone deacetylases (HDACs) 
and Polycomb repressors. This was later followed by DNA methylation and silencing of 
multiple downstream targets, including the progesterone receptor (PR). Re-expression 
of ESR1could not trigger the re-expression of PR and subsequent demethylation of the 
PR promoter was required. This suggests that maintaining active transcription may be 
required to retain an unmethylated promoter and expression of a gene. Additionally, 
DNA methylation changes induced by altered expression of regulatory gene can lead to 
permanent silencing of target sequences (Leu et al., 2004). 
 
Increased levels of the active chromatin mark, dimethylated lysine 4 of histone H3 
(H3K4me2), have been described at active, unmethylated promoters. Inactive promoters 
with H3K4me2 marks are suggested to remain unmethylated, whilst inactive and 
methylated promoters are not enriched for H3K4me2, suggesting the presence of 
specific histone modifications may also be involved in protecting against the acquisition 
of aberrant methylation (Weber et al., 2007).  
 
Enrichment for genomic CpG islands followed by sequencing found that approximately 
50% of mammalian CpG islands are at so called “orphan promoters” which are not 
associated with annotated genes, but share some features of promoters, such as 
overlapping H3K4Me2/3, a mark of active chromatin. These “orphan promoters” are 
much more likely to be methylated than the CpG islands associated with annotated gene 
promoters (Illingworth et al., 2010). 
 
Only a small number of genes have extensive methylation of their promoter regions, 
predominantly imprinted genes or those subjected to X chromosome inactivation 
(Weber et al., 2007). Genome wide microarray analysis of CpG islands in human blood 
have revealed 4% of approximately 5,500 autosomal genes to be densely methylated. 
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Such methylation was associated with silenced expression in a subset of genes selected 
for further investigation, and re-expression could be induced by DNA demethylation 
treatment or DNMT knockout. This implies that DNA methylation, and not other 
regulatory factors, was responsible for controlling expression at these genes (Shen et al., 
2007). 
 
Methylation of CpG islands in exons, introns or between genes is much more frequent 
than within promoters. A study found that of the 6-8% of CpG islands which were 
methylated in several human tissues including blood, brain, muscle and spleen, the vast 
majority were intergenic or intragenic rather than promoter associated (Illingworth et 
al., 2008). Additional data found that although the majority of these non-promoter CpG 
islands are methylated (~71% in at least one tissue), a proportion of those which are 
unmethylated demonstrate binding of RNA polymerase II and show enrichment for the 
H3K4me3 active chromatin mark, suggesting either that transcription may be 
originating from some of these sites or that they may function as transcriptional 
regulators (Rakyan et al., 2008).  
 
Investigating the features of genes which acquire methylation at CpG islands has 
suggested that the underlying DNA sequence, predicted DNA structure and an 
enrichment for particular sequence patterns (namely CACC/GGTG) could all predict the 
susceptibility of the CpG island to becoming methylated (Bock et al., 2006).  Other 
studies have suggested that overall CpG content could also predispose to gains of 
methylation; genes with an intermediate CpG content, or ‘weak CpG islands’ appear 
more likely to be methylated, than those with traditional CpG islands (Weber et al., 
2007).   
 
1.1.4 Non-CpG Island methylation 
 
The majority (approximately 80-89%) of CpG dinucleotides outside of CpG islands, in 
the bulk of DNA, are methylated (Eckhardt et al., 2006; Gibney and Nolan, 2010; 
Gronniger et al., 2010), but the purpose of such methylation is less clearly understood 
than CpG island methylation. 
 
The presence of DNA methylation in the intragenic region of a gene has been linked to 
transcriptional silencing. This was demonstrated by inserting a transgene of the human 
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p16 promoter which was driving expression of green fluorescent protein (GFP) into 
murine erythroleukaemia cells. The transgene promoter region was unmethylated whilst 
the downstream gene body region was methylated. Reduced GFP expression was 
observed when compared to a completely unmethylated control, and a corresponding 
lack of association with RNA polymerase II, absence of H3K4me2/3, the active 
chromatin marks at the methylated region and the formation of tightly packaged 
chromatin; all of which is incompatible with transcriptional elongation (Lorincz et al., 
2004). Conversely, DNA methylation in the gene body region of loci in human B cells 
has been correlated with active expression, rather than repression (Rauch et al., 2009). 
A specific example is the active form of the X allele in females which demonstrate a 
greater proportion of gene body methylation after X inactivation has occurred (Hellman 
and Chess, 2007). However, there is no evidence that such DNA methylation present in 
gene bodies is directly influencing transcription. 
 
Other studies have linked non-CpG methylation to determining tissue specificity. 
Analysis of CpG shores, located several kilobases (kb) from CpG islands, revealed an 
association between differential methylation of these sites and tissue specific differences 
in gene expression. The hypermethylated CpG shores of silenced genes within specific 
tissues showed upregulated expression with either 5’aza-2’deoxycytidine treatment, or 
after knockout of both DNMT1 and DNMT3B, suggesting methylation of these regions 
is regulating expression, at least in part. Additionally, CpG shores showed greater extent 
of aberrant DNA methylation in cancer tissue, than CpG dinucleotides within an island 
or gene promoter, and therefore may be responsible for some of the dysfunction gene 
expression associated with cancer, but this remains to be verified (Irizarry et al., 2009).  
 
1.1.5 DNA methylation at repetitive regions 
 
A large proportion of the human genome is represented by two main types of repetitive 
DNA sequences, which are usually densely methylated and silenced. Tandem repeats, 
are highly repetitive simple nucleotide repeats including satellite DNA, minisatellites 
and microsatellites; usually associated with centromeric or heterochromatic regions. 
Interspersed repeats are typically transposable elements, able to induce recombination 
events in the genome, comprising of either short interspersed nuclear elements (SINEs) 
or long interspersed nuclear elements (LINEs). Most of these are artefacts and are no 
longer able to induce transpositions even if not silenced by methylation (Weisenberger 
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et al., 2005). However, the requirement for silencing of these elements is notable in 
some rare cases of human cancer where the re-activation of transposable elements 
disrupts important genes, such as the Myc oncogene in breast cancer (Morse et al., 
1988) and the APC tumour suppressor in a colorectal tumour (Miki et al., 1992), both of 
which were disrupted by the insertion of a mobile LINE-1 element. Hypomethylation of 
LINE-1transposable elements is frequently observed in tumours compared to normal 
cells, such as hepatocellular carcinoma, but this was not associated with increased 
expression (Lin et al., 2001). Conversely in chronic myeloid leukaemia (CML), loss of 
LINE-1 methylation was related to activation of transcription, and poor prognosis 
(Roman-Gomez et al., 2005). Despite this, there is no direct evidence for demethylation 
of transposable elements resulting in their activation.  
 
1.1.6 DNA Methyltransferases 
 
Three major functional DNA methyltransferase enzymes have been described; DNMT1, 
DNMT3A and DNMT3B. These enzymes are characterised by the presence of an N-
terminal domain, responsible for protein localisation to the nucleus and interactions 
with other proteins, and the C-terminal active domain responsible for DNA association 
and active catalytic function (Jurkowska et al., 2011). 
 
1.1.6.1 DNMT1: Maintenance methylation 
 
In somatic cells, the faithful inheritance of DNA methylation in successive cell 
divisions depends mainly on the mitosis-linked enzyme DNA methyltransferase 1 
(DNMT1), first identified in 1988 (Bestor et al., 1988). DNMT1 has a high preference 
for the hemimethylated CpG sites which are present on the newly synthesised DNA 
strand after replication, as opposed to completely unmethylated DNA (Goll and Bestor, 
2005). This is likely to be mediated via UHFR1 protein which is comprised of domains 
able to bind both hemimethylated DNA and DNMT1 (Bostick et al., 2007). DNMT1 is 
localised with newly replicated DNA at the replication fork during S phase (Leonhardt 
et al., 1992) and is possibly recruited there via a direct interaction with part of the 
replication machinery, PCNA (Schermelleh et al., 2007). The symmetry of CpG 
dinucleotides in a complementary sequence ensures that the pattern of methylation can 
be retained after DNA replication and the gene expression patterns of the progeny cells 
reflect those of the parental cell (Wigler et al., 1981; Stein et al., 1982). However, the 
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ability of DNMT1 to authentically copy methylation patterns is imperfect under certain 
conditions, such as in CpG dense repetitive regions and the de novo methyltransferases 
(discussed below) are also required for maintaining methylation (Leonhardt et al., 
1992).  
 
Maintaining methylation is essential for development in mice; knockout of Dnmt1 
causes abnormalities in growth, severely reduced levels of DNA methylation and 
embryonic lethality at mid gestation  (Li et al., 1992). Initial experiments of DNMT1 
knockout in a human colorectal cancer cell line (HCT116) resulted in a global reduction 
of methylation level by approximately 20%. However, these cells were able to continue 
to survive and proliferate, and the p16 tumour suppressor gene promoter remained 
densely hypermethylated and silenced (Rhee et al., 2000). Subsequent investigations 
revealed that this method failed to produce incomplete knockouts and instead led to the 
formation of hypomorphs, resulting in only partial loss of function. A truncated protein 
is produced which can still function as a methyltransferase, albeit less efficiently, 
despite no longer being able to associate with the replication fork, explaining the limited 
phenotypic effects observed in the previous study (Egger et al., 2006). When complete 
inactivation of the catalytic domains of DNMT1 was induced in HTC116 cell lines, the 
presence of hemimethylated DNA and a small reduction in global DNA methylation 
was observed. In addition, the majority of cells stopped proliferating. Of those which 
did proliferate, there was a high frequency of chromosomal abnormalities, which 
triggered a DNA damage response and these cells ultimately underwent apoptosis. This 
suggests that DNMT1 is essential for proliferation and survival in human cells (Chen et 
al., 2007). 
 
1.1.6.2 DNMT3A and DNMT3B: De novo methylation 
 
There are two types of methyltransferases which are responsible for the establishment of 
de novo methylation in vivo, DNMT3A and DNMT3B. Whilst these enzymes are 
primarily responsible for de novo DNA methylation, they also demonstrate some 
affinity for hemimethylated sites. Both Dnmt3a and Dnmt3b are expressed at high levels 
in undifferentiated cells and embryos in the mouse, which decreases upon 
differentiation and in adult cells, suggesting these enzymes may function to completely 
re-establish genome wide methylation patterns in the early stages of development 
(Okano et al., 1998). Both proteins are essential; complete inactivation of Dnmt3a and 
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Dnmt3b in mouse embryonic stem cells and embryos resulted in failure to establish de 
novo methylation after the genome wide demethylation which occurs in very early 
development. Knockout of Dnmt3a resulted in apparently healthy offspring, which soon 
exhibited stunted growth and death within 4 weeks of birth. Knockout of Dnmt3b was 
lethal and failed to generate any live offspring, with embryos demonstrating numerous 
defects in development. Double Dnmt3a and Dnmt3b knockouts had a more severe 
phenotype which was lethal extremely early on in development. This suggests some 
overlapping functions of the two methyltransferases in early development, but not at 
later stages (Okano et al., 1999). The genomic targets for DNA methylation by these 
enzymes appear to be slightly different. For example Dnmt3b, but not Dnmt3a, 
knockouts demonstrated clearly reduced methylation of satellite repeat sequences, 
suggesting such sequences are a unique target of Dnmt3b (Okano et al., 1999). 
 
In humans, mutations of DNMT3B affecting the catalytically active part of the enzyme 
are responsible for an extremely rare disease termed Immunodeficiency, Centromeric 
region instability and Facial anomalies syndrome (ICF syndrome). ICF syndrome is 
characterised by chromosome breakage and reduced levels of DNA methylation 
particularly at heterochromatin surrounding the centromeres. Patients with this 
syndrome demonstrate severely impaired immunity due to reduced levels of B-cells, T-
cells and serum immunoglobulins, and typically die in early childhood due to 
susceptibility to infection (Ehrlich, 2003).  Additionally, mutations in DNMT3A are 
frequently observed in acute myeloid leukaemia (AML) patients and linked with poor 
prognosis. A recent study demonstrated disrupted methylation processivity in these 
patients, providing a possible explanation for some of the highly aberrant methylation 
patterns observed in AML (Holz-Schietinger et al., 2012). 
 
1.1.6.3 DNMT3L 
 
DNMT3L protein is highly related to the de novo methylating enzymes although not a 
functional methyltransferase itself. DNMT3L is unable to bind DNA but has been 
shown to increase the activity of mouse Dnmt3a and Dnmt3b by approximately 1.5-3 
fold (Suetake et al., 2004). Crystallography imaging suggests DNMT3L interacts with 
chromatin structure through the binding of unmethylated H3K4. However, this 
interaction could be completely prevented when H3K4 tails were trimethylated, a mark 
of active chromatin, proposing a possible mechanism by which actively expressed genes 
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are protected from de novo methylation (Ooi et al., 2007).  DNMT3L also binds the 
catalytic domain of DNMT3a (Jia et al., 2007) In addition, DNMT3L has been shown to 
improve the processivity of DNMT3A. Experiments show that approximately 5-8 
consecutive CpG sites are methylated by DNMT3A before a significant proportion of 
the enzyme becomes unbound, whereas the presence of DNMT3L increases the number 
of sites progressively methylated, proposing an important role to ensure spreading of 
methylation within a particular region (Holz-Schietinger and Reich, 2010). DNMT3L 
function is also important for establishment of imprinting patterns. Disturbance of 
Dnmt3l expression in mouse embryonic stem cells is lethal to female homozygotes part 
way through gestation and subsequent analysis of embryos revealed a loss of maternal 
methylation and transcriptional control at imprinted loci. Homozygous males fail to 
produce sperm (Bourc'his et al., 2001). 
 
1.1.6.4 DNMT2 
 
Despite similarity to other DNMTs, knockout of Dnmt2 has no effect on DNA 
methylation in mice, and human DNMT2 has been shown not to methylate DNA, rather 
acting to methylate a form of transfer RNA (Goll et al., 2006). 
 
1.1.7 DNA methylation during development 
 
After the zygote is formed at fertilisation, there is a genome wide demethylation of 
DNA, removing parental methylation patterns and allowing the cell totipotency. At 
implantation, the blastocyst is subjected to a round of de novo methylation, dependent 
on DNMT3A and DNMT3B, to establish correct methylation patterns which are 
maintained in the somatic cells. The formation of the germ cells require an additional 
round of methylation loss and de novo methylation in order to establish correct marks of 
imprinting dependant upon parental origin (Jurkowska et al., 2011).  
 
1.1.8 DNA methylation and gene expression 
1.1.8.1 Relationship between DNA methylation levels and transcription 
 
Unmethylated gene promoters are associated with gene transcription whereas the 
presence of dense hypermethylation of the region surrounding the transcription start site 
of genes is strongly concomitant with transcriptional silencing (Eckhardt et al., 2006; 
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Bell et al., 2011). DNA methylation was determined to be responsible for a large 
proportion of gene silencing by experiments with DNMT inhibitors such as 
5’azacytidine, leading to demethylation and re-expression of genes (Christman, 2002). 
Not all unmethylated genes are actively transcribed in every cell (Weber et al., 2007), 
and expression likely depends on the binding of additional transcriptional activators. 
For example, unmethylated gene promoters of active genes are more frequently 
associated with RNA polymerase II binding close to proposed transcriptional start sites 
(Weber et al., 2007). The effect of partial methylation at gene promoters on gene 
trasncription is unclear and is likely to be position dependent. Silencing of the XAF1 
gene has been found in both gastric and colon cancer, with DNA methylation at specific 
CpG sites in the promoter demonstrating differing ability to repress expression (Zou et 
al., 2006). In addition, the differential methylation status of a single CpG site in the IL-6 
promoter region between rheumatoid arthritis (RA) patients and controls was related to 
expression levels of the protein (Nile et al., 2008). However, the methylation 
differences at these sites have not been proven to be causative for the observed 
discrepancies in gene expression. 
 
1.1.8.2 Mechanisms of DNA methylation based gene silencing 
 
 
1.1.8.2.1 Transcription factor binding 
 
One manner in which DNA methylation is thought to repress gene expression is by 
preventing the direct physical interaction between transcription factors and other 
activators of transcription with such promoters. Methylation of CpG sites within the 
target sequences of protein binding sites is thought prevent the recognition by the 
appropriate proteins. Specific examples include methylation at the imprinting centre on 
the paternally inherited allele of IGF2, which prevents binding of the CTCF insulator 
protein. CTCF is therefore unable to block initiation of transcription at the IGF2 
promoter driven by upstream enhancers and the gene is expressed (Bell and Felsenfeld, 
2000). Additionally, a second study found that DNA methylation in the promoter of 
both the mouse and human insulin gene (specifically at the cAMP responsive element) 
repressed transcription and preventing binding of ATF2 and CREB proteins, which are 
thought be involved in promotion of insulin transcription (Kuroda et al., 2009). 
However, only a relatively small number of transcription factors are unable to  bind 
 15 
 
their target sequence due to the presence of methylation (Chen et al., 2011), and thus 
alternative methods for transcriptional silencing must exist. 
 
Transcriptional control at the single gene level may be partly achieved by the ability of 
certain transcription factors to associate with gene promoters and form a direct 
interaction with the de novo DNA methyltransferase enzymes Dnmt3a and Dnmt3b, 
recruiting them for site specific methylation at particular loci. In the following study, 
interaction between Dnmt3a and the c-myc transcription factor could trigger the 
methylation of CpG sites in c-myc boxes located in downstream target genes, such as 
CDKN2A. In total, 42 transcription factors interacting with both Dnmt3a and Dnmt3b 
were described, proposing a possible role for transcription factors in driving 
hypermethylation (Hervouet et al., 2009). Once methylation has been established it is 
likely followed by the by the recruitment of either proteins which bind methylated 
DNA, or proteins which modify chromatin structure, in order to repress individual 
genes (Gibney and Nolan, 2010). The DNA methyltransferases have also been shown to 
associate with a variety of chromatin modifying enzymes, suggesting these enzymes 
may have a silencing function in addition to the catalysis of DNA methylation (Klose 
and Bird, 2006). 
 
1.1.8.2.2 Interaction between DNA methylation and histone modification 
 
DNA contained within cells is packaged around histone proteins to form chromatin. The 
tails of these proteins are subjected to a variety of post-translational modification, which 
govern the resulting chromatin structure. An alternative mechanism for control of gene 
transcription involves the interaction between both DNA methylation and these histones 
modifications via the recruitment of histone remodelling complexes which will be 
discussed later in further detail (Section 1.2.5).  
 
1.1.9 Imprinted genes, tissue & gender specific methylation patterns  
 
1.1.9.1 Imprinted genes 
   
Imprinted genes demonstrate monoallelic expression due to DNA methylation and 
silencing of one copy of the gene, dependent on parental origin (Li et al., 1993). Such 
imprinting is established upon formation of the germline cells and is critical for normal 
 16 
 
development and growth. Several genetic diseases are caused by defects in imprinted 
regions including Prader-willi syndrome, Angelman syndrome and Beckwith-
Wiederman syndrome (Butler, 2009). One example of an imprinted gene is IGF2, which 
regulates foetal growth. The alleles are differentially methylated such that the paternally 
derived allele is expressed, whilst expression is repressed from the maternal allele. This 
regulation appears to play a key role in controlling offspring size, as when a mutated 
copy of Igf2 was paternally inherited in mice, the resulting offspring were dwarfs 
(DeChiara et al., 1991).  
 
1.1.9.2 Tissue specific methylation patterns  
 
All cells types contain the same underlying DNA sequence, but have a multitude of 
diverse functions. It has already been determined by genome wide analysis that different 
tissues can have vastly diverse methylation patterns and it is hypothesised that tissue 
specific methylation (in addition to other epigenetics modifications) may be responsible 
for regulating tissue specific gene expression profiles. However, it is unclear the extent 
to which tissue specific patterns of DNA methylation are required for the establishment 
and maintenance of tissue specific gene expression. 
 
In humans, only a small proportion of tissue specific methylation appears to occur in 
gene promoter regions, with rest located within gene bodies (Eckhardt et al., 2006). 
Analysis of chromosome 1 revealed DNA methylation differences in several tissues 
including heart, liver, lung and separate brain regions which were conserved between 
individuals. Closer investigation demonstrated that the vast majority of the variability in 
DNA methylation was predominantly in regions outside of CpG islands (De Bustos et 
al., 2009). Other studies have shown that certain genes can have differential methylation 
of their CpG islands, including those associated with the 5’ end of the gene, in different 
tissues of the same individual, suggesting methylation may impact upon tissue specific 
expression (Ghosh et al., 2010). Analysis of promoter associated CpG islands which 
were methylated in a tissue specific manner in blood, brain, muscle and spleen found an 
enrichment for genes involved in developmental processes and transcription factors 
such as the HOX gene family (Illingworth et al., 2008). A comprehensive genome wide 
methylated DNA immunoprecipitation (MeDIP) combined with microarray analysis 
suggested that around 18% of all genomic regions could be defined as tissue specific 
differentially methylated regions (tDMRs) in a range of somatic tissues and sperm. Such 
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tDMRs were observed across all genomic regions, including promoters, but were most 
frequent at lower CpG density promoters. Hypomethylated DNA unique to sperm was 
responsible for 27% of all tDMRs. A comparison of tDMRs and gene expression levels 
in individual tissues found promoter tDMRs were negatively correlated with gene 
expression, implying a fundamental role for such methylation in determining tissue 
specific expression profiles. An association between higher methylation levels in gene 
bodies and upregulated expression was also observed although the significance of this is 
unclear. Finally, gene ontology analysis showed that tDMR promoters were over-
represented by genes with a tissue specific function, adding evidence that methylation is 
imperative for defining tissue specific differences (Rakyan et al., 2008). 
 
1.1.9.3 Gender and Methylation 
 
Numerous investigations have suggested that DNA differences in methylation exist 
between males and females in addition to those due to X inactivation. Global DNA 
methylation is usually estimated by measuring methylation levels at repetitive elements 
as a surrogate marker, since they contribute the greatest proportion to total methylation 
levels. The reported differences of global methylation levels between the sexes are often 
conflicting. Several investigations of healthy volunteers have found significantly 
increased methylation of LINE-1, or both LINE-1 and Alu in males (El-Maarri et al., 
2007; Zhang et al., 2011); however, others reported that males have lower methylation 
of Alu than females (Zhu et al., 2012). This inconsistency may arise due to the different 
techniques used for methylation analysis. At the level of single genes, a study of a 
healthy Singapore Chinese population found significantly higher methylation of 
CALCA, MGMT and MTHFR in males even though these genes had relatively little 
methylation in any individual (Sarter et al., 2005). The imprinted genes PEG3, NESP55 
and H19 also demonstrated a slight tendency towards higher methylation in males 
although this was not significant (El-Maarri et al., 2007). A genome wide study of over 
20,000 CpG sites in saliva samples revealed a total of 580 sites which were 
differentially methylated between males and females, of which approximately 53% 
were more highly methylated in females and 47% in males. The study also looked at 
1,298 CpG sites in human blood and only 36 demonstrated gender differences, 21 sites 
were higher in females and the remaining were increased in males. The overlap of genes 
showing sex specific methylation in both tissues was minor (Liu et al., 2010). This data 
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suggests that neither sex is particularly predisposed to increased methylation at a global 
level; however gender variation may be loci and tissue specific. 
 
1.1.10 DNA demethylation 
 
As previously described, the complete removal of DNA methylation marks is essential 
in germline cells, in order to remove and re-establish marks of imprinting. Additionally, 
the loss of methylation is a key feature of both cancer and ageing cells. The passive 
mechanism by which methylation marks are removed from DNA typically follows from 
the reduced activity of DNMT1, leading to failure to recognise the hemi-methylated 
CpG sites produced on newly synthesised DNA strands during progressive rounds of 
replication, causing cytosine nucleotides to remain unmethylated after replication. DNA 
methylation inhibitors such as 5’azacytidine typically induce passive demethylation as 
they become incorporated into the DNA, causing DNMT1 to become irreversibly bound 
and unable to function (Christman, 2002). 
 
The presence of an active mechanism for DNA demethylation was inferred from the 
rapid demethylation which exists in early development, and although many speculated 
about the manner by which active demethylation of DNA was occurring; there was little 
firm evidence until relatively recently. Unlike the passive loss of DNA methylation, 
active demethylation is not reliant upon replication and requires enzymatic activity to 
remove methylated cytosine and replace with cytosine. The identification of an enzyme 
with demethylation activity remained elusive until the discovery of the Ten-Eleven-
Translocation (TET) enzymes in 2009, which actively convert 5’methylcytosine into 
5’hydroxymethylcytosine (5hmC) (Tahiliani et al., 2009). The presence of 5hmC 
appears dependent on the prior existence of 5’methylcytosine as there is a complete 
absence of 5hmC in Dnmt1-/-, Dnmt3a-/-, Dnmt3b-/- triple knockout mouse ESCs (Ficz 
et al., 2011). Furthermore, the TET enzymes are involved in the formation of other 
intermediates; 5’formylcytosine and 5’carboxylcytosine from methylated cytosine. This 
outlines a plausible pathway for the replacement of 5’methylcytosine by cytosine via a 
decarboxylation reaction, which as yet remains to be elucidated (Ito et al., 2011). 
IDH1/2 mutations which lead to the inactivation of TET2 are often observed in myeloid 
malignancies alongside genome wide hypermethylation. A methylation array analysis of 
approximately 14,000 gene promoters revealed that methylation levels at promoters 
were significantly higher in IDH1/2 mutant acute myeloid leukaemia (AML) compared 
 19 
 
to wild type AML patients, generating a hypothesis that higher levels of aberrant 
methylation accumulate in cells with dysfunctional TET, due to an ineffective 
mechanism for demethylation of DNA (Figueroa et al., 2010).  
 
A genome wide study in mouse ESCs found both high expression of TET1 and TET2 
enzymes and high levels of 5hmC widely spread throughout the genome, although this 
was enriched at CpG islands and promoters and associated with increased transcription. 
Decreasing TET levels during differentiation or by TET1 and TET2 knockdown was 
associated with declining 5hmC at promoters of developmental associated promoters 
and accompanied by increasing 5’methylcytosine and loss of gene expression (Ficz et 
al., 2011), suggesting a possible additional role for 5hmC in maintaining pluripotency. 
However, others have found that TET1 may repress transcription, by recruitment of a 
Sin3a histone deacetylase complex. Additionally, only ~10% of TET1 target genes 
change expression following TET1 knockdown and a greater proportion of these genes 
were up regulated, contradictory to previous findings (Williams et al., 2011). 
 
In addition to the demethylation produced by the oxidation of methylcytosine by the 
TET proteins, an alternative mechanism for demethylation is though to involve DNA 
repair. The growth arrest and DNA damage, or Gadd45a, gene was identified from 
expression screening for possible DNA demethylases in Xenopus laevis. In addition, 
active DNA demethylation was shown to be mediated by DNA repair processes via the 
interaction of Gadd45a with XPG, the endonuclease responsible for the 3’ incision of 
damaged DNA during nucleotide excision repair (NER) (Barreto et al., 2007). Since 
Gadd45a demonstrates no catalytic activity by itself, the mechanism behind its role in 
demethylation appears to be via DNA repair pathways. Several models have been 
hypothesised as to how Gadd45a and additional cofactors can mediate demethylation. 
The proposed mechanisms involve either the excision of methylated cytosines and 
repair (NER) or by the deamination of methylated cytosine followed by base excision 
repair (BER) (Niehrs and Schafer, 2012).  
 
1.1.11 Trangenerational inheritance of DNA methylation 
 
There is debate as to whether epigenetic transgenerational inheritance exists in 
mammals, whereby epigenetic memories can be transmitted to subsequent generations 
via the germline cells. It seems unlikely as most DNA methylation and histone 
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modifying marks are eradicated during the meiotic formation of the germ cells (Sasaki 
and Matsui, 2008), however the epigenetic state of some regions, such as the 
Intracisternal A-particle (IAP) at the agouti variable yellow (A
vy
) and axin-fused (Axin
fu
) 
loci in mice, can be partially inherited by offspring due to incomplete erasure of 
methylation marks at these loci (Morgan et al., 1999; Rakyan et al., 2003). There is 
little indication that such transgenerational inheritance exists in humans, and it remains 
difficult to determine as there is high degree of genetic variability in the population and 
it is now apparent that underlying genetic sequence is important for defining 
methylation patterns (Morgan and Whitelaw, 2008). If any transgenerational inheritance 
could be shown to exist in humans, then this could significantly impact upon DNA 
methylation levels at birth and the accumulation of DNA methylation during ageing. 
 
1.2 Histone Modification 
 
1.2.1 Histone Structure 
 
In all mammalian cells, the DNA is compacted and packaged into chromatin, consisting 
of repeating components termed nucleosomes. Nucleosomes consist of a core of key 
histone proteins; an octamer of H2A, H2B, H3 and H4 to which 147bp of DNA is 
bound, with the linker histone H1 separating repeating nucleosomes. Histones are 
positively charged and so form a tight interaction with the negative charge of DNA 
phosphate groups producing dense chromatin (Cedar and Bergman, 2009). The N-
terminal tails of these histone proteins are exposed in the area surrounding the 
nucleosomes and are subjected to a multitude of post translational modifications 
including acetylation, methylation, phosphorylation and ubiquitinylation (Grant, 2001). 
The presence of such modifications alters the structure and function of chromatin, 
subsequently leading to changes in gene expression. The many combinations and 
permutations caused by the different types of modification possible at various amino 
acid residues of different histones have generated a hypothesis that they may form a 
complex “histone code”, whereby a particular pattern of histone modifications is 
translated by recruitment of specific proteins in order to exert a downstream effect 
(Agalioti et al., 2002; Lennartsson and Ekwall, 2009).  
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1.2.2 Histone acetyltransferase  
 
The most frequently studied modification is the acetylation of lysine residues which is 
executed by histone acetyltransferase (HAT), a large family of enzymes with multiple 
catalytic subunits. HATs can form large multi-protein complexes with other subunits, 
enabling specific targeting to unique target sites (Lee and Workman, 2007). Presence of 
histone acetylation is well known for its disruptive effect on the conformation of tightly 
compacted chromatin (Garcia-Ramirez et al., 1995) and is associated with active 
transcription, possibly by making the DNA within nucleosomes more accessible for 
transcriptional machinery binding. Nucleosomes with experimentally hyper-acetylated 
histone tails within nucleosomes, demonstrated an increased rate transcriptional 
elongation compared to nucleosomes with histones in their native state (Protacio et al., 
2000), suggesting the presence of acetylation may ease the recruitment, or passage, of 
proteins necessary for transcription along the DNA strands.  
 
1.2.3 Histone deacetylase 
 
Histone deacetylase (HDAC) form a large family of enzymes, which have the opposite 
function to HATs, acting to remove acetyl marks from lysine residues and encourage 
the reformation of dense chromatin. HDACs have a key role in transcriptional 
suppression and are vital for mammalian development and cellular differentiation. 
Disruption of Hdac1 in mice is lethal at mid gestation and associated with aberrant up 
regulation of genes controlling cell cycle progression (Lagger et al., 2002). Zupkovtiz et 
al (2006), also described a subset of genes which were abnormally regulated in mouse 
ESCs lacking Hdac1 compared to wild type (WT) cells, the majority of which were up 
regulated. There was direct recruitment of HDAC1 to target gene promoters with 
repressed transcription in WT, and increased levels of acetylation at H3 and H4 of these 
same target genes in the absence of Hdac1 (Zupkovitz et al., 2006). This suggests a 
robust link between HDAC binding, decreased acetylation and reduced expression.   
 
1.2.4 Methylation of histones 
 
The affect of methylation at histone residues can depend on the position of the affected 
amino acid. Several are associated with transcriptional activation including 
trimethylation of lysine 4, or dimethylation of lysine 79 on H3 (H3K4Me3 and 
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H3K79Me2), which are both found at high levels at the promoter region of expressed 
genes (Schneider et al., 2004; Schubeler et al., 2004). Others are linked to gene 
silencing due to their association with repressed promoters including trimethylation of 
lysine 9 or 27 on H3 (H3K9Me3 and H3K27Me3) (Barski et al., 2007). The 
methylation of lysine 36 on histone H3 (H3K36Me), is catalysed by the Set2 
methyltransferase, which is linked to RNA polymerase II. Both di- and trimethylation of 
H3K36 are localised to the 3’ end of the open reading frame (ORF) and these marks are 
recognised by part of the RpD3S HDAC complex, leading to deacetylation and 
localised compaction of chromatin structure at the ends of coding regions, in order to 
supress spurious initiation transcription from within the ORF (Carrozza et al., 2005). 
These examples highlight the complex nature of histone modifications such that 
methylation of histone may promote, supress or refine gene expression. 
 
 
1.2.5 Relationship between DNA methylation, histone modification and gene 
expression 
 
As previously described, gene activity is thought to be determined, at least in part, by 
the interaction between both DNA methylation and histone modifications via their 
effect on chromatin structure. The presence of methylated DNA indirectly represses 
gene transcription by the binding of methyl binding domain containing proteins (MBPs) 
including MBD1, MBD2, MBD3 and MeCP2. These proteins specifically recognise and 
bind 5’methylcytosine. MBPs silence gene expression by their interaction with co-
repressor proteins and recruitment of large complexes of HDACs and chromatin 
remodelling factors, to the DNA, facilitating the formation dense heterochromatin 
which is incompatible with transcription (Jones et al., 1998) (Figure 1.2). Such multi-
protein complexes include NuRD (Tyler and Kadonaga, 1999) and Sin3A (Nan et al., 
1998). The recruitment of MBPs is an important mechanism by which methylated genes 
are transcriptionally silenced, as demonstrated by cells lacking MeCP1 which are unable 
to effectively repress methylated genes (Boyes and Bird, 1991). In addition, the DNA 
methylation induced recruitment of chromatin modifiers and subsequent changes to 
chromatin structure may prevent the physical interaction of DNA and transcription 
machinery. 
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1.2.6 Histone modification in embryonic stem cells 
 
In ESCs, key genes associated with development have been defined by the presence of 
bivalent chromatin, marked by both active (methylated H3K4) and repressive 
(methylated H3K27) histone modifications in the same region. Such genes are poised 
for either rapid activation or inactivation. In pluripotent cells these genes are typically 
expressed at low levels (Bernstein et al., 2006). The existence of bivalent chromatin in 
ESCs is associated with targets of Polycomb group (PcG) proteins, which form 
Polycomb repressor complexes (PRCs). PRC2 catalyses the methylation of H3K27, 
which is then accompanied by the recruitment of PRC1 members. This leads to the 
formation of repressive chromatin (Cao et al., 2002). However, this repression is not 
permanent; upon differentiation, bivalent promoters have the potential to be activated or 
silenced, usually retaining only one of the modifications depending on transcriptional 
status (Cui et al., 2009). Demethylation of H3K27 by histone demethylase (HDM) is 
likely to be responsible for activation of lineage specific genes; whereas long term 
silencing is associated with loss of methylated H3K4 and the local recruitment of DNA 
methylation (Surface et al., 2010). 
 
1.3 Non-coding RNA 
 
Non-coding RNA (ncRNA) does not form a functional protein product; however it has 
been demonstrated to play an important role in chromatin remodelling and regulation of 
gene expression. 
 
1.3.1 Role of non-coding RNA (ncRNA) 
 
One function for ncRNA is the X inactivation which occurs in every female mammalian 
cell. One copy of the X chromosome is randomly condensed into extremely dense 
heterochromatin via the X inactivation centre, which includes the non-coding RNA 
Xist. The inactive X is covered by Xist RNA which prevents binding of transcriptional 
machinery and permanent silencing is achieved by recruitment of chromatin modifying 
proteins including PRCs, followed  by DNA methylation (Wutz and Gribnau, 2007). 
ncRNAs have also been implicated in the control of monoallelic expression at imprinted 
loci and silencing transposons (Costa, 2008). Additionally, ncRNA may regulate 
expression of the HOX genes, which are located within four clusters on separate 
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chromosomes. Analysis of the HOX clusters found 231 ncRNAs originating from these 
regions, which seem to play a role in long-range regulation of expression of genes at 
distance sites. For example, HOTAIR, a trans-acting ncRNA within the HOXC locus is 
able to interact with PRC2 and trigger H3K27 methylation at the HOXD locus to 
repress expression (Rinn et al., 2007).  
 
1.3.2 microRNA (miRNA) 
 
Small single stranded molecules, approximately 22bp in length are termed microRNA 
(miRNA). It is estimated that approximately 30% of genes may be regulated by 
miRNAs, which are thought to exert their action via recognition and binding of mRNA 
sequences, but several alternative mechanisms underlying such action have been 
proposed. It is thought that the number of potential targets of any specific miRNA is 
large (Nilsen, 2007). The potential importance of miRNA based regulation is 
emphasised by a number of diseases associated with dysfunctional miRNA including 
the overexpression of miR-21 and a reduction of miR-125a in tumour cells, and altered 
miR-1 and miR-133 in cardiovascular disease (Lu et al., 2008), although direct 
causation is yet to be determined. 
 
1.4 Epigenetics and cancer 
 
The epigenome of a cancer cell is highly abnormal, typically demonstrating reduced 
levels of DNA methylation overall compared to its normal counterpart due to loss of 
methylation in the bulk of the genome. This is accompanied by localised increases of 
DNA methylation, particularly at promoter CpG islands and accompanied by gene 
silencing, particularly at tumour suppressor genes (Ehrlich, 2002). Additionally, histone 
modifications are frequently altered in tumour cells, although this could simply be 
reflecting gene expression changes.  
 
1.4.1 Altered histone modifications and cancer  
 
Aberrations in the pattern of histone modifications have been described in cancer 
compared to normal cells. One particular genome wide study found a loss of H4 lysine 
13 acetylation and trimethylation of H4 lysine 20 (H4K13ac and H4K20me3) in cancer 
cells which was associated with loss of DNA methylation at repetitive stretches of 
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DNA. These losses were observed in early stages of malignancy and accumulated with 
advancing disease in a mouse skin cancer model (Fraga et al., 2005b). Silencing of 
specific genes is associated with increased H3K9 methylation and reduced methylation 
of the active mark H3K4 (Nguyen et al., 2002), in addition to the trimethylation of 
H3K27 mediated by PcG proteins (Kondo et al., 2008). However, these likely represent 
modifications which occur as a consequence of the altered expression state of genes 
after transformation, rather than being directly involved in the initiation of cancer 
associated expression changes. Overexpression of HDACs results in repression of 
tumour suppressors, likely due to the removal of activating acetylation marks, and has 
been frequently associated with poor prognosis in cancer (Kawai et al., 2003; Song et 
al., 2005; Hayashi et al., 2010). In addition, the overexpression of several histone 
methyltransferase (HMT) enzymes responsible for addition of a variety of repressive 
marks have been noted in several types of cancer including leukaemia, breast and 
prostate and are responsible for the addition of a variety of repressive marks. Such 
changes are thought to play a key role in inactivation of key tumour suppressor genes 
(Sharma et al., 2010). 
 
Recent analyses involving whole exome sequencing of human cancer cells has revealed 
the presence of mutations within proteins which form part of histone remodelling 
complexes. These mutations have been associated with subsequent disruptions to 
histone modification patterns and chromatin structure with potential downstream effects 
on gene expression (You and Jones, 2012). A specific example is EZH2, a component 
of the polycomb repressor complex 2 (PRC2) which is responsible for the repressive 
methylation of H3K27. Overexpression of EZH2 is often associated with invasive and 
metastatic disease in breast and prostate cancer, and acquired mutations within EZH2 
have been identified in lymphoid and myeloid leukaemia, where the resulting effect was 
increased function of the gene (Chase and Cross, 2011). This example highlights the 
potential overlapping role between genetic mutation and epigenetic alterations in cancer 
development.   
 
The presence of frequent abnormalities in histone modification patterns in cancer cells 
has led to a great interest in the use of therapies for reversal, with the hope of treating 
the disease. Various inhibitory compounds have been subjected to clinical trials and 
elicited diverse consequences for tumour cells including apoptosis, stimulation of 
differentiation and growth arrest at the G1/S phase (Carew et al., 2008). HDAC 
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inhibitors have been investigated in an attempt to prevent the abnormal loss of 
acetylation observed in cancer. Despite the exact mechanisms of action being unknown, 
the outcomes of clinical trials utilising HDAC inhibitors have demonstrated good 
success (Wagner et al., 2010). HDAC inhibitors are able to effectively induce the re-
expression of some genes silenced in cancer cells (Yang et al., 2000), however, it 
appears that only a proportion of genes are affected by HDAC inhibitors in this manner 
and a number of loci are actually suppressed (Richon and O'Brien, 2002). In addition, 
since these enzymes can also act as deacetylases for other proteins, such as α-tubulin 
and p53, the effects of inhibition may not be mediated through altered histone 
modification (Glozak et al., 2005). Inhibition of HMT enzymes has also been shown to 
effectively re-express genes silenced in AML, including p15 (Lakshmikuttyamma et al., 
2010). 
 
1.4.2 Hypomethylation and cancer 
 
Hypomethylation affects a much larger proportion of the genome than hypermethylation 
but the functional consequence of such DNA methylation loss in cancer is much less 
clear than the role of hypermethylation. Sequences which are susceptible to 
hypomethylation in cancer are those which are normally highly methylated including 
retrotransposons, satellite DNA, imprinted genes and much more rarely, single copy 
genes (Ehrlich, 2002). It has been suggested that the hypomethylation of 
retrotransposable elements in cancer may be associated with their increased expression, 
initiating transposition events and genome instability, although there is limited evidence 
to support such a hypothesis (Daskalos et al., 2009). A possible functional consequence 
of global hypomethylation in cancer is suggested by ICF syndrome (mutations in 
DNMT3B) which is accompanied by loss of DNA methylation at repetitive sequences 
and chromosome instability (Ehrlich, 2003), drawing similarities with the genetic 
instability which is a hallmark of a cancer cell (Rodriguez et al., 2006). Gene specific 
DNA methylation loss has been described much more rarely, however there are some 
examples such as the hypomethylation of growth regulating genes in colorectal 
neoplasms compared to their normal counterparts (Goelz et al., 1985); and although 
reduced methylation levels of the oncogenes c-Myc and c-Jun was associated with up 
regulated expression in mouse liver tumours, the effect of c-Myc hypomethylation in 
human colorectal cancer and hepatocellular malignancies is undetermined (Ehrlich, 
2002). 
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1.4.3 Hypermethylation and cancer 
 
Hypermethylation of DNA typically occurs at CpG islands. This has been much more 
widely studied in cancer and has clearly important functional consequences, as 
hypermethylation of promoter associated CpG islands leads to transcriptional 
inactivation of the linked gene. Many genes have been shown to be inactivated by this 
mechanism in cancer, including well established tumour suppressors and genes which 
regulate the DNA damage response and cell cycle control (Baylin, 2005). The 
epigenetic marking of these genes provides an alternative mechanism of silencing in 
addition to classical genetic mutations which are well described in cancer (Jones and 
Baylin, 2002). Indeed studies suggest that gene silencing by hypermethylation may be a 
more frequent event than inactivation of genes by DNA sequence mutation (Schuebel et 
al., 2007). Germline mutations in several tumours suppressors including MLH1 and 
BRCA1 greatly increase the risk of developing a familial colorectal or breast cancer 
respectively (Bronner et al., 1994; Lancaster et al., 1997), and these genes are also 
frequent targets for inactivation by hypermethylation in sporadic tumours (Herman et 
al., 1998; Esteller et al., 2000a).  
 
In addition to these single gene methylation events, the methylation of multiple genes in 
a tumour cell is a recognised phenomenon referred to as the CpG island methylator 
phenotype (CIMP), initially identified in colon cancer (Toyota et al., 1999).  This 
phenotype refers to the simultaneous methylation of multiple loci in a subset of 
tumours. Such tumours are liable to hypermethylate several important tumour 
suppressor genes concurrently and contain numerous transcriptionally inactivated genes. 
Whether there is a specific defect causing the concordant aberrant methylation of 
specific loci in these tumours is undetermined. 
 
The suggestion that certain genes may be more susceptible to acquiring methylation has 
gained support from several recent papers describing a link between PcG target genes 
and DNA methylation. PcG proteins form a complex which acts as a transcriptional 
repressor by inducing suppressive histone modifications in undifferentiated cells 
(Klauke and de Haan, 2011). Results from genome wide methylation arrays have shown 
that genes which acquire cancer associated hypermethylation are more likely to be 
targets of PcG complex binding in stem cells (Ohm et al., 2007). This finding suggests 
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that PcG complexes may have a specific role in the induction of aberrant methylation 
during cancer development, and may also alter the susceptibility to DNA methylation of 
a subset of genes to methylation in different cell types, as regulation of genes by the 
PRC2 can be cell type specific (Margueron and Reinberg, 2011).  
 
1.5 Epigenetics and ageing 
 
We are living in an ageing population. The world health organisation (WHO) estimates 
that between the year 2000 and 2050, the number of over 60s in the world will vastly 
increase from 600 million to 2 billion individuals. With the passage of time, molecular 
changes are accrued which are often detrimental to the normal activity of cells and 
organs, meaning the elderly often experience frailty, a term for the collection of several 
functional impairments (Fulop et al., 2010). There is often a high degree of variability 
with regards to the degree of frailty experienced on an individual level (Collerton et al., 
2009). The role of altered epigenetics in ageing and in age-related disease is unclear, but 
could play a significant part in determining health status, or frailty, particularly in later 
life. 
 
1.5.1 Histone modifications and ageing 
 
The potential role of histone modifications in regulating lifespan was proposed by 
observations of decreased lifespan in S. cerevisiae when the HDAC, sir2 was deleted. 
Conversely, up regulation of sir2 dramatically extends the lifespan and replicative 
potential of the yeast. The activation of sir2 orthologs in other species such as C. 
elegans and D. melanogaster produces an equivalent lifespan effect, however the exact 
mechanisms responsible for this effect are unclear (Longo and Kennedy, 2006). In 
mammals, recent data has shown that the lifespan of male mice can be significantly 
extended by overexpression of Sirt6. Altered Sirt6 expression triggered differential 
expression of many downstream genes and reduced the activating phosphorylation 
levels of members of the IGF1 signalling pathway (Kanfi et al., 2012).  Disruption of 
this pathway has previously been demonstrated to have a role in determining longevity 
(Holzenberger et al., 2003). In various model organisms, multiple other enzymes 
including HMT and histone demethylases have been shown to affect levels of 
methylation at specific lysine residues, leading to aberrant gene expression and altered 
lifespan (Berdasco and Esteller, 2012). In mammals, more specific ageing associated 
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histone modifications have been uncovered, such as a genome wide increase in H4 
lysine 20 trimethylation (H4K20me3) in old mouse tissues compared to young (Sarg et 
al., 2002) and such changes have been implicated with functional decline. For example, 
aged mice have been shown to have decreased H4 lysine 12 acetylation levels in the 
hippocampus and an associated failure to express downstream gene targets associated 
with learning and memory (Peleg et al., 2010). 
 
The role for altered histone modifications in age-related diseases has been proposed. For 
example, altered histone acetylation patterns and an increase in phosphorylated H3 have 
been detected in Alzheimer’s disease (Mastroeni et al., 2011). However, these 
observations have not been shown to be causative in the disease process. Treatment of 
age-related diseases with epigenetic therapies has attracted attention. In cardiovascular 
disease (CVD), the use of HDAC inhibitors stimulates changes within cells of the 
arterial wall, such as reduced VEGF signalling and decreased macrophage adherence to 
the endothelium, leading to inhibition of atherosclerosis, but whether the mechanism of 
action occurs via alterations to histone proteins is unclear (Ordovas and Smith, 2010).  
 
1.5.2 DNA methylation and ageing 
 
The altered pattern of DNA methylation occurring throughout ageing has mostly been 
investigated by comparisons of young and old individuals, but despite this, the 
consequences of such methylation changes are not well understood. 
 
1.5.2.1 Global DNA methylation and ageing 
 
Global 5’methylcytosine content appears to be reduced in several organisms, including 
mouse, rat and humans, as a consequence of the ageing process suggesting genome 
wide hypomethylation is occurring (Vanyushin et al., 1973; Wilson et al., 1987; Fuke et 
al., 2004). However, a measure of methylated cytosine content creates no assessment of 
the genomic location of methylation loss; therefore it is not possible to determine the 
consequences of the age related reduction in global methylation from these studies. 
Also, some studies have failed to find any effect of age on global DNA methylation 
levels. For example, an analysis of entire chromosomes involving various tissue types 
and ages suggested that there was no effect of age on global CpG methylation content 
(Eckhardt et al., 2006). However, this study used pooled data from age and sex matched 
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samples meaning the effect of age on DNA methylation levels may be lost due to 
variation, with some individuals displaying more hypomethylation, whilst others may 
be more susceptible to gene specific hypermethylation 
 
1.5.2.2 DNA methylation at repetitive regions and ageing 
 
In addition, it has been reported that the epigenetic control of retrotransposons may be 
disrupted with age. Methylation of an IAP located in the mouse m.nocturnin gene was 
progressively lost throughout ageing, which was associated with its activation (Barbot 
et al., 2002).  
 
1.5.2.3 Genome wide DNA methylation and ageing 
 
A comparison of DNA methylation patterns at the extreme ends of human lifespan by 
whole genome bisulfite sequencing, and methylation array containing 450,000 CpG 
sites, revealed that centenarian DNA was hypomethylated overall compared to newborn 
DNA samples. This decreased methylation was seen in gene bodies and intergenic 
regions, as well as at promoters, although these were mostly associated with tissue 
specific genes and did not contain a CpG island. (Heyn et al., 2012). 
 
In order to examine the frequency of age-related methylation changes in CpG islands, 
Tra et al. (2002) utilised a restriction landmark genome scanning (RLGS) approach to 
inspect around 2000 loci in T lymphocytes from newborns, adult (average 27 years of 
age) and elderly donors (65+ years of age). Their analysis suggested only 1% of loci 
were differentially methylated with age, and proposed that methylation is not significant 
affected by ageing, at least in T lymphocytes (Tra et al., 2002). However, other analyses 
have disagreed with these findings. A methylated CpG island amplification and 
microarray (MCAM) analysis representing almost 9,000 genes in normal human colon 
samples from young (35 years) and older (68 years) individuals found increased 
methylation at 10% of loci, whereas 1% of loci has lower methylation in the older 
individuals. A similar analysis in young (3 month) and old (35 month) mice revealed 
and even higher frequency of changes, 21% of genes has higher methylation and 13% 
showed lower methylation in old compared to young mice (Maegawa et al., 2010). This 
suggests that age-related methylation changes may affect a significant proportion of the 
genome in mammals. Such discrepancies indicate that the analysis of specific tissues 
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and the use of different techniques for detecting DNA methylation may impact upon the 
reported findings. 
 
1.5.2.4 Tissue specific DNA methylation and ageing 
 
In order to determine the tissue specificity of age-related methylation changes, 
Christensen et al performed an analysis of CpG sites in almost 800 genes, using normal 
samples from ten anatomical sites including bladder, blood, brain, cervix, head & neck, 
kidney, lung, pleura and small intestine. A comparison of methylation differences both 
between individuals, and across tissues within the same individual found that CpG sites 
within islands had methylation increases, whereas the trend was for decreased DNA 
methylation in non CpG island sites in all tissues; confirming the genome wide 
hypomethylation and gene specific hypermethylation associated with the ageing 
epigenome. Interestingly, this study observed that methylation levels of DNMT3B 
decreased as a function of age, proposing a mechanism by which the deregulation of 
proteins involved in the DNA methylation reaction could impact upon DNA 
methylation levels (Christensen et al., 2009).  
 
1.5.2.5 Gene specific DNA methylation and ageing 
 
On the basis of the observed relationship between DNA methylation and age, a recent 
study published that the methylation levels of three CpG sites located within three gene 
promoters, EDERADD, NPTX2 and TOM1L1 in saliva samples, was sufficient to 
accurately determine a person age to within approximately 5 years. Suggesting that, at 
least at these loci, DNA methylation changes are occurring at a highly similar linear rate 
with ageing at a population level (Bocklandt et al., 2011).  
 
The consequences of age-associated methylation changes which are not cancer 
associated have been investigated by a recent epigenome wide association study 
(EWAS) of monozygotic twins (MZ) which identified a number of DMRs displaying 
hypermethylation in association with chronological age, and also DMRs which were 
linked to several age-related phenotypes such as cholesterol levels, lung function, 
maternal longevity and blood pressure. However, only one DMR was overlapping 
between these groups, suggesting that methylation changes accumulated during ageing 
are not contributing to age associated phenotypes (Bell et al., 2012). Further 
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understanding of DNA methylation changes with age are clearly required to elucidate 
the functional consequences. 
 
1.6 Environmental mediators of age-associated DNA methylation changes 
 
Although 5’methylcytosine is a stable modification, it is not fixed and several factors 
are known to be significant for determining or altering DNA methylation patterns. 
Therefore, distinct exposures may be important regulators of age associated methylation 
changes. 
 
1.6.1 Nutrition and DNA methylation 
 
The critical methyl donor for the DNA methylation reaction is S-adenosyl methionine 
(SAM), which is derived from methionine and ATP. After the methyl (CH3) group from 
SAM has been transferred to DNA, its unmethylated form, S-adenosyl homocysteine 
(SAH), is converted to homocysteine. Homocysteine can be converted back to 
methionine in a reaction which is dependent on 5’methyltetrahydrofolate as a cofactor 
alongside the methionine synthase (MS) enzyme and vitamin B12. The formation of 
active 5’methyltetrahydrofolate is dependent on a series of folate reduction reactions, 
also involving 5,10-methylene tetrahydrofolate reductase (MTHFR) (Scott, 1999). The 
efficiency of this pathway determines how effectively SAM can be produced. This 
means that levels of components of this cycle including folate and vitamin B12, as well 
as single nucleotide polymorphisms (SNPs) affecting the function of enzymes required 
for these reactions, can directly impact upon SAM formation and consequently, DNA 
methylation levels (Feil, 2006; Hazra et al., 2010). 
 
 
1.6.2 In utero exposures 
 
It is likely that the genome is more vulnerable to altered methylation in utero. In order 
to establish cell lineages in the developing embryo, there is radical reprogramming of 
DNA methylation, facilitated by highly active DNMTs. Anything which influences the 
regulation of this dynamic process could result in DNA methylation arising at spurious 
locations, or else accumulating to abnormally high levels during the prenatal period.  
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1.6.2.1 Altered maternal nutrition during pregnancy 
 
There are several examples of altered nutrition during pregnancy influencing DNA 
methylation levels, gene expression and phenotype of the offspring, particularly in 
animal models where diet can be easily controlled and manipulated.  
 
1.6.2.1.1 The agouti mouse model 
 
The effect of altering intake of methyl donors within the diet has been elegantly 
demonstrated by mouse models featuring the viable yellow agouti locus (A
vy
). These 
mice are inbred; however coat colour is determined by DNA methylation of an intra-
cisternal A particle (IAP) transposon. Agouti (brown) coloured mice have complete 
methylation of IAP and are healthy and lean, whereas viable yellow mice have 
completely unmethylated IAP transposons, aberrant agouti expression driven by a long 
terminal repeat region within the IAP, and are prone to obesity and hyperinsulinemia. 
Epigenetic mosaicism leads to a range of variable coat colours between these two 
extremes. Increasing methyl donor supply in the diet of pregnant dams by 
supplementation with folate, vitamin B12, choline and betaine increased DNA 
methylation at the agouti locus of their offspring leading to expression changes and 
altered coat colour towards agouti (Wolff et al., 1998).  
 
1.6.2.1.2 Methyl donors 
 
Restricting folate, vitamin B12 and methionine supply in sheep peri-conceptually led to 
offspring which were fatter and heavier, had higher blood pressure and showed 
evidence of insulin resistance compared with offspring from mothers fed a control diet 
with adequate methyl donor supply and resulted in hypomethylation at several CpG 
sites across the genome (Sinclair et al., 2007).  
 
1.6.2.1.3 Under nutrition 
 
In humans, maternal under nutrition can be experienced during times of famine, such as 
the Dutch hunger winter in 1944. At its worst, the average calorie intake of pregnant 
women fell to around 400-800 calories per day. Children in utero during this time were 
born smaller, with altered methylation patterns which persisted into adulthood 
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(Heijmans et al., 2008). Additionally, they appear to have an increased incidence of 
symptoms of poor health in later life such as impaired glucose tolerance, coronary heart 
disease and obesity (Roseboom et al., 2006). It has been hypothesised that these 
modifications may enhance survival of the foetus but could cause undesirable gene 
expression in the adult leading to disease, so called the “developmental origin of adult 
disease” hypothesis (Barker, 2004), but the mechanisms underlying these observation 
are unclear.   
 
1.6.2.2 Environmental exposures (cigarette smoking) 
 
Maternal smoking during pregnancy has been linked to adverse health effects including 
low birth weight and impaired lung function (Hofhuis et al., 2003), and interestingly 
children prenatally exposed to smoking display global hypomethylation and increased 
methylation of specific gene promoters, similar to the aberrant methylation pattern of 
many diseases (Breton et al., 2009). Again however, whether altered DNA methylation 
contributes towards these adverse health markers, or ensues as a consequence, is 
undetermined. 
 
1.6.3 Postnatal Exposures 
 
1.6.3.1 Postnatal nutrition and diet 
 
The most widely studied postnatal dietary components known to influence methylation 
are those which modify the availability of methyl donors including folate, vitamin B12, 
betaine and choline. Food sources of these compounds include green vegetables, eggs 
and meat. Patients with hyperhomocysteinaemia demonstrate hypomethylation of DNA, 
due to the accumulation of high levels of homosysteine which inhibits the action of 
DNMTs. DNA methylation levels in these individuals could be corrected by 
supplementation with folate, presumably by increasing levels of the reduced folate 
derivatives which are essential for SAM generation and the subsequent methylation 
reaction (Ingrosso et al., 2003). A study in rats demonstrated that feeding a high fat diet 
was associated with increased DNA methylation of the leptin promoter and reduced 
circulating leptin levels. Leptin is vital for appetite regulation (mice with loss of 
functional leptin are obese), suggesting that diet can lead to altered DNA methylation 
and regulation of functionally relevant genes (Milagro et al., 2009). 
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1.6.3.2 Postnatal environmental exposures 
 
1.6.3.2.1 Exposure to pollutants/alcohol 
 
Recent exposure to environmental pollutants, particularly those particulates caused by 
traffic, has been linked to reduced global methylation measurements (Baccarelli et al., 
2009). The effect of numerous environmental exposures in a genome wide analysis of 
DNA methylation found several associations of interest. Higher methylation levels of 
CpG sites in the lung were observed in individuals in contact with asbestos compared to 
unexposed individuals. Additionally, differential methylation was observed in the 
peripheral blood of people who drank alcohol as opposed to those who abstain 
(Christensen et al., 2009).  
 
1.6.3.2.2 Exposure to cigarette smoke 
 
Smoking has been frequently linked to aberrant methylation, including over 100 CpG 
sites (almost 10% of those analysed) in the lung. Also, in peripheral blood, increasing 
packyears was significantly related to methylation levels of two genes including MLH1 
which is known to be frequently hypermethylated in cancer cells (Christensen et al., 
2009) . The functional significance of these changes is yet to be established, but an 
additional study has shown that a number of tumour suppressor genes are targets for 
aberrant methylation in the lungs of current and former smokers. These same targets are 
similarly hypermethylated in lung tumour cells (Belinsky et al., 2002). However, it is 
possible that smoking leads to early pre-neoplastic transformation of cells, inducing 
many molecular changes including altered DNA methylation as a consequence, even in 
cells with apparently normal morphology. 
 
1.7 Parallels between methylation in ageing and cancer 
 
It is now becoming apparent that similar epigenetic changes can be observed with 
advancing age to those seen in cancer in many tissues; however the consequences of this 
are not fully understood (Richardson, 2003).  
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1.7.1 Hypomethylation 
 
Similar to the observation in cancer cells, methylation is characteristically lost at 
repetitive regions of the genome, such as Alu elements, which exhibit a linear decline in 
methylation levels with advancing age (Bollati et al., 2009). 
 
1.7.2 Hypermethylation 
 
The presence of age related gene specific hypermethylation was first appreciated by 
researchers focusing on DNA methylation of the ESR1 gene and its subsequent loss of 
expression in breast cancer cells and other types of cancer. They discovered a very high 
level of methylation in colorectal cancer samples, and surprisingly also in normal 
colorectal tissue samples with no associated tumours (Ottaviano et al., 1994). Further 
analysis of ESR1 showed that although normal colorectal mucosa from young 
individuals was almost completely unmethylated, the amount of methylation in a subset 
of cells increased progressively with advancing age. This could be correlated with a 
decrease of ESR1 expression, implying that this age associated DNA methylation had a 
functional impact (Issa et al., 1994). 
 
Examination of colorectal tissue has since identified several genes which follow the 
same pattern as ESR1, being hypermethylated in cancer and progressively methylated 
with age including TUSC3 and MYOD; In contrast, no such effect was seen in other 
genes, implying that the acquisition of methylation is partially loci dependent (Ahuja et 
al., 1998). Interestingly, this study also found that some individuals may be more 
susceptible to acquiring methylation at multiple loci than others; a young individual 
with very high methylation and several older individuals with very low methylation 
showed this consistent pattern across several genes tested (Ahuja et al., 1998). It is 
possible that these individuals’ differences may be phenotypically relevant. 
 
Genome wide DNA methylation studies have been utilised to replicate the initial 
findings, and previously reported genes, including ESR1, MGMT, and RARB2, also 
show age related methylation increases and hypermethylation in cancer and can be 
identified by these types of analysis, validating the observations of single gene studies 
(Christensen et al., 2009). 
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The overlap between the types of genes susceptible to increased DNA methylation 
during ageing and the loci which are hypermethylated in cancer has been a key outcome 
from many genome wide analyses. Developmental genes which are silent in stem cells, 
characterised by the presence of bivalent chromatin domains in their promoter region 
and targeted for PcG protein binding, are highly enriched targets for preferential 
methylation in both ageing and cancer, proposing that the mechanisms by which 
methylation is occurring in ageing and cancer are similar, if not the same (Rakyan et al., 
2010; Teschendorff et al., 2010).   
 
The premise that DNA methylation changes during ageing may precede those observed 
in neoplastic cells has been explored. Analysis of specific genes such as ESR1, found 
that the same promoter associated CpG sites which were hypermethylated in colorectal 
tumours and polyps were also hypermethylated in a subset of cells in the normal colon 
and that this became more marked with increasing age, suggesting that ageing 
associated methylation changes may precede cancer onset (Issa et al., 1994). Recent 
genome wide investigation of 27,000 CpG sites in normal cervical cells found 
substantial DNA methylation variability in women who developed cervical cancer after 
three years compared to those remaining disease free. Furthermore, these highly 
variable sites were overlapping with those displaying aberrant methylation during 
ageing, including Polycomb group targets. A total of 140 ‘risk’ CpG sites were used to 
accurately predict neoplastic transformation in an independent sample set (Teschendorff 
et al., 2012). These findings propose that DNA methylation changes are occurring prior 
to the appearance clinically detectable disease and could be useful for identifying at risk 
individuals. 
 
Whilst the age related increased DNA methylation of specific genes in normal samples 
and hypermethylation of tumour suppressors in cancer tissues have frequently been 
observed in human samples, it remained unclear whether this is specific to long lived 
humans or is evident in other species. Methylated CpG island amplification and 
microarray analysis of old (35 month) compared to young (3 month) mouse intestine 
revealed numerous methylation increases (774 genes) and decreases (466 genes). There 
was partial conservation in age related methylation patterns in human and mouse 
microarrays. Several candidate genes which were reported to be hypermethylated in 
normal ageing colon or in colon cancer were also hypermethylated in the older mouse 
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samples, suggesting that age related methylation is not restricted to humans, but also 
affects mice despite their relatively short lifespan (Maegawa et al., 2010). 
 
1.8 Inter-individual variation in DNA methylation 
 
Currently, little is known about how the accumulation, or progressive loss, of DNA 
methylation may vary on an individual level during ageing and whether this may 
contribute to susceptibility to diseases such as cancer, for which advancing age is a 
significant risk factor. 
 
1.8.1 DNA methylation in twins 
 
Comparisons of monozygotic (MZ) twins, who have the same DNA nucleotide 
sequence, as opposed to dizygotic (DZ) twins sharing approximately half the same 
genetic sequence, are useful for studying the effects of heritability and environment. 
Phenotypic or methylation differences in an MZ twin pair are likely to be due to the 
effects of the environment or a random process, rather than have a genetic basis. 
Microarray data suggests that DZ twins have significantly higher methylation 
differences than MZ twins, providing some evidence for a type of genetic control of 
DNA methylation at specific regions of the genome (Kaminsky et al., 2009). Others 
have also confirmed this tendency for hereditability, observing a trend of more similar 
DNA methylation in MZ compared to DZ twin pairs (Schneider et al., 2010).  
 
The theory that aberrant DNA methylation is accumulated during a lifetime is illustrated 
by MZ twins pairs who display either no or exceedingly little differences at very early 
ages, whereas older twins often have much more divergent and variable DNA 
methylation profiles. This disparity presents as both global 5’methylcytosine content, 
and methylation of specific genes which could be linked with more gene expression 
differences in older compared to younger twin pairs. Twin pairs with the most divergent 
methylation profiles were often older, had spent less time in a shared environment and 
had more dissimilar health status (Fraga et al., 2005a). This implies that DNA 
methylation mechanisms may become less controlled over time, or that differential 
exposures may influence the accumulation of DNA methylation over time. 
Identification of several loci differentially methylated in an age related manner has since 
been confirmed in both twins and singletons (Boks et al., 2009). Combined longitudinal 
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(10 year follow up) and cross-sectional (age range 18-89 years) analysis was used to 
examine age-related methylation alterations at several disease associated promoters 
including GNASAS, IGF2, INS and LEP for MZ twin pairs. Similarly to findings 
described above, it was also found that variable DNA methylation patterns were more 
pronounced in older twins and that twin pairs become more divergent with advancing 
age. During the longitudinal study of older twins, a similar pattern of methylation 
changes were observed after 10 years to those seen when comparing young to elderly 
twins (Talens et al., 2012). These studies suggest that the degree of DNA methylation 
variability at an individual level progressively increases throughout life in twins.  
 
1.8.2 DNA methylation changes over time 
 
A further investigation comparing global levels of DNA methylation in PBL DNA of 
healthy volunteers taken approximately 11 years apart found almost 30% of individuals 
had a greater than 10% loss or gain of methylation (Bjornsson et al., 2008). 
Additionally, analysis of up to three generations of the same family revealed not only 
intra-individual variation after 16 years between sample collections, but also that those 
samples from within families were clustered together. This again implies that there may 
be a genetic component to maintaining methylation states, especially since the majority 
of family members tested were not living within a shared environment for the years 
between sampling (Bjornsson et al., 2008). 
 
However, analysis of COMT, a gene implicated in psychiatric disorders, found 
differential methylation in MZ twin pairs at age 5. As the twins were likely to have had 
largely shared environmental exposures at this young age, this suggests that 
environment, shared genetics or the passage of time was not a factor in producing the 
variable DNA methylation of these genes (Mill et al., 2006). Bisulfite sequencing of 
1,760 CpG sites in the human major histocompatibility complex uncovered highly 
variable DNA methylation in both MZ and DZ twins, implying little heritability in this 
region (Gervin et al., 2011). Methylation of an imprinted locus, IGF2/H19, measured in 
blood samples from adolescents compared to middle aged MZ and DZ twins found 
DNA methylation of IGF2 ranged from 43-62%, with much variation across the 
individual that did not appear to be related to age (Heijmans et al., 2007). A 
longitudinal analysis of genes implicated in cardiovascular and metabolic disease found 
that although methylation levels were highly variable between individuals, they were 
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relatively stable after 11-20 years of follow up in blood samples and after 2-8 years in 
buccal swabs from individuals ranging from 14-62 years (Talens et al., 2010). These 
examples highlight that individual variation is not only a feature advancing age, but can 
be present throughout life and the role of genetics in determining methylation status is 
unresolved. 
 
1.9 Mechanisms for individual variation of DNA methylation 
 
Whitelaw and Whitelaw (2006) outlined several hypotheses proposing why individual 
variation of DNA methylation may be observed, particularly at advanced ages 
(Whitelaw and Whitelaw, 2006). 
 
1.9.1 Altered activity of DNA methyltransferases 
 
Analysis of human fetal lung fibroblast cells found DNMT1 gene expression, protein 
levels and enzymatic activity was reduced in aged cells, whereas DNMT3A and 
DNMT3B levels and activity was increased. This implies a direct role for DNMT’s 
causing the aberrant methylation which is frequently observed in many tissues and 
species at increasing ages. Global DNA hypomethylation may be due to reduced 
maintenance of methylation, and gene specific hypermethylation possibly occurs due to 
increased activity of the de novo methylating enzymes. Activities of all DNMT’s are 
also increased after neoplastic transformation which demonstrates a very similar pattern 
of aberrant methylation to that of age related DNA methylation patterns (Casillas et al., 
2003). In human liver samples, the expression levels of DNMT3A and DNMT3B were 
significantly higher in older compared to younger individuals and levels varied among 
individuals, implying that such differences could underlie inter-individual differences in 
DNA methylation (Xiao et al., 2008). However, others have failed to find any 
association between DNMT1 levels and age (Hammons et al., 1999). 
 
The biological effect of increased expression of the de novo methylating enzymes is 
illustrated by the overexpression of Dnmt3a and Dnmt3b in Apc
min/+
 mice which are 
susceptible to colon tumours. Increased Dnmt3b was associated with an increased 
number of tumours, as well as higher levels of DNA methylation and silencing of 
several tumour suppressor genes. The gene targets displaying increased methylation 
induced by Dnmt3b overexpression were the same in normal, as well as the cancerous 
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tissue (Linhart et al., 2007). This suggests that certain loci may be more susceptible to 
acquiring DNA methylation than others when DNMTs are abnormally expressed. 
 
1.9.2 Genetic effects (SNPs) 
 
Underlying genetic sequence has been proposed to affect methylation levels, 
demonstrated by MZ twin pairs demonstrating more epigenetic similarity than DZ twins 
(Kaminsky et al., 2009; Schneider et al., 2010). To examine this link further, genome 
wide DNA methylation analysis of over 22,000 CpG sites in lymphoblastoid cell lines 
from 77 individuals was integrated with data from over 3 million SNPs. Methylation 
levels at 180 CpG sites were associated with a cis-acting SNP within 5kb and at a 
significant proportion of these genes; methylation was negatively associated with 
expression (Bell et al., 2011). A recent EWAS of twins calculated the average genome 
wide heritability of DNA methylation to be around 18%, still leaving a significant 
proportion of methylation changes which cannot be explained by underlying genetic 
sequence (Bell et al., 2012). 
 
1.9.3 Stochastic events linked to replication 
 
Variation could also occur due to a lack of fidelity of the enzyme responsible for 
maintaining methylation patterns. An in vitro study in mice suggests that although 
Dnmt1 has an initial 30-40 fold preference for hemimethylated DNA; it is diminished 
by the addition of fully methylated sequences. This suggests that as newly synthesised 
DNA becomes methylated in vivo, the function of Dnmt1 could be detrimentally 
affected (Goyal et al., 2006). Additionally, the de novo methylation rate of this enzyme 
could be as high as 5% per replication (Vilkaitis et al., 2005). Examining the fidelity of 
methylation patterns at unmethylated CpG islands suggest an error rate of 
approximately 0.1% per cell replication at any CpG site. This rate is doubled at sites 
outside of the promoter region. Methylated CpG sites have a much lower error rate 
(Ushijima et al., 2003). 
 
1.9.4 Differential environmental exposures 
 
Nutritional factors such as folate, vitamin B12, choline and betaine modify the 
availability of methyl donors so variable intakes of these nutrients can affect DNA 
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methylation levels during a person’s lifetime (Feil, 2006). The phenotypic effect of this 
is can be observed by increasing methyl donor supply in the diet of pregnant dams by 
supplementation, which caused increased DNA methylation at the agouti locus of their 
offspring and altered coat colour (Wolff et al., 1998). Further discussion of the effect of 
differential environmental exposures, such as pollutants and cigarette smoking, on DNA 
methylation is detailed in previous sections (see section 1.6.3.2). 
 
1.9.5 Replication independent events 
 
DNA methylation can also be altered in non-replicative tissues such as the brain. The 
licking and grooming behaviour of parent rats towards their offspring induced 
differences in DNA methylation and expression of the glucocorticoid receptor (GR) in 
their offspring. Such changes were correlated with deregulation of the hypothalamic-
pituitary-adrenal stress response which persisted to adulthood (Weaver et al., 2004). 
Human studies of suicides have linked increased DNA methylation, decreased 
expression of neuron specific GR and altered stress response with childhood abuse, 
compared to suicides with no history of abuse or non-suicidal death (McGowan et al., 
2009).  
 
1.10 Summary 
 
In summary, the role of DNA methylation is well characterised in certain circumstances, 
particularly in cancer cells where hypermethylation of gene promoter regions typically 
results in transcriptional silencing. It is apparent that similar methylation changes 
accumulate with ageing, although usually not at such dramatic levels, therefore the 
consequences of age-related methylation, particularly methylation increases at the 
promoter region are unknown. This accumulation of DNA methylation with advancing 
age can vary between individuals, and together with the fact that methylation marks are 
modifiable by diet and environmental exposures, make it an attractive target worthy of 
investigation for a possible role in determining individual differences age-related health 
or disease status. 
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1.11 Hypotheses 
 
In addition to the highly abnormal DNA methylation patterns evident in malignant cells, 
it is becoming apparent that supposedly unmethylated gene promoters may also acquire 
methylation at CpG sites with progressing time. However, the absolute amount of 
methylation present in an elderly population at specific genes is not well understood. 
Secondly, it is unclear whether all loci or just a subset are susceptible to increasing 
levels of DNA methylation. Lastly, although altered methylation is attracting study for 
its potential role in disease predisposition, it needs to be established that levels of DNA 
methylation are variable in the population, as it is the presence of such variability which 
may underlie differences in disease susceptibility. If changes in DNA methylation levels 
are uniform between individuals during ageing, then it is unlikely to play a role in 
differential disease susceptibility in individuals of the same age.  
 
Our hypothesis for this study was that individuals at age 85 would demonstrate highly 
variable levels of DNA methylation at promoter associated CpG islands and that certain 
individuals may be at more susceptible to acquiring gene specific DNA methylation 
across the genome (possibly due to genetic background or differential environmental 
exposures). We hypothesised that an individual predisposed to increased levels of DNA 
methylation during ageing would be at an increased risk of cancer, since key genes 
(including tumour suppressor genes) may be methylated and transcriptionally silenced. 
This theory could partly explain the strong link between increasing age and increasing 
cancer incidence.  
 
1.12 Aims 
 
In order to more clearly investigate the age related changes in promoter associated CpG 
island methylation, we had four specific aims which are detailed below. Firstly,  
 
1. To measure the extent and inter-individual variability of gene specific promoter 
associated CpG island methylation in a normal elderly population. 
 
The presence of aberrant methylation in cancer has been frequently described; however 
whether these changes occur as a consequence of neoplastic transformation, or are 
evident before cancer is initiated remains to be demonstrated. Since advancing age is a 
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significant risk factor for the majority of cancer, it is possible that age-related DNA 
methylation increases may be responsible for this increased risk. In order to investigate 
this further, our second aim is, 
 
2. To determine if individuals with either a previous history or future diagnosis of 
cancer, where hypermethylation of numerous genes is a frequent observation; 
have increased levels of DNA methylation suggesting they may be more 
susceptible to cancer? 
 
The presence, and potential role, of altered DNA methylation in other age-related 
diseases is not as well defined as in cancer, but since there is a wealth of clinical 
information accompanying participants in the Newcastle 85+ study, our third aim asks, 
 
3. Are differences in DNA methylation levels associated with the presence of other 
clinical features in the Newcastle 85+ study participants? 
 
Finally, others have recently reported a significant overlap between sets of genes which 
become hypermethylated in cancer and sets of genes that become methylated during 
ageing. Therefore our final aim will be, 
 
4. To begin to assess whether identification of methylation of a gene in cancer 
implies susceptibility to age related methylation in the corresponding normal 
tissue. 
 
1.13 Objectives 
 
In order to demonstrate that levels of DNA are highly variable in the very elderly 
population, a panel of genes will be chosen to represent gene specific loci throughout 
the genome. Methylation levels at the promoter region of these genes will be measured 
by Pyrosequencing, a highly quantitative technique for DNA methylation 
measurements, in DNA isolated from peripheral blood leukocytes (PBL) of participants 
in the Newcastle 85+ study. All participants were aged 85 years at the time of sample 
collection. 
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Next, to establish whether elderly individuals with higher methylation levels in PBL 
DNA are at increased risk of cancer in the Newcastle 85+ study, the DNA methylation 
measurements of participants both with and without cancer will be compared. Both 
retrospective comparison of participants with a previous history of any cancer 
(excluding non melanoma skin cancer) prior to their recruitment on the study, and 
prospective analysis of participants diagnosed with cancer during the study (within three 
years of DNA sample donation) will be performed. 
 
Subsequently, to identify a possible role for altered DNA methylation in other age-
related diseases, DNA methylation measurements of participants in Newcastle 85+ 
study with cardiovascular disease, dementia, type II diabetes and stroke will be 
compared to individuals without the disease. This has the potential to identify whether 
differential DNA methylation may play a role in other age-related diseases.  
 
Lastly, to determine whether methylation of a gene in cancer implies susceptibility to 
age related methylation in the corresponding normal tissue, novel cancer associated 
hypermethylated loci will be identified by genome wide methylated DNA enrichment of 
lymphoma cells lines combined with high throughput sequencing. Targets will be 
chosen at random for further confirmation of their methylated status in primary cancer 
samples (ALL). Finally, DNA methylation levels of these same genes will be measured 
in normal PBL DNA samples from the 85 year old population, to conclude whether 
increased methylation is evident. 
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Chapter 2 – Methodology 
 
2.1 Newcastle 85+ Study samples for gene specific DNA methylation analysis 
 
The Newcastle 85+ Study invited all eligible participants who were born in 1921, 
therefore aged 85 upon commencement of the study in 2006, and registered with a GP 
surgery based in Newcastle upon Tyne or Tyneside to take part in the study (Collerton 
et al., 2007). In total, 1042 individuals were recruited including participants who were 
living in care homes, those with disabilities or cognitive impairments; representative of 
the characteristics of the population at that age (Martin-Ruiz et al., 2011). Informed 
consent was provided by all participants or their carers if individuals lacked capacity to 
consent (Collerton et al., 2009). Comprehensive GP record reviews were performed 
detailing disease and medication use. In addition, a more detailed assessment of health 
status was completed by a nurse visiting the home residence of each participant; 
including blood sampling, questionnaires, measurements and functional tests (Collerton 
et al., 2009). These assessments were carried out at baseline (Phase I) and then again at 
18 (Phase II) and 36 months (Phase III) after initial recruitment.  
 
Blood samples were taken after an overnight fast where possible and were subjected to 
routine hematological tests including a full blood count using standard automated 
analysis systems, and measurement of nutritional markers including red cell folate, 
plasma vitamin B12 and total plasma homocysteine. More extensive details regarding 
these methods can be found elsewhere (Martin-Ruiz et al., 2011). In addition, DNA was 
extracted from peripheral blood leukocytes (PBL) and peripheral blood mononuclear 
cells (PBMC) with the QiaAmp DNA Maxi kit (Qiagen Ltd, Crawley, UK) for future 
analyses (including this study of DNA methylation) (Collerton et al., 2007; Den Elzen 
et al., 2011). All measures were carried out by the Newcastle 85+ study team. 
 
2.1.1 Chapter 3 Newcastle 85+ study participant samples (Pilot study) 
 
DNA from peripheral blood leukocytes (PBL) samples were selected from a random 
sample of 50 participants at Phase I of the Newcastle 85+ Study and the corresponding 
peripheral blood mononuclear cell (PBMC) DNA samples for 37 of these individuals 
which were available for analysis at Phase II of the study. 
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2.1.2 Chapter 4 Newcastle 85+ study samples (Association with clinical outcomes) 
 
2.1.2.1 Initial analysis 
 
DNA from PBL was obtained at Phase I of the Newcastle 85+ study. For the initial 
analysis, DNA samples were obtained from 113 participants with a diagnosis of any 
cancer (excluding non-melanoma skin cancer) prior to recruitment onto the study 
(previous cancer). The control group for this analysis comprised of 113 participants 
randomly selected from all remaining participants. The total number of DNA samples 
analysed in the first analysis was 226, however only 220 of these were unique as six 
participants with a previous diagnosis of cancer had been included in the pilot study. 
 
2.1.2.2 Validation analysis 
 
For the validation analysis, the 72 individuals diagnosed with any cancer (excluding 
non-melanoma skin cancer) during the 3 year duration of the study (future cancer) were 
selected. However, 36 of these participants had been unknowingly included in the first 
analysis (as data on cancer development during the study had not been available at the 
time), meaning 36 individuals remained for analysis. In addition, all 24 current smokers, 
36 dementia patients, and 57 participants diagnosed with Type II diabetes were selected 
to validate associations observed in the first analysis, however due to an overlap of 
participants in more than one group, for example individuals with both Type II diabetes 
and dementia, this represented 103 unique DNA samples. For this analysis, the control 
group was comprised of 71 participants randomly selected from all remaining 
individuals. In total, the number of DNA samples analysed in the validation analysis 
was therefore 210 and thus 436 individuals were analysed in Chapter 2.  
 
In total, 480 Newcastle 85+ study DNA samples were tested for the complete analysis 
including the samples from the pilot study, and associations with cancer and other 
clinical outcomes (Table 2.1). 
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2.1.3 Chapter 5 Newcastle 85+ study participant samples (Examination of targets 
identified via genome wide methylation analysis) 
 
In order to measure the DNA methylation levels of genes identified from a genome 
wide DNA methylation analysis of lymphoma cell lines in PBL DNA from the 
Newcastle 85+ study, DNA samples were largely selected from individuals in the pilot 
study, with the exception of 3 samples which removed and replaced with 3 samples 
from the larger 481 sample set, to ensure an equal proportion of these 50 samples fell 
within each quartile of the larger sample set, based on average methylation levels of the 
five variably methylated genes. 
 
  Selection 
Number of 
Unique Samples 
Chapter 1 Pilot Study Random 50 
Chapter 2 First Analysis 
Previous Cancer 107 
No Previous Cancer (Random) 113 
Chapter 2 
Validation 
Analysis 
Control Group (Random) 71 
Future Cancer 31 
Type II Diabetes 50 
Dementia 27 
Current Smoker 18 
Dementia + Diabetes 4 
Dementia + Current Smoking 4 
Future Cancer + Diabetes 2 
Future Cancer + Current Smoking 1 
Future Cancer, Current Smoking + 
Diabetes 
1 
Future Cancer, Diabetes + 
Dementia 
1 
 Total 480 
 
Table 2.1: Selection of PBL DNA samples from Newcastle 85+ Study participants 
for gene specific DNA methylation analysis 
Table shows the selection criteria used and the number of participants analysed for 
different stages of the study. 
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2.2 Pyrosequencing assay design 
 
Gene sequences, including predicted transcriptional start sites, for primer design were 
obtained from the GenBank entry on NCBI and the region surrounding transcription 
start site (promoter and first exon) was examined for the presence of a CpG island. Gene 
sequences were altered to reflect their expected sequence pattern after bisulfite 
modification and input into PSQ assay design software (Qiagen, Crawley, UK). 
Forward, reverse and sequencing primers were designed according to the software 
criteria to amplify a region within the CpG island. Sequencing primers were designed to 
be positioned close to a minimum of three consecutive CpG sites, with the first site 
being within 10 base pairs of the primer sequence. The exception was the imprinted 
gene IGF2, for which the CpG sites examined were located in the differentially 
methylated region 0 (DMR0) upstream of exon 2, which is known to be important in 
control of imprinting (Murrell et al., 2008). Either the forward or reverse primer was 
labelled with biotin, dependent on which strand the sequencing primer is 
complementary to, to allow specific separation of the strand which was to be sequenced 
during Pyrosequencing. Primers containing a CpG site were designed with a degenerate 
base at the position of the cytosine to allow amplification of both methylated and 
unmethylated sequences (Y = C/T nucleotide, R = A/G nucleotide on complementary 
strand). Gene loci primer sequences are listed, along with the number of CpG sites 
analysed and their location relative to the transcriptional start site (TSS) (Table 2.2).  
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Gene Forward Primer Reverse Primer Sequencing Primer 
CpG 
Sites 
Distance from 
TSS 
APOE 
GGAGTTTTATAATTGGATAAG
T 
AAAATCCCAACTCTTTCT (Bio) GGGATTTTTGAGTTTTATT 3 -24  +123 
EPHA10 
ATTATTTATGGGAATTAATTA
TTAG 
CCCACCAATTAAATATTC 
(Bio) 
TATTTATGGGAATTAATTATT
AGGTA 
3 +28  +143 
ESR1 
GGAGATTAGTATTTAAAGTTG
GAGGT 
CCTAAAAAAAAAACACAACC
C (Bio) 
TGGGATTGTATTTGTTTT 5 +92  +294 
HAND2 
CCAAATTTTAATTATCTTATA 
(Bio) 
GGATTTTTTAGTAAGATTT ATTTTATTACCCAAAACTC 4 -29  +185 
HLXB9 TAGTTYGGGTTGTTTAGGAT 
TACRCTACAACCCTCAAA 
(Bio) 
GAAGTYGYGTTGAGTTTTAAG 4 -161  +61 
HOXA4 
TACACTTCACAAATTAATAAC
CATAAACTC (Bio) 
GTTGTTGTAGYGGTAGGTGTT
G 
AACCCAAATTCCCTCCCTT 4 +31  +219 
HOXA5 
CCACAAATCAAACACACATAT
C (Bio) 
GGTTGGTTGTATTTGGGT 
CTACRACTACAATAACATAAA
TCT 
5 +30  +327 
HOXD4 GAAATTAATGGTTATGAGT 
CCCRAAACTAAAAATCTA 
(Bio) 
ATTTGTAGGGYGGTTATTTAG
GYGAG 
5 +242  +398 
IGF2 
GGGTTAAGGTAGTTTTTTTGG
GAATG 
AAATATAAAAACCTCCTCCAC
CTCC (Bio) 
AGGGGGTTTATTTTTTTAGGA
A 
3 DMR0 
MLH1 
AGTTTTTTTTTTAGGAGTGAA
GG 
ATAAAACCCTATACCTAATCT
ATC (Bio) 
GTAGTATTYGTGTTTAGTTT 6 -569  -375 
TUSC3 
GAATAGGATGTTTTGTTAGTT 
(Bio) 
TAACTAAACCCTCCCAAATA CCAAATAACAACCACTTTAC 6 +25  +116 
p15 GGTTTGGGGTTTYTGTAGTGG 
CRACCCCTTAACCCAACTAAA
AAC (Bio) 
GAGGAAGTAGTTTAGTTTAAA
G 
5 -207  +41 
RARB2 
TATAGAGGAATTTAAAGTGTG
GGTTG 
AAAACTTAAAAACTCCCAAC
AACCCT (Bio) 
GTTTTTAAGGTGAGAAATAG 4 -416  -118 
RASSF1A GGGGGAGTTTGAGTTTATTGA 
CTACCCCTTAACTACCCCTTC
C (Bio) 
GGGTYGTATTYGGTTGGAG 5 +136  +434 
TWIST2 
AACAACTATTTAACAACCCAA
CCCAAC 
GGGYGAGTTGGAGTTTTTTTT
TATGG (Bio) 
CAAAACCTTTCCAACAAC 4 -26  +208 
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Table 2.2: The fifteen gene loci selected for DNA methylation analysis by 
Pyrosequencing in the Newcastle 85+ study participants 
For each gene the forward, reverse and sequencing primer sequences are shown and the 
biotin labelled primer is indicated (Bio). Degenerate bases are used at the cytosine 
position of CpG sites (Y = C/T nucleotide, R = A/G nucleotide on reverse strand). The 
number of CpG sites analysed in the Pyrosequencing assay and the region amplified by 
forward and reverse primers relative to the transcriptional start site are also listed.  
 
2.3 Sodium bisulfite modification of DNA 
 
Sodium bisulfite modification of DNA is widely used as the first step in many 
procedures for DNA methylation analysis. It is a chemical based treatment which 
converts unmethylated cytosine to uracil (replaced with thymine after PCR 
amplification) by a deamination reaction, whereas methylated cytosine is protected from 
this conversion (Clark et al., 2006).  
 
A detailed diagram of the steps involved in sodium bisulfite conversion of cytosine to 
uracil is shown in Figure 2.1. 
 
 
Figure 2.1: Diagram of sodium bisulfite conversion of cytosine to uracil 
 
The degree of methylation is subsequently determined via the ratio of C:T nucleotides at 
a particular CpG site, the converted sequence of an unmethylated site being TG and a 
methylated site represented by CG (illustrated in Figure 2.2). The main purpose of this 
is to fix the DNA methylation pattern as a sequence change, since methyl groups are 
lost from DNA during PCR amplification. For all samples, 200ng of DNA was bisulfite 
modified using the Epigentek Methylamp™ One-Step DNA Modification Kit 
(Cambridge BioScience, Cambridge, UK) according to the manufacturer’s protocol. 
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Briefly, DNA was mixed with sodium bisulfite (DNA modification reagent) and 
denatured by incubation of DNA at 99°C for 6 minutes, followed by incubation at 65°C 
for 90 minutes, for optimal deamination of cytosines on single stranded DNA with 
minimal degradation. DNA samples were then bound to a column with DNA capture 
reagent and washed with cleaning reagent and 90% ethanol to allow efficient removal of 
sodium bisulfite salts, followed by elution in 15μl of DNA elution solution. Modified 
DNA was stored at -20°C. A full protocol is detailed in the appendix (A1.1).  
 
 
Figure 2.2: Nucleotide sequence change induced by treatment of DNA with sodium 
bisulfite and subsequent PCR amplification.  
Methylated cytosine (green C) is protected from sequence change whereas 
unmethylated cytosine (red C) is susceptible to uracil conversion after sodium bisulfite 
treatment, which is replaced with thymine during PCR amplification 
 
2.4 PCR amplification 
 
All PCR reactions were carried out in a final volume of 25μl, using 1μl (14ng) of 
sodium bisulfite modified DNA for each PCR amplification with 0.2μl FastStart taq 
polymerase (Roche, Welwyn Garden City, UK), 2.5μl of manufacturers’ buffer, 0.5μl of 
dNTPs, 1-4mM of MgCl2 and 150ng of forward and reverse primer (Eurofins MWG 
Biotech, London, UK), with the exception of ESR1 and HOXA5 for which 75ng of each 
primer was used. PCR amplification was performed using either the G-Storm GS1 
(Gene Technologies, Braintree, UK) or Thermo Hybaid PxE (Thermo Fisher) thermal 
cycler with the following conditions: one incubation at 95°C for 5 minutes, followed by 
40 cycles of 95°C for 30 seconds, primer set specific annealing temperature of 51°C 
(HAND2), 52°C (HOXD4), 53°C (EPHA10), 55°C (APOE, ESR1, HLXB9, TUSC3), 
58°C (HOXA5, MLH1, APP, CYGB, ERN2, HAP1,  SH2D4A), 61°C (p15, RARB2) or 
63°C (HOXA4, IGF2, RASSF1A, TWIST2) for 30 seconds and 72°C for 30 seconds 
followed by a final elongation step of 72°C for 5 minutes (Table 2.3). Forty cycles of 
PCR were performed to reduce the presence of unused biotin labelled primer. 
Amplification of all DNA samples was checked prior to Pyrosequencing analysis by gel 
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electrophoresis using 1.5% agarose (Alpha Laboratories, Hampshire, UK) gel in 1xTAE 
(Tris base, acetic acid and EDTA) (Appendix A1.2) and visualised with GelRed™ 
(Cambridge BioScience, Cambridge, UK) staining. 
 
Stage Temperature (°C) Time (seconds) Cycles 
Hot Start 95 5 1 
Denaturing 95 30 
40 Annealing Primer set specific 30 
Elongation 72 30 
Final Elongation 72 5 1 
Hold 4 ∞  
 
Table 2.3: Thermal cycler conditions for PCR reactions 
 
 
2.5 Pyrosequencing 
 
Quantification of DNA methylation levels was carried out by Pyrosequencing analysis 
using the PyroMark MD instrument (Qiagen, Crawley, UK). Pyrosequencing is based 
on sequencing by synthesis approach and is routinely used for genotyping, as well as 
DNA methylation analysis. This technique utilises a biotin labelled, single stranded 
DNA template to which a sequencing primer is annealed followed by synthesis of the 
complementary DNA strand. Firstly, dNTP’s are added in turn and DNA polymerase 
catalyses the insertion of complementary nucleotides. Upon nucleotide incorporation, a 
pyrophosphate (PPi) is released in an equivalent proportion to the number of 
incorporated nucleotides. The PPi is converted to ATP by the ATP sufurylase enzyme 
in the presence of adenosine 5’ phosphosulfate (APS). This ATP becomes a substrate 
for luciferase to convert luciferin to oxyleuciferin and generates light. Light is detected 
and presented as a peak in the data output file (pyrogram) and the intensity of the light 
emission and peak corresponds to the frequency of that particular nucleotide in the 
sequence, allowing the complementary DNA strand sequence to be determined. The 
apyrase enzyme degrades unincorporated nucleotides and ATP before the next 
nucleotide is added so that the light signal can be correctly attributed to a specific 
nucleotide (Ahmadian et al., 2006) (Figure 2.3). For DNA methylation analysis, 
methylation status at a CpG site is determined by the presence of either a C 
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(methylated) or T (unmethylated) nucleotide in the sequence (or a G (methylated) or A 
(unmethylated) nucleotide if the complementary strand is sequenced), and the ratio of 
C:T allows quantification of percentage methylation at a specific CpG site. All 
Pyrosequencing assays attempt to incorporate non complimentary bases into the newly 
synthesised strand to confirm the specificity of the assay, and that only expected 
nucleotides are being integrated. In addition, a bisulfite control is performed at a non 
CpG cytosine base (which should always be converted to thymine after sodium bisulfite 
modification) by also adding cytosine nucleotides at this position. If any become 
incorporated into the synthesised strand, this indicates that sodium bisulfite 
modification of DNA was incomplete and methylation measurements maybe inflated 
and inaccurate. Samples with cytosine levels >4.5% detected at this position are 
automatically failed. Biotin-labelled Pyrosequencing PCR products were bound to 
streptavidin coated sepharose beads (GE Healthcare Life Sciences) and made into single 
stranded DNA templates by performing strand separation using a vacuum pump tool on 
the Pyromark Q96 Vacuum Workstation (Qiagen, Crawley, UK). The vacuum tool 
picks up the PCR product, bound to the beads which are then washed with 70% ethanol. 
Next, the vacuum tool is added to sodium hydroxide (NaOH) to denature the DNA, 
causing the biotin labelled strand to remain associated with the beads and vacuum, 
whilst the other strand is removed. After washing with a 10mnM tris acetate buffer 
(Qiagen, Crawley, UK), the vacuum is switched off and the biotin labelled single 
stranded DNA dissociates and is added to a Pyrosequencing plate containing 10pmol of 
gene specific sequencing primer (Eurofins MWG Biotech, London, UK), which 
becomes annealed to this template. Pyrosequencing reaction enzymes, substrates and 
nucleotides were obtained from the PyroGold Q96 Reagent kit (Qiagen, Crawley, UK). 
A full protocol can be found in the appendix (A1.3). Each DNA sample was measured 
in duplicate. For each gene, methylation was measured at multiple consecutive CpG 
sites (3-6), each of which are shaded grey on the resulting pyrogram (see example 
Figure 2.4), and the average amount of methylation pooled across all CpG sites was 
calculated. The PyroMark MD instrument scores the results of the methylation analysis 
by a colour coded system which is visible on the pyrogram output file. In the following 
example pyrograms, blue colouring represents a sample which passes necessary quality 
controls including a check for complete bisulfite conversation (Figure 2.4), yellow 
samples have warnings and need to be manually checked for quality (Figure 2.5) and 
red samples are judged to have failed the Pyrosequencing analysis so should be 
discarded and repeated (Figure 2.6). 
 55 
 
 
 
 
 
 
Figure 2.3: Pyrosequencing reactions and example output pyrogram 
After the incorporation of a complementary nucleotide, a series of reactions trigger the 
emission of light. This light is detected and presented as a peak on the pyrogram output. 
Height of the peaks is directly proportional to the amount of incorporated nucleotide. 
Non complimentary bases do not generate light or a peak. From the pyrogram, the 
sequence of the complementary DNA strand can be determined. 
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Figure 2.4: Pyrogram of a passed IGF2 Pyrosequencing assay sample 
The pyrogram features three CpG sites, and the level of DNA methylation (%) at each 
particular CpG site (shaded grey) is calculated by the ratio of cytosines and thymines 
incorporated into newly synthesised DNA strand. The blue colour of the methylation 
percentage indicates the sample has passed quality control checks, including the specific 
incorporation of expected nucleotides. The site at which complete bisulfite conversion 
of DNA is checked is shaded yellow. 
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Figure 2.5: Pyrogram of an IGF2 Pyrosequencing assay sample with warnings 
The yellow colour of the methylation percentage calculations indicate that there may be 
a problem with some of the quality control checks performed on this sample. In this 
case, the warning was for wide peaks, which is caused by too much product in the 
reaction. Samples with warnings should be repeated to ensure methylation 
measurements are accurate. 
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Figure 2.6: Program of a failed IGF2 Pyrosequencing assay sample 
Methylation measurements which are coloured red are deemed to have failed quality 
control checks. In this case, the heights of the peaks generated by nucleotide 
incorporation are very low. This is due to insufficient product in the analysis and these 
results are likely to be highly unreliable. 
 
2.5.1 Pyrosequencing validation 
 
Each Pyrosequencing assay was individually validated to ensure that the observed levels 
of methylation measured by the Pyrosequencer are accurately reflecting the true amount 
of DNA methylation. Measured methylation data from the Pyrosequencer is plotted 
against the expected methylation of known standards to give a validation curve. 
Standards of 0%, 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70% and 100% 
methylation were created by diluting CpGenome™ Universal Methylated Control DNA 
(Millipore Ltd, Watford, UK) which represents a human in vitro 100% methylated 
sample, with DNA from peripheral blood lymphocytes from a young volunteer, which 
represents mostly unmethylated CpG islands. These known methylation DNA standards 
were subjected to bisulfite modification prior to Pyrosequencing.  
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2.6 Sodium bisulfite sequencing of single PCR amplified DNA molecules 
 
In order to decipher methylation status at all allelic level, de novo sequencing of a single 
PCR amplified sodium bisulfite modified DNA molecule (which has a sequence 
equivalent to a single allele in the original DNA sample) was performed. This analysis 
has two advantages over Pyrosequencing; one that it allows determination of the 
methylation status of all CpG sites within the amplified region (a greater number of 
CpG sites than analysed by Pyrosequencing) and secondly that it allows determination 
of methylation is distributed amongst individual alleles. Firstly, the sample was 
subjected to PCR amplification and cloning of the PCR products into competent E. coli 
cells using the TA Cloning® Kit (Invitrogen Ltd, Paisley, UK). Briefly, 1μl of PCR 
product was added to 1μl 10x Ligation buffer, 2μl pCR®2.1 vector and 1μl T4 DNA 
Ligase for overnight incubation at 14°C. 2μl of the ligation product was added to 50μl 
of One Shot® aTOP10 Chemically Competent E. coli cells and incubated on ice for 30 
minutes followed by transformation by heat shock treatment of 42°C for 30 seconds. 
Cells were briefly shaken (225 rpm) in 250μl S.O.C. medium at 37°C for 1 hour prior to 
plating of 80μl and 160μl of cells on LB agar containing kanamycin (50μg/ml) 
(appendix A1.4) for overnight incubation.  Transformants were selected by culturing 
individual colonies overnight at 37°C in 5 ml of LB media with kanamycin (50μg/ml) 
(Appendix A1.4). Vector DNA was isolated and purified by lysis of bacterial cells and 
adsorption of DNA using QIAprep Spin Miniprep kit (Qiagen, Crawley, UK) according 
to the manufacturer’s protocol and eluted in 50μl of elution buffer (Appendix A1.5). 
The presence of the PCR amplified region of interest was confirmed by EcoRI 
(Fermentas, York, UK) restriction enzyme digestion which cuts the vector either side of 
the incorporated PCR product. Ten microlitres of DNA was added to 0.5μl EcoRI 
enzyme, 2μl Buffer H and 2μl BSA (10x) in a final reaction volume of 20μl and 
incubated at 37°C for 2 hours. Samples were separated by gel electrophoresis using 2% 
agarose gel in 1xTAE and visualised with GelRed™ (Cambridge BioScience, 
Cambridge, UK) staining. The DNA concentration of vectors containing the insert was 
determined using a NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific) 
and all samples were sent to Source Bioscience, at a concentration of 100ng/μl, for 
Sanger sequencing (Source Bioscience LifeSciences plc, Nottingham, UK). The 
methylation status of all CpG sites within the amplicon was determined by the DNA 
sequence after bisulfite modification, TG indicating the cytosine was unmethylated, CG 
representing a methylated cytosine. 
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2.7 Samples for genome wide DNA methylation analysis 
 
2.7.1 Cell lines 
 
A total of four human lymphoma cell lines were used for genome wide methylation 
analysis; DB, HT, Karpas-422 and SUDHL8. All four are diffuse large B-cell 
lymphoma cell lines, a subtype of B-cell non-Hodgkin lymphoma (B-NHL). 
 
2.7.2 Primary acute lymphoblastic leukaemia (ALL) samples 
 
The methylation status of gene targets identified from the genome wide methylation 
analysis was confirmed in 18 primary adult ALL primary samples. Age and ALL 
immunophenotype associated with each sample can be found in Table 2.4. 
 
2.8 Cell culture of lymphoma cell lines 
 
A total of four lymphoma cell lines were cultured; DB, HT, Karpas-422 and SUDHL8. 
All cell lines were maintained in RPMI 1640 with 10% fetal bovine serum (FBS) and 
1% PenStrep antibiotic in 95% air/5% CO2 at 37°C. All cell lines were grown in 
suspension in T75 flasks containing 15ml RPMI media, with FBS and PenStrep at a 
density of 0.5-2x10
6
 cells/ml and passaged every 3-4 days at a ratio of 4:1. 
 
2.9 DNA extraction 
 
DNA was extracted from 4-5 million pelleted cells using a phenol chloroform 
extraction, by adding 340µl of Reagent B (Nucleon – Appendix A1.6) to lyse cells 
followed by RNase treatment for degradation of RNA using 2.5µl RNase A (50µg/ml) 
solution and incubation at 37°C for 30 minutes. Then, 100µl of 5M Sodium Perchlorate 
was added and samples incubated at 37°C for 20 minutes followed by 65°C for 20 
minutes, to prevent precipitation of proteins alongside DNA. A combination of 440µl 
phenol and 440µl chloroform was added to samples, mixed and centrifuged at full speed 
for 10 minutes, which results in separation into two distinct phases, a lower phase of 
phenol associated with proteins, and an upper aqueous phase containing DNA. The 
upper phase was removed into a new microcentrifuge tube and 880µl of chloroform 
added followed by centrifugation at full speed for 10 minutes to remove lipids and 
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ensure complete removal of the phenol phase. The supernatant was again transferred to 
a new microcentrifuge tube and DNA precipitated with 2 volumes of cold 100% 
ethanol, followed by centrifugation at full speed for 10 minutes. If no DNA precipitate 
was visible upon addition of the ethanol, samples were incubated overnight at -20°C 
prior to centrifugation. Finally, samples were washed with 70% ethanol and centrifuged 
at full speed for 5 minutes. The DNA pellet was dried briefly and resuspended in 
appropriate volume of TE buffer (Appendix A1.7). DNA concentration was tested using 
a NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific). 
 
 
Sample ID Age at Diagnosis Immunophenotype 
1628 48 T 
3322 59 CALLA 
3517 49 T 
3684 46 PRE-PRE B 
4508 49 CALLA 
5031 71 CALLA 
6095 70 B 
6654 19 T 
7431 23 PRE-PRE B 
7769 15 CALLA 
8849 19 CALLA 
10140 20 CALLA 
10226 40 PRE B 
12032 63 B 
12439 23 CALLA 
12868 65 CALLA 
12896 29 CALLA 
15566 20 PRE B 
 
Table 2.4: ALL sample characteristics 
For each sample, age at diagnosis and immunophenotype, determined by detection of 
expressed cell surface markers is shown. B = B-cell ALL, CALLA = common acute 
lymphoblastic leukaemia antigen, PRE B = Precursor B-cell ALL, PRE-PRE B = 
Precursor B-cell ALL, T = T-cell ALL 
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2.10 Preparing DNA fragments for sequencing 
 
2.10.1 Bioruptor® Plus sonication system 
 
The Bioruptor® Plus sonication system (Diagenode SA, Liege, Belgium) allows up to 
six samples in sealed 1.5ml tubes to be sonicated simultaneously. This system utilises 
ultrasound energy to stress and fragment DNA whilst the tubes containing DNA 
samples are rotated in an iced water bath, allowing an equal distribution of energy. 
Conditions were optimised prior to analysis to determine cycle length, number of cycles 
and the amount and concentration of DNA required to reproducibly yield fragments of 
the required 300-500 base pairs in length. The 1.5ml microcentrifuge tubes required a 
volume of at least 100µl of DNA for successful sonication, and the optimal 
concentration was found to be 100ng/µl, therefore a total of 10µg of DNA was used for 
sonication, comprising of 2.5µg of DNA extracted from each of the four lymphoma cell 
lines DB, HT, Karpas-422 and SUDHL. Samples were vortexed vigorously for 5 
seconds prior to sonication was this was found to improve the consistency of fragment 
size between different samples during testing. The sonication was performed on the 
high power setting and the programme consisted of 20 cycles of power on for 30 
seconds, then power off for 30 seconds. 500ng of sonicated DNA was subjected gel 
electrophoresis using 1% agarose gel in 1xTAE, visualised with GelRed™ staining and 
size determined with 1 Kb Plus DNA Ladder (Invitrogen Ltd, Paisley, UK) to check 
DNA fragment distribution.  
 
2.10.2 Covaris Instrument 
 
The Covaris instrument (KBiosciences, Hoddesdon, UK) utilises Adaptive Focused 
Acoustics™ technology, using shorter wavelengths of energy which can be focused 
more precisely on the sample. It is more efficient than traditional sonication, where 
energy is often lost as heat and samples can be exposed to overheating. To further 
fragment DNA which was larger than the required 200-300bp size for Illumina GAIIx 
sequencing, a total of 6.7µg of DNA was input into the optimised Covaris instrument 
with the assistance of Dr Thahira Rahman, with the following settings:  
Duty cycle 20% (percentage of time energy output is “on”) 
Intensity 4.0 (acoustic power) 
Cycles per burst 200 (number of pressure waves in a burst) 
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Time 60 seconds x2 
Temperature 6°C 
 
2.10.3 Fragment profile measurements 
 
Sizing of DNA fragments was measured with the assistance of Dr Thahira Rahman after 
Bioruptor® Plus sonication, Covaris sonication and upon ligation of sequencing 
adapters on the 2100 Bioanalyzer (Agilent Technologies UK Ltd, Cheshire, UK). 
Reagents, including DNA dye and gel matrix, and DNA LabChip were obtained from 
the Agilent DNA 1000 Kit (Agilent Technologies UK Ltd, Cheshire, UK) for sizing of 
DNA in 25-2000bp range. The 2100 Bioanalyzer assay programme used was 
electrophoresis  dsDNA  DNA 1000. The sonicated DNA sample and reagents 
were added to appropriate wells on the DNA LabChip using the Chip Priming Station 
(Agilent Technologies UK Ltd, Cheshire, UK). Sizing accuracy was confirmed by the 
inclusion of a size ladder, and two internal markers at 15bp and 1500bp.  
 
2.10.4 DNA purification 
 
DNA was purified after fragmentation, during sequencing library preparation and after 
MethylCap enrichment of DNA to remove very short nucleotide fragments <40bp, 
primers, salts and enzymes using the QIAquick PCR Purification Kit (Qiagen, Crawley, 
UK) according to the manufacturer’s protocol. DNA fragments are bound to the column 
membrane in high salt concentrations (pH<7.5) whilst contaminants are lost, and DNA 
is eluted once pH is increased by the addition of elution buffer (pH 8.5). The full 
protocol is listed in the appendix (A1.8). 
 
2.11 Sequencing library preparation 
 
Sequencing library preparation was performed with the assistance of Dr Thahira 
Rahman. The lymphoma cell line DNA sample was prepared for sequencing using the 
Paired-End DNA Sample Preperation Kit (Illumina) to add adapter sequences onto the 
ends of DNA fragments for 75bp paired end reads. 
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2.11.1 Perform end repair 
 
After DNA fragmentation, the ends of DNA are not uniform and are comprised of both 
3’ and 5’ overhangs and blunt ends. All fragments were made into blunt ends by filling 
in 5’ overhangs and removing 3’ overhangs by T4 DNA polymerase and Klenow 
enzyme. T4 PNK catalysed phosphorylation at the 5’ blunt end of DNA allowing 
subsequent ligation. A total of 6.7µg DNA was incubated with 10µl DNA Ligase Buffer 
with 10mM ATP, 4µl of 10mM dNTP Mix, 5µl of T4 DNA Polymerase, 1µl Klenow 
Enzyme and 5µl T4 PNK in a total reaction volume of 100µl was incubated at 20°C for 
45 minutes. Samples were purified with QIAquick PCR Purification kit (Qiagen, 
Crawley, UK) in 32µl of Qiagen EB (Appendix A1.8). 
 
2.11.2 Adenylate 3’ ends 
 
The 3’ end of the blunt DNA fragment was adenylated with a single ‘A’ nucleotide, 
which prevents fragments ligating to each other. The adapter sequences contain a 
complementary ‘T’ nucleotide for ligation with the DNA fragment. The 32µl DNA 
sample was incubated at 37°C for 45 minutes with 5µl Klenow buffer, 10µl mM dATP 
and 3µl Klenow Exo - in a total volume of 50µl. Samples were purified with QIAquick 
MinElute PCR Purification kit (Qiagen, Crawley, UK) according to manufacturer’s 
protocol and eluted in 10µl Qiagen EB (Appendix A1.8). The protocol for the QIAquick 
MinElute PCR Purification kit is identical to the QIAquick PCR Purification kit but 
includes a specifically designed column which allows elution of DNA in very small 
volumes. 
 
2.11.3 Ligate adapters 
 
In this step, the sequencing adapters were ligated to the ends of the DNA fragments. 
Distinctive sequences were added to the 5’ and 3’ ends of each strand. The 10µl purified 
DNA sample was incubated at 20°C for 45 minutes with 25µl DNA Ligase Buffer 2X, 
10µl PE adapter Oligo Mix and 5µl DNA Ligase in a total volume of 50µl. 
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2.11.4 Purify adapter ligated fragments 
 
Purification of the adapter ligated DNA fragments was performed using Agencourt 
AMPure XP magnetic beads (Beckman Coulter). DNA and magnetic beads were 
incubated for 30 minutes at room temperature prior to separation of the DNA bound 
magnetic beads in a magnetic rack. Beads were washed with 70% ethanol and dried. 
DNA was eluted by adding 17µl of nuclease free H2O followed by incubation at room 
temperature for 30 minutes before placing on a magnetic rack and removing the DNA 
containing supernatant.  
 
2.12 Enrichment of methylated sequences 
 
In order to recover DNA fragments containing methylated regions within total genomic 
DNA, the MethylCap kit (Diagenode SA, Liege, Belgium) was utilised to selectively 
bind fragments containing methylated CpG sites. This technique utilises a H6-GST-
MBD fusion protein, comprising of a C-terminal methyl binding domain (MBD) 
isolated from the human methyl binding protein MeCP2, with Glutathoione-S-
transferase (GST) and an N-terminal His6-tag, for the capture and isolation of DNA 
fragments that contain one or more methylated cytosines. 
 
2.12.1 Capture of methylated DNA 
 
Firstly, the capture reaction mix was prepared by adding 1.2µg of the adapter ligated 
DNA fragments at a concentration of 100ng/µl to 129.8µl of buffer B in a total volume 
of 141.8µl. Per capture reaction, 119µl of the capture reaction mix was mixed with 1µl 
H6-GST-MBD fusion protein and incubated on a rotating wheel at 40rpm at 4°C for 2 
hours; forming a complex between the H6-GST-MBD fusion protein and methylated 
DNA. The remaining excess capture reaction mix of 22.8µl served as an INPUT control 
sample. Thirty microlitres of meDNA Capture beads were washed several times with 
Wash Buffer 1 prior to their addition to the capture reaction mix containing H6-GST-
MBD fusion protein and methylated DNA and subsequently incubated on a rotating 
wheel at 40rpm at 4°C for 1 hour. 
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2.12.2 Bead washes 
 
After the capture reaction, samples were placed in a Magnetic Rack (Diagenode SA, 
Liege, Belgium), and the buffer containing DNA which has not bound to magnetic 
beads was removed. The methylated DNA bound magnetic beads were washed several 
times by incubation with Wash Buffer 1 and then Wash Buffer 2, on a rotating wheel at 
40rpm at 4°C for 5 minutes. 
 
2.12.3 Elution of captured DNA 
 
The MethylCap kit includes three elution buffers of progressively increasing salt 
concentration which enable differential fractionation of double-stranded DNA based on 
increasing CpG methylation density. To elute captured DNA, 150µl of low salt buffer 
was added to magnetic beads and incubated on a rotating wheel at 40rpm at 4°C for 10 
minutes, then placed in magnetic rack. The supernatant solution contained methylated 
DNA fragments eluted by the low salt fraction. These steps were repeated with medium 
and high salt buffers and the INPUT DNA (no enrichment for methylated sequences) 
was eluted with the high salt buffer. DNA from all fractions was purified with 
QIAquick PCR Purification Kit (Qiagen, Crawley, UK) according to the manufacturer’s 
protocol and eluted in 30µl ddH2O (Appendix 1.8). 
 
2.13 Quantitative PCR (qPCR) 
 
Successful enrichment for methylated fractions of the genome was confirmed by 
measuring the amount of DNA template present in each of the salt eluted fractions at a 
known methylated (HOXA5) and unmethylated (GAPDH) gene by qPCR. Reactions 
were carried out in a final volume of 10μl with 5μl SYBR® Green JumpStart™ Taq 
ReadyMix (Sigma, Gillingham, UK), 37.5ng of forward and reverse primer and 0.5μl of 
DNA template and the reaction performed by the TaqMan 7900HT (Applied 
Biosystems, Warrington, UK) with the following cycling conditions; one cycle of 94
o
C 
for 15min, followed by cycles of 94°C for 30sec, 57°C (GAPDH) or 64°C (HOXA5) for 
30sec and 72°C for 30sec, with plate reads carried out at 86°C (GAPDH) or 91°C 
(HOXA5). Each sample was tested in triplicate. The primer sequences for HOXA5 were 
forward primer 5’TCGGAAGCTGGGCGATGAG and reverse primer 
5’GTGCACTAATAGGGGAGTTGGG and for GAPDH were forward primer 
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5’CTCAGGCCTCAAGACCTTG and reverse primer 
5’GACAGTCAGCCGCATCTTC. 
 
2.14 Illumina Genome Analyzer IIx sequencing 
 
Paired end, high throughput sequencing of MBD enriched DNA fragments was 
performed on the Illumina Genome Analyzer IIx (GAIIx) sequencing platform using a 
sequencing by synthesis approach. Library prepared samples were placed on a flow cell 
where the single stranded fragments anneal to oligos on the surface via the 
complementary adapter ligated sequences. PCR was performed whereby double 
stranded bridge sequences were formed on the flow cell surface, generating millions of 
clusters containing clonally amplified fragments utilising the TruSeq PE ClusterKit V5 
CS-GA (Illumina). Reverse strand fragments were removed, forward strand ends 
blocked and sequencing primers annealed to the forward strand template to begin 
sequencing of reverse strand (read 1). Clusters were simultaneously sequenced on the 
GAIIx platform. Paired end 75bp sequencing reads were performed on the Genome 
Analyzer IIx (GAIIx) platform using 2x TruSeq SBS Kit V5-GA 36 cycles (Illumina). 
Briefly, fluorescently labelled, reversibly terminated dNTPs and polymerase were added 
to the synthesis reaction. After single nucleotide incorporation, the base is identified by 
colour imaging and the fluorescent dye removed along with reversible terminator. This 
process continues for a further 74 cycles. After this, cluster generation was repeated 
utilising the paired end module of the GAIIx platform, to enable synthesis of the 
forward strand (read 2). Paired end sequencing allows greater confidence in identifying 
fragments, as both 5’ and 3’ ends of the fragment can be mapped back to the genome, as 
opposed to a single read, enabling a more precise alignment of reads. 
 
2.15 Bioinformatics analysis 
 
Analysis was performed by Dr Simon Cockell from the Newcastle University 
Bioinformatics support unit. Raw sequencing data from the Illumina GAIIx platform in 
FASTQ format was subjected to quality control analysis by FastQC 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/), which removes problem 
sequencing reads. This analysis considers quality scores along the length of the 75bp 
read, nucleotide content and proportion of N (undetermined bases) in the sequencing 
reads. Filtered sequencing reads were mapped to the human reference genome using the 
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Burrows-Wheeler Aligner (BWA) (http://bio-bwa.sourceforge.net/) program, for rapid 
identification of reads. Regions of genome which were enriched by MethylCap analysis 
were determined by the peak calling algorithm, Model-based Analysis of ChIP-Seq 
(MACS) (http://liulab.dfci.harvard.edu/MACS/). The alignment files were used to 
identify regions which deviate from an expected Poisson distribution of aligned 
sequence reads, generating approximately 150,000 peaks. Peaks were filtered to exclude 
those in repetitive regions, as these are more likely to be sequenced and are usually 
highly methylated. Remaining peaks were intersected with a gene list to assign each 
peak to its closest gene. Only peaks which were within 300bp of, or overlapped, the 
transcriptional start site of a gene were retained, leaving 10,000 peaks. Peaks were 
assigned to their respective genes according to the above criteria, and those which 
matched to pseudo genes were removed. This left a total of 7,266 genes, of which 
approximately 1,500 were RNA genes (particularly ribosomal), of which a significant 
proportion are thought to be methylated in normal cells (Gagnon-Kugler et al., 2009). 
Remaining peaks were assigned into the top or bottom 10% of all sequenced peaks 
based on their p-values, representing a confidence score of the observed peak, 
determined by MACS, generating a list of genes associated with the top and bottom 
10% of the filtered peaks. 
 
2.16 COBRA assay 
 
Validation of the methylation status of gene sequences from high-throughput 
sequencing analysis was performed by the COmbined Bisulfite Restriction Analysis 
(COBRA) assay (Xiong and Laird, 1997). The genes for validation were chosen at 
random (using the random number generator function in Microsoft Excel) and primers 
were designed to produce equivalent amplification of unmethylated and methylated 
DNA, either by ensuring that the primer sites did not contain any potentially methylated 
sites or contained a “wobble” base at any CpG sites which were included (i.e. either Y 
instead of C or R instead of G at the CpG site) (Table 2.5). PCR amplification was 
performed as described in section 2.4, with primer specific annealing temperatures of 
55°C (CELF4), 58°C (APP, CACNA1B, CYGB, ERN2, HAP1, SH2D4A), 61°C (HCK, 
TCL1B) or 63°C (EBF4, PDCD5) followed by digestion with restriction enzymes to 
discriminate between methylated and unmethylated sequences after sodium bisulfite 
modification. The identification of appropriate restriction enzymes was determined 
using NEBcutter V2.0 software (New England BioLabs, URL: 
 69 
 
http://tools.neb.com/NEBcutter2/). The sequence of the DNA amplicon after bisulfite 
modification was input into the software, with CpG sites remaining as CG, which 
returns a list of restriction enzymes which will cut somewhere within the sequence. The 
restriction enzymes utilised for this analysis with their associated recognition sequences 
can be found in Figure 2.7. Enzymes with recognition sequences containing a cytosine 
and guanine can therefore be used to distinguish between methylated (CG – will cut) 
and unmethylated (TG – will not cut) sequences (demonstrated in Figure 2.8). For each 
COBRA assay, 11.5μl of gene specific PCR product was mixed with 0.5μl of either 
BsiEI, BstUI, HhaI, HinFI, HpyCH4IV, RsaI or TaqI (New England BioLabs, Hitchin, 
UK) (Table 2.6), 2μl of the appropriate enzyme buffer and 2μl BSA (10x) in a final 
volume of 20μl and incubated at 37°C (HhaI, HinFI, HpyCH4IV, RsaI), 60°C (BsiEI, 
BstUI) or 65°C (TaqI) for 2 hours. Digested PCR products were separated on 2–3% 
agarose gels, visualized by GelRed™ (Biotium) staining and size determined with 1 Kb 
Plus DNA Ladder (Invitrogen Ltd, Paisley, UK). Standards of known methylation status 
(100%, 66%, 33%, and 0%) were created by diluting in vitro methylated DNA 
(Millipore Ltd, Watford, UK) into DNA extracted from normal peripheral blood 
(typically unmethylated/low levels of methylation) to allow a comparison with tested 
samples and also for confirmation of efficient restriction digestion. 
 
2.16.1 Development of Pyrosequencing assays corresponding to COBRA assays 
 
A more sensitive technique than COBRA was required for testing the methylation status 
of genes identified by genome wide DNA methylation analysis in the Newcastle 85+ 
study samples, as it is not possible to determine small differences in methylation (which 
is expected in normal human samples) using COBRA. For this reason we developed 
Pyrosequencing assays corresponding to the same region as the COBRA primers (Table 
2.7). Pyrosequencing assay design was carried out as described (see section 2.2).
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Gene Forward Primer Reverse Primer Distance from TSS Size (bp) 
 Genes associated with top 10% of sequencing peaks 
APP TGGGGGTTAAAAAATGAGGTT TCRTCCCCRTAAACTTAAATCATC -499  -280 219 
CACNA1B GGYGGTTAGAGGTTTTTTTGAGTTGAGAT TAAATACCCTCRACTCCTCAAACTC -563  -279 284 
CELF4 AGGTTGGATYGGTTTAAGTTTTTAGTTAG ACRCCTCCCRAAAAACCATAC -11  +248 256 
CYGB GGATTTTTTTYGTTATTAGTTGGGTTAGAA CTCTAAACRCCCAAACTCTAAAAAATT -656  -393 263 
ERN2 GGGATTYGTTGGTGTAATGATAAAGAG CCRCCCTTCTCATCACACT -80  +182 262 
HAP1 TTYGGAGATGGAGAGGGTAGAAAA TCRAAATCCTACTCTCTATCCAATACC -243  +171 414 
SH2D4A GTGGAAAGGTTTAGATTTGTAGATTTAAT ACCCRAACRCAAAACAACTCTTATA -190  +119 309 
 Genes associated with bottom 10% of sequencing peaks 
EBF4 GTTTTTTTYGAGGGAGYGTTTAAGAGG CATCCAAAAACRCACTAAACCCAAAC +600  +864 264 
HCK GGGTTTGGGATTTTTTTTGTAGGA TCCTACACTATCTAAATCCCTTCC -108  +129 238 
PDCD5 ATAGAGGTTGGTYGAGTTGTAGGTT AACCCRCTCCAAACTAAAAAACCC +106  +404 298 
TCL1B GGAAAGTTATAYGTGTGAGTTTAGAG ATTACTACRCTCCTAAACCTACAC +1  +355 354 
 
Table 2.5: COBRA assay primer sequences of genes associated with sequencing peaks from the genome wide DNA methylation analysis  
The forward and reverse primer sequences for each amplicon are shown with the location of primers relative to the transcriptional start site and overall 
size of the PCR product amplicon (Y = C/T nucleotide, R = A/G nucleotide on reverse strand). 
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Figure 2.7: COBRA assay restriction enzyme recognition sequences and cut sites  
The seven enzymes shown will cut only when the DNA sequence contained a 
methylated cytosine nucleotide (green C). The BsiEI, BstUI and HhaI enzymes will 
only cut when two consecutive cytosines are methylated. Cut sites are indicated by 
purple triangles. (N = any nucleotide, R = either A/G nucleotide, Y = either C/T 
nucleotide). 
 
 
 
Figure 2.8: COBRA assay example 
A sodium bisulfite modified and methylated amplicon sequence will be recognised and 
cut into smaller fragments by restriction enzymes, whilst unmethylated amplicons 
remain full length. DNA methylation status can then be determined by sizing of DNA 
fragments visualised by gel electrophoresis. 
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Gene 
 
Size 
(bp) 
Restriction 
Enzymes 
Number 
of cuts 
Enzyme cut position 
 Genes associated with top 10% of sequencing peaks 
APP 219 
HpyCH4IV 2 91/93, 142/144 
TaqI 1 113/115 
CACNA1B 284 
HinFI 3 119/122, 154/157, 269/272 
BstUI 2 101, 117 
CELF4 256 
BsiEI 1 126/124 
TaqI 1 203/205 
CYGB 263 
TaqI 3 114/116, 167/169, 192/194 
BstUI 1 103 
ERN2 262 
RsaI 2 130, 142 
BstUI 1 227 
HAP1 414 
HhaI 2 133/131, 286/284 
RsaI 1 383 
SH2D4A 309 
BstUI 5 235, 137, 222, 258, 271 
TaqI 2 151/153, 178/180 
 Genes associated with bottom 10% of sequencing peaks 
EBF4 264 
BstUI 3 33, 159, 161 
HinFI 3 50/53, 129/132, 220/223 
HCK 238 
BstUI 1 130 
HinFI 1 47/50 
PDCD5 298 
BstUI 3 69, 101, 208 
HhaI 1 101/99 
TCL1B 354 
BstUI 2 176, 279 
TaqI 1 58/60 
 
Table 2.6: Restriction enzymes used in COBRA assays 
For each assay, the size of the amplicon, the two restriction enzymes used, the number 
and position of cuts in the sequence are shown. 
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Gene 
Forward Primer Reverse Primer Sequencing Primer 
CpG 
Sites 
APP 
TGGGGGTTAAAAAATGAGGTT 
(bio) 
Same as COBRA CCCCRTAACTTAAATCA 3 
CACNA1B No suitable Pyrosequencing assay could be designed 
CELF4 No suitable Pyrosequencing assay could be designed 
CYGB Same as COBRA 
CTCTAAACRCCCAAACTCTAAAAAATT 
(bio) 
GGTYGGAGGTGYGTTTAAG 4 
ERN2 Same as COBRA CCRCCCTTCTCATCACACT (bio) GTGTTTGGTGGGGTGATT 3 
HAP1 Same as COBRA TCRAAATCCTACTCTCTATCCAATACC (bio) ATTYGGGGATTTAGTAGTAT 3 
SH2D4A Same as COBRA ACCCRAACRCAAAACAACTCTTATA (bio) GGTTTTGGAGAGTTTTTAG 5 
 
Table 2.7: Primers for Pyrosequencing analysis of genes identified from genome wide methylation analysis 
For APP, CYGB, ERN2, HAP1 and SH2D4A the sequence of the primer and reverse are indentical to those used for COBRA assays with the addition of 
a biotin label (bio) on either the forward or reverse primer. Sequencing primers were generated by the PSQ assay design software. The number of CpG 
sites measured by the assay is also shown. No suitable Pyrosequencing assays could be designed for either CACNA1B or CELF4
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2.17 Data analysis and Statistics 
 
2.17.1 Bonferroni correction 
 
This is applied in order to compensate for the effects of multiple testing and 
comparisons, which increase the likelihood of discovering a significant effect purely by 
chance. The significance level of the p value is altered from a standard 0.05 level, to a 
more stringent level by the following formula:  
 
Bonferroni significance level  =   0.05 significance 
            Number of comparisons 
 
2.17.2 Pearson Correlation coefficient 
 
The strength of correlation between two data variables was measured by calculating the 
Pearson Correlation coefficient (r) and corresponding p value for determining 
significance of the relationship. The Pearson Correlation coefficient was calculated by 
Wessa.net statistical software version 1.1.23-r7 (URL http://www.wessa.net/) (Wessa, 
2012). 
 
2.17.3 Linear regression analysis 
 
Linear regression analysis was performed in Excel 2010 (Microsoft Office) to 
investigate the relationship between two variables. The r
2
 value of the regression 
indicates how well the regression line fits the actual data. An r
2
 value of +1 or -1 
represents a perfect linear positive or negative relationship between the variables 
respectively, whilst an r
2
 value of 0 signifies no relationship. 
 
2.17.4 Student’s t-test 
 
An Independent-Samples Student’s t-test was performed using SPSS Statistics (version 
19) for testing the hypothesised differences in DNA methylation levels between groups. 
The null hypothesis (no difference between groups) can be rejected if a significance 
level below 0.05 is reached. 
 
 75 
 
2.17.5 Z-Score 
 
The Z-score is an indication of how variable a measurement is compared to the 
population mean measurement, by determining how many standard deviations separate 
the measurement and the mean, calculated by the following formula: 
 
Z-Score= (Individual measurement – Population mean) 
   Population SD 
 
2.17.6 Linear regression analysis model 
 
2.17.6.1 DNA methylation levels and clinical outcomes in the Newcastle 85+ study 
 
Construction of a step-down linear regression analysis model was performed with the 
assistance of Andrew Kingston (Newcastle 85+ study statistician), using SPSS Statistics 
(version 19). The methylation level of each gene, HOXD4, TUSC3, TWIST2, HAND2, 
EPHA10, the overall mean of these 5 genes and HOXA5 were individually analysed as 
the dependent variable whilst other variables including lymphocyte percentage, previous 
history of cancer, subsequent diagnosis of cancer, gender, smoking, history of 
cardiovascular events, type II diabetes, dementia, stroke and survival were built into the 
model as independent variables. Non-significant associations were removed (exclusion 
criteria p>0.10) and only the effects of significant associations on methylation levels 
were retained (retention criteria p<0.05). 
 
2.17.6.2 DNA methylation levels and mitochondrial haplogroup in the Newcastle 
85+ study 
 
Construction of a step-down linear regression analysis model was performed with the 
assistance of Mohammad Yadegarfar (Newcastle 85+ study statistician)  using SPSS 
Statistics (version 19). The methylation level of each gene, HOXD4, TUSC3, TWIST2, 
HAND2, EPHA10 and the overall mean of these 5 genes were analysed as the dependent 
variables whilst lymphocyte percentage, gender and mitochondrial haplogroup were 
built into the model. Non-significant associations were removed (exclusion criteria 
p>0.10) and only the effects of significant associations on methylation levels were 
retained (retention criteria p<0.05). 
 76 
 
Chapter 3  – Inter-individual variation of DNA methylation in an 
elderly population 
 
3.1 Introduction 
 
The extent to which epigenetic marks vary across the population and the impact that 
such variation has on health and ageing are not clear. Therefore, in order to begin 
understand the consequence of altered DNA methylation in ageing, we performed a 
pilot study using DNA extracted from peripheral blood leukocytes of 50 volunteers in 
the Newcastle 85+ study. Our aim was to quantify the levels of promoter DNA 
methylation in this population, and to investigate the extent of inter-individual variation 
in DNA methylation levels at a panel of genes, using a Pyrosequencing-based approach. 
The purpose of this pilot study was to determine whether there was evidence of 
significant inter-individual differences in the degree of methylation at specific loci 
across the genome. Such inter-individual variation may result in reciprocal changes in 
gene expression and, therefore, in cell function. This could ultimately play a role in 
determining inter-individual variation in biological ageing and in susceptibility to age 
related disease. 
 
3.2 Selection of genes for gene specific methylation analysis 
 
A total of 18 genes were selected to act as markers of promoter methylation levels 
throughout the genome, to enable us to examine both the extent and amount of variation 
in DNA methylation levels in PBL samples from a population of 85 year olds. This 
number of genes was chosen on pragmatic grounds since it was a realistic target given 
the time intensive nature of developing and validating gene specific Pyrosequencing 
assays. 
 
Several genes were chosen because they had been the focus of previous or on-going 
study by our group and were known to be hypermethylated in haematological 
malignancies. These genes included TWIST2 (Thathia et al., 2012), TUSC3 (Scholz et 
al., 2005), HOXA4 (Strathdee et al., 2007a; Irving et al., 2011), HOXA5 (Strathdee et 
al., 2007a), HOXD4, HLXB9 (Ferguson et al., 2011) and HOXB6 (Strathdee et al., 
2007a).  
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Additional genes were selected from a literature search for genes displaying aberrant 
DNA methylation in any subtype of leukaemia with some evidence of methylation in 
normal individuals. These genes included EPHA10 (Kuang et al., 2010), HAND2 (Tong 
et al., 2010), ESR1 (Issa et al., 1996b), IGF2, p15 (Wong et al., 2000) and FZD9 
(Martin-Subero et al., 2009) .  
 
Finally, genes were chosen from a literature search for genes which display age related 
DNA methylation increases in normal tissues. These genes included APOE (Wang et 
al., 2008), RARB2 (Brait et al., 2009), RASSF1A (Dammann et al., 2005), MLH1 
(Nakagawa et al., 2001) and NKX2-5 (Kwabi-Addo et al., 2007).  
 
3.3 Pyrosequencing assay design 
 
We used Pyrosequencing to examine gene promoter methylation status. This is a highly 
quantitative method which enables the detection of low levels of, or small changes in, 
methylation levels with high accuracy. PSQ assay design software was used to design 
suitable forward, reverse and sequencing primers for each assay, based on the sequences 
which would be obtained following sodium bisulfite modification of DNA. Primer sets 
for the candidate genes were designed to amplify a region close to the transcriptional 
start site, corresponding to the promoter region or first exon of the gene, as this region is 
the most frequent site of aberrant hypermethylation in ageing (Richardson, 2003) and in 
cancer cells (van Vlodrop et al., 2011). 
 
Optimisation of PCR was performed to ensure good amplification of products for 
Pyrosequencing. Several primer sets had to be redesigned at this stage due to inadequate 
amplification including primers for ESR1 and IGF2. Once a suitable PCR amplicon was 
obtained, a small number of samples were subjected to Pyrosequencing analysis to 
ensure correct binding of the sequencing primer and that the nucleotide peaks generated 
matched the expected sequence. We experienced issues at this stage caused by 
mispriming of the specific sequencing primer to the amplicon. This problem is due to 
the decreased sequence specificity caused by sodium bisulfite modification of DNA, 
which reduces the frequency of unique sequence combinations, and affected several 
assays including HOXA4, TUSC3 and RARB2. This resulted in inconsistency in the 
position where the primer anneals on the amplicon, leading to erroneous nucleotide 
signal peaks which do not match the sequence adjacent to where the sequencing primer 
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was expected to anneal. These issues were resolved by redesigning new sequencing 
primers. Only assays which demonstrated strong PCR amplification and yielded the 
expected sequencing signals were taken forward for validation. 
 
3.4 Validation of Pyrosequencing assays 
 
Validation of each Pyrosequencing assay was carried out using a series of samples of 
known methylation status, created by diluting in vitro methylated DNA (where the 
methylation level approaches 100%) with peripheral blood lymphocytes DNA from a 
young volunteer (expected to have very low methylation), to confirm that the 
methylation values measured by the Pyrosequencer were as expected and that there was 
no preferential amplification of methylated or unmethylated DNA during PCR.  
 
For each assay, measurements across all the CpG sites (3-6 depending on the assay) 
were used to calculate an average methylation measurement for the sample. Each 
sample was tested in duplicate to verify that the assay was reproducible.  
 
Linear regression analysis was used to analyse the relationship between the methylation 
levels measured by the Pyrosequencer and the expected methylation of the known 
standards. The r
2
 value of the regression indicates how well the regression line fits the 
actual data points. An r
2
 value of 1 indicates a perfect fit. The regression lines for each 
assay illustrate a strong positive relationship between measured and expected 
methylation measurements, with all r
2
 values close to 1 (Figure 3.1). This confirms that 
the Pyrosequencing assays provide an accurate measure of true methylation in each 
assay and that the assays could then be taken forward to assess methylation levels in the 
Newcastle 85+ study participants. 
 
Initial validation was unsuccessful for several of these genes including HOXA5, TUSC3, 
TWIST2, FZD9, HOXB6 and NKX2-5, as the DNA methylation levels measured by the 
Pyrosequencer were significantly different from expected values (>5% difference in 
methylation measurement between PCR repeats of the same sample). Sequencing 
primer redesign followed by repeated validation was successful for HOXA5, TUSC3 and 
TWIST2. However, despite attempting alternative primers, we were unable to validate 
the assays for FZD9, HOXB6 and NKX2-5 and found that these assay were not 
reproducible i.e. repeat assays of the same sample gave variable results which 
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demonstrated that the assay was unlikely to be reliable for detection of small between-
sample differences (from 0-20%) in DNA methylation. 
 
APOE, EPHA10, ESR1, HAND2, HLXB9, HOXD4, MLH1, TUSC3, p15, RARB2, 
RASSF1A and TWIST2 are genes which were expected to be either unmethylated, or 
have very low levels of methylation in normal peripheral blood either due to our own 
observations, or findings reported by others (Issa et al., 1996b; Cameron et al., 1999; 
Zemlyakova et al., 2003; Wang et al., 2008; Avraham et al., 2010; Cho et al., 2010; 
Kuang et al., 2010; Tong et al., 2010; Ferguson et al., 2011; Pineda et al., 2012; Thathia 
et al., 2012). Validation of Pyrosequencing assays was performed using known 
methylated controls of 0%, 5%, 10%, 15%, 20%, 50% 70% and 100% methylation, to 
cover the whole range of methylation levels from zero to 100% and enable 
quantification of any level of methylation. More controls were included at the lower end 
of the range, since age related methylation increases in genes with already low levels of 
methylation may be small. 
 
The validation of these twelve genes demonstrated high reproducibility between repeats 
and a strongly linear relationship between expected and measured methylation across 
the whole range of methylation from 0 – 100%. The results also suggested that small 
differences in methylation (5%) can be successfully detected by these Pyrosequencing 
assays (Figure 3.1).  
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APOE Assay Validation: Expected and Measured Methylation
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EPHA10 Assay Validation: Expected and Measured Methylation
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ESR1 Assay Validation: Expected and Measured Methylation
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HAND2 Assay Validation: Expected and Measured Methylation
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HLXB9 Assay Validation: Expected and Measured Methylation
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HOXD4 Assay Validation: Expected and Measured Methylation
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MLH1 Assay Validation: Expected and Measured Methylation
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TUSC3 Assay Validation: Measured and Expected Methylation
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p15 Assay Validation: Expected and Measured Methylation
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RARB2 Assay Validation: Expected and Measured Methylation
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RASSF1A Assay Validation: Expected and Measured Methylation
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Twist2 Assay Validation: Measured & Expected Methylation
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Figure 3.1: Validation of Pyrosequencing assays using for twelve loci with low 
levels of methylation in normal PBL DNA.  
Expected DNA methylation controls were created by mixing normal PBL DNA with in 
vitro methylated DNA prior to PCR amplification. Linear regression analysis was 
performed by plotting the expected methylation of each sample against the methylation 
levels measured by the PyroMark MD instrument, with all assays demonstrating a 
robust positive relationship between these measurements (respective r
2
 values shown on 
each graph), confirming that a range of methylation levels from 0-100% can be reliably 
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quantified. All samples were tested in duplicate and an average of 3-6 CpG sites 
calculated.  
 
Due to differences in the intrinsic methylation status of certain genes which are not 
low/unmethylated in normal peripheral blood (including HOXA4, HOXA5 and the 
imprinted gene IGF2), the validation curves for these assays were performed in a 
similar fashion, but with known standards primarily covering the range from 50-100%. 
 
Normal IGF2 expression is controlled by imprinting, specifically the maternal allele is 
densely methylated whilst the paternal allele remains free of methylation (Giannoukakis 
et al., 1993; Issa et al., 1996a). The peripheral blood leukocyte (PBL) sample used to 
create standards of known methylation represents the in vivo methylation status, which 
is around 50% in the case of IGF2. For validation of this gene the controls used were 
50%, 65%, 70%, 75%, 80%, 85% and 100% methylation and the data in Figure 3.2A 
demonstrate successful validation of this assay. 
 
We had expected that the promoter of HOXA4 would be unmethylated (Strathdee et al., 
2004b), but when carrying out validation of this assay using 0%, 5%, 10%, 15%, 20%, 
50% 70% and 100% controls, the measured methylation in normal PBL samples 
isolated from young volunteers was much higher than anticipated, at around 50%. To 
test whether this was due to an artefact of the Pyrosequencing measurement, cloned 
HOXA4 mRNA sequence which had been inserted into a vector was sodium bisulfite 
modified. This represents unmethylated HOXA4 sequence as the procedure of cloning 
requires a PCR step during which methylation marks are lost prior to sodium bisulfite 
modification. Subsequent Pyrosequencing analysis of this sequence revealed an average 
methylation of 3.5%, suggesting that the assay is able to accurately identify sequences 
which are unmethylated or exhibit low levels of DNA methylation, so it is likely that 
the high methylation observed in the PBL samples from the young volunteers is a true 
indication of high methylation levels in vivo. Due to the intrinsic methylation present in 
normal PBL samples, the methylation standards used represent expected methylation 
levels were 50%, 52.5%, 55%, 57.5%, 60%, 75%, 85% and 100% at the HOXA4 locus 
and the measured methylation levels fit with this pattern (Figure 3.2B). In agreement 
with my finding, a recent publication reported approximately 60% methylation in 
HOXA4 in DNA from normal white blood cells (Avraham et al., 2010). 
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The promoter region of the HOXA5 gene has around 50% in normal haematopoietic cell 
types (Strathdee et al., 2007b). Therefore the known methylation standards used for 
validation of this gene were 50%, 65%, 70%, 75%, 80%, 85% and 100% (Figure 3.2C). 
 
After Pyrosequencing validation, a panel of 15 genes in total remained for assessment 
of methylation levels in DNA from participants in the Newcastle 85+ study. 
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IGF2 Assay Validation: Expected and Measured Methylation
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HOXA4 Assay Validation: Expected and Measured Methylation
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Figure 3.2: Validation of Pyrosequencing assays using for three loci which are 
partially methylated in normal PBL DNA.  
The IGF2 DMR (A) and the HOXA4 (B) and HOXA5 (C) promoters are typically 
around 50% methylated in normal peripheral blood. Expected methylation controls were 
created by mixing normal PBL DNA with in vitro methylated DNA prior to PCR 
amplification. Linear regression analysis was performed by plotting the expected 
methylation of each sample against the methylation levels measured by the PyroMark 
MD instrument, with these assays demonstrating a strong positive relationship between 
these measurements (respective r
2
 values shown on each graph). All samples were 
tested in duplicate and an average of 3-6 CpG sites calculated. 
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3.5 Pyrosequencing results reveal the presence of genes with inter-individual 
variation 
 
Having established the reliability of the Pyrosequencing assays for accurate 
quantification of DNA methylation levels, DNA samples from a subset of 50 Newcastle 
85+ study participants were selected at random to perform a pilot study, examining 
DNA methylation status at the panel of 15 gene promoters in an 85 year old population. 
 
For each sample, PCR was performed in duplicate before being subjected to 
Pyrosequencing analysis. Reproducibility of the Pyrosequencing measurement itself 
was tested by repeating the Pyrosequencing measurement on exactly the same sample 
(i.e. same PCR amplified product) which revealed highly consistent results for all 
assays, typically less than 1% difference between the two measures. As an example, the 
results of the TWIST2 gene tested in the Newcastle 85+ population demonstrate very 
small differences; an average of 0.29 ± 0.29% [mean ± SD], difference in DNA 
methylation measurements between two separate Pyrosequencing runs. Likewise, two 
separate PCR reactions using the same sample template also exhibit high levels of 
reproducibility, typically less than 3% difference between the two PCR reactions with 
an average of 1.46 ± 1.1% difference in TWIST2 DNA methylation levels between 
repeats (Table 3.1). More detailed data can be found in the appendix (A2.1 and A2.2). 
 
 
Duplicate analysis of the 
same PCR product 
Analysis of duplicate PCR 
products 
Number of samples 23 25 
Range of methylation 
difference (%) 
0-1.05 0.18-4.05 
Mean difference (%) 0.29 1.46 
Standard deviation (%) 0.29 1.10 
 
Table 3.1: Reproducibility of DNA methylation measurements by Pyrosequencing 
after duplicate analysis of the same PCR product and duplicate PCR products for 
the TWIST2 gene 
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Any sample which had >5% methylation difference between PCR repeats was repeated 
a third time and the two repeats which were within 5% of each other used to calculate 
the sample average. If methylation difference of >5% persisted after three repeats, the 
sample was discarded from the analysis due to low reproducibility. 
 
Table 3.2 describes the DNA methylation levels measured at all fifteen gene promoters 
for all 50 participants. The two most variably methylated genes were HOXA5 
(measurements from 28-92%) and HOXA4 (measurements from 13-64%), followed by 
the imprinted gene IGF2 (measurements from 30-50%) which showed a much wider 
range of methylation measurements than any of the other loci (Figure 3.3). The extreme 
range of methylation observed for the two HOXA genes may be related to the highly 
variable methylation we have observed across the region of the HOXA cluster. There 
are multiple regions of 0, 50% or 100% methylation, which presumably is required for 
normal control of this gene cluster which may become less tightly controlled at an 
elderly age. We tested a small number of PBL DNA samples from young adults and 
found methylation levels at the HOXA5 proximal promoter are close to 50% and show 
far lesser inter individual variation (52.5 ± 6.1% [mean ± SD]), which is clearly 
different from the measurements we obtained for the 85+ study participants (Table 3.3). 
The HOXA4 promoter appears similarly more tightly controlled in the younger 
volunteers than the 85+ population, with the exception of one sample for which the 
DNA methylation levels were unusually low, which has a dramatic effect on the mean 
and standard deviation measurements given the low number of samples (47.7 ± 11.5% - 
Table 3.4). In addition, at the DMR of IGF2, although DNA methylation levels varied 
from 30-50% in this population of 85 year olds, we also observed similar variation at 
this IGF2 locus when we tested a small number of PBL DNA samples from younger 
individuals (45 ± 4.7%) which suggests that the variation we observed in the 85 year 
olds participants is not unusual or age associated (Table 3.5). These three genes all 
represent loci with partially methylated promoters. The fact that methylation is already 
pre-existing may mean that increased variability is observed due to the fact that 
methylation can change in two directions, either increase or decrease; as opposed to 
genes with an unmethylated promoter region which can only show a methylation 
change in one direction (increase). 
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Gene Methylation range (%) Mean Methylation (%) Standard Deviation (%) 
HOXA5 28-92 61.5 15.1 
HOXA4 13-64 41.5 11.8 
HOXD4 7-35 14.8 6.0 
IGF2 30-50 40.2 4.4 
EPHA10 7-31 12.0 3.9 
TUSC3 4-22 8.9 3.4 
TWIST2 4-20 8.4 3.3 
HAND2 2-18 7.3 2.8 
HLXB9 1-15 3.3 2.1 
APOE 6-13 8.4 1.9 
p15 2-12 4.9 1.9 
ESR1 4-11 5.5 1.6 
RARB2 1-5 2.5 1.0 
RASSF1A 1-4 2.5 0.7 
MLH1 1-2 1.3 0.3 
 
Table 3.2: Properties of fifteen genes analysed by Pyrosequencing in 50 PBL 
samples from the Newcastle 85+ study participants 
For each gene, the minimum and maximum DNA methylation levels of all the samples 
is shown, alongside average DNA methylation calculated from all CpG sites in all 
samples, and the standard deviation as a measure of variation. 
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Methylation of HOXA4 in 50 PBL DNA Newcastle 85+ Study Samples
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Methylation of IGF2 in 50 PBL DNA Newcastle 85+ Study Samples
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Figure 3.3: DNA methylation levels of HOXA5, HOXA4 and IGF2 in PBL samples 
from the Newcastle 85+ population 
HOXA5, HOXA4 and IGF2 are the three most variably methylated genes measured by 
Pyrosequencing. 
 89 
 
Sample Mean Methylation (%) 
PBL 1 50.8 
PBL 2 52.3 
PBL 3 49.6 
PBL 4 47.3 
PBL 5 48.5 
PBL 6 55.8 
PBL 7 66.1 
PBL 8 50.0 
Range 47-66 
Mean 52.5 
SD 6.1 
 
Table 3.3: DNA methylation levels of HOXA5 in PBL samples from eight young 
volunteers measured by Pyrosequencing 
 
 
Sample Mean Methylation (%) 
PBL 1 43.4 
PBL 3 53.6 
PBL 4 59.4 
PBL 5 53.6 
PBL 6 24.1 
PBL 7 49.8 
PBL 8 50.2 
Range 24-59 
Mean 47.7 
SD 11.5 
 
Table 3.4: DNA methylation levels of HOXA4 in PBL samples from seven young 
volunteers measured by Pyrosequencing 
 
 
Sample Mean Methylation (%) 
PBL 2 46.2 
PBL 3 45.3 
PBL 4 36.1 
PBL 5 49.4 
PBL 6 42.8 
PBL 7 50.0 
PBL 8 45.3 
Range 36-50 
Mean 45.0 
SD 4.7 
 
Table 3.5: DNA methylation levels of IGF2 in PBL samples measured from seven 
young volunteers by Pyrosequencing 
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Of the remaining twelve genes with a theoretically unmethylated promoter region, five 
were noted to have both increased DNA methylation with a considerable amount of 
inter-individual variation (Figure 3.4). These genes were HOXD4 (14.8 ± 6.0%), 
EPHA10 (12.0 ± 3.9%), TUSC3 (8.9 ± 3.4%), TWIST2 (8.4 ± 3.3%) and HAND2 (7.3 ± 
2.8%).  
 
Other genes including HLXB9 (3.3 ± 2.1%), APOE (8.4 ± 1.9%), p15 (4.9 ± 1.9%) and 
ESR1 (5.5 ± 1.6%) showed some evidence towards variability although these genes 
tended to show less inter-individual variation than the genes described above, and 
overall methylation levels were typically lower at these loci (Figure 3.5). 
 
Finally, the remaining three genes: RARB2 (2.5 ± 1%), RASSF1A (2.5 ± 0.67%) and 
MLH1 (1.3 ± 0.3%), exhibited either very little methylation or low variation in any of 
the pilot study participants (Figure 3.6). The amount of methylation observed here is 
likely to be below the limit of detection for the Pyrosequencing assay so we could not 
be confident that any observation of inter-individual variation at these loci is accurate. 
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Methylation of EPHA10 in 50 PBL DNA Newcastle 85+ Study Samples
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Methylation of TUSC3 in 50 PBL DNA Newcastle 85+ Study Samples
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Methylation of TWIST2 in 50 PBL DNA Newcastle 85+ Study Samples
Sample ID
N
E
0
0
0
0
0
0
3
7
N
E
0
0
0
0
0
0
4
5
N
E
0
0
0
0
0
0
5
0
N
E
0
0
0
0
0
0
7
8
N
E
0
0
0
0
0
0
8
0
N
E
0
0
0
0
0
0
8
4
N
E
0
0
0
0
0
1
0
8
N
E
0
0
0
0
0
1
1
2
N
E
0
0
0
0
0
1
1
9
N
E
0
0
0
0
0
1
2
5
N
E
0
0
0
0
0
1
2
8
N
E
0
0
0
0
0
1
4
8
N
E
0
0
0
0
0
1
6
1
N
E
0
0
0
0
0
1
6
6
N
E
0
0
0
0
0
1
8
1
N
E
0
0
0
0
0
1
8
5
N
E
0
0
0
0
0
1
8
6
N
E
0
0
0
0
0
1
9
3
N
E
0
0
0
0
0
1
9
4
N
E
0
0
0
0
0
1
9
9
N
E
0
0
0
0
0
2
0
5
N
E
0
0
0
0
0
2
1
3
N
E
0
0
0
0
0
2
2
1
N
E
0
0
0
0
0
3
0
5
N
E
0
0
0
0
0
3
1
2
N
E
0
0
0
0
0
3
1
3
N
E
0
0
0
0
0
3
1
6
N
E
0
0
0
0
0
3
2
9
N
E
0
0
0
0
0
3
3
2
N
E
0
0
0
0
0
3
3
4
N
E
0
0
0
0
0
3
4
0
N
E
0
0
0
0
0
3
4
1
N
E
0
0
0
0
0
3
4
3
N
E
0
0
0
0
0
3
6
5
N
E
0
0
0
0
0
3
6
7
N
E
0
0
0
0
0
3
7
6
N
E
0
0
0
0
0
4
1
4
N
E
0
0
0
0
0
5
7
4
N
E
0
0
0
0
0
5
8
7
N
E
0
0
0
0
0
6
5
8
N
E
0
0
0
0
0
6
6
4
N
E
0
0
0
0
0
6
8
4
N
E
0
0
0
0
0
7
4
5
N
E
0
0
0
0
0
7
7
4
N
E
0
0
0
0
0
8
1
9
N
E
0
0
0
0
0
9
1
2
N
E
0
0
0
0
0
9
1
5
N
E
0
0
0
0
0
9
1
7
N
E
0
0
0
0
1
2
8
5
N
E
0
0
0
0
1
9
8
1
M
e
th
y
la
ti
o
n
 (
%
)
0
5
10
15
20
25
 
 
Methylation of HAND2 in 50 PBL DNA Newcastle 85+ Study Samples
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Figure 3.4: DNA methylation levels of HOXD4, EPHA10, TUSC3, TWIST2 and 
HAND2 genes in PBL samples from the Newcastle 85+ study participants  
These five genes display significant inter-individual variation in DNA methylation 
levels measured by Pyrosequencing. Lack of reproducible methylation measurements 
meant one sample was excluded from HOXD4 result. 
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Methylation of HLXB9 in 50 PBL DNA Newcastle 85+ Study Samples
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Methylation of APOE in 25 PBL DNA Newcastle 85+ Study Samples
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Methylation of p15 in 50 PBL DNA Newcastle 85+ Study Samples
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Methylation of ESR1 in 25 PBL DNA Newcastle 85+ Study Samples
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Figure 3.5: DNA methylation levels of HLXB9, APOE, p15 and ESR1 genes in PBL 
samples from the Newcastle 85+ study participants.  
These four genes display limited inter-individual variability of methylation levels 
measured by Pyrosequencing. Pyrosequencing of the APOE and ESR1 promoter was 
performed for only 25 Newcastle 85+ study participants. 
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Methylation of RARB2 in 50 PBL DNA Newcastle 85+ Study Samples
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Methylation of RASSF1A in 49 PBL DNA Newcastle 85+ Study Samples
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Methylation of MLH1 in 49 PBL DNA Newcastle 85+ Study Samples
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Figure 3.6: DNA methylation levels of RARB2, RASSF1A and MLH1 genes in PBL 
samples from the Newcastle 85+ Study participants 
These three genes exhibit both low levels of methylation and a lack of inter-individual 
variation, measured by Pyrosequencing. Lack of reproducible methylation 
measurements meant one sample was excluded from RASSF1A and MLH1 result. 
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The results of the pilot study indicate that aberrant DNA methylation was fairly 
common at many of the loci examined and that substantial amounts of methylation were 
detected in some individuals at certain gene promoters which are expected to be free of 
methylation. In addition to this, we found DNA methylation was also highly variable 
between individuals of the same elderly age, within this population.  
 
These observations imply that the propensity to aberrantly hypermethylate CpG islands, 
at least at certain loci, varies between individuals of the same age within the study 
group; and therefore may underlie, at least partially, the vast differences between 
individuals in their susceptibility to age related disease.  
 
3.6 Features of variably methylated genes 
 
3.6.1 DNA methylation levels between pairs of genes are strongly correlated 
 
We performed pairwise correlations of DNA methylation levels for each of the twelve 
genes with evidence of variation for all the fifty individuals in the Newcastle 85+ study, 
using the Pearson correlation coefficient test. The genes were assessed in two groups; 
one composed of nine genes (TWIST2, HOXD4, EPHA10, TUSC3, HAND2, p15, 
HLXB9, ESR1 and APOE) for which the promoter regions typically have low levels of 
DNA methylation. The other group contained those genes which are regulated by DNA 
methylation (IGF2, HOXA5 and HOXA4); therefore the promoter regions of these genes 
are partially methylated in normal haematopoietic cells.   
 
For the first group of nine genes, DNA methylation levels were strongly positively 
correlated within individuals with high significance at the majority of genes (Table 3.6), 
meaning that individuals with high levels of DNA methylation at one loci, are likely to 
have high levels of methylation at any other loci. This suggests that a subset of the 
Newcastle 85+ study participants exhibited high DNA methylation levels at most/all of 
the genes assessed. Consequently, when methylation was averaged across multiple 
genes, the overall levels of methylation also varied widely in this population, since 
individuals were likely to have high or low methylation at several genes simultaneously. 
The exceptions to this were APOE and p15. APOE was not significantly correlated with 
any other loci after correction for multiple comparisons. This may be due to the fact that 
all the other genes have evidence of hypermethylation in leukaemia, whereas APOE 
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does not, suggesting the acquisition of methylation for this gene in haematopoietic cells 
may be different to the other genes. Similarly, DNA methylation levels of p15 were not 
significantly correlated with TWIST2, EPHA10, HLXB9 or ESR1 and only displayed a 
weakly significant association with TUSC3 or HAND2 methylation levels, suggesting 
that this gene does not show the same pattern of methylation acquisition as the other 
seven genes in this group. This may be partly due to the observation that p15 
methylation is more frequently found to be methylated in myeloid forms of leukaemia, 
whereas the other genes are associated with lymphoid leukaemia, demonstrating the 
differential DNA methylation status of specific genes in distinct haematopoietic cell 
types.  
 
The three genes with partially methylated promoters, HOXA4, HOXA5 and IGF2, which 
demonstrated significant inter-individual variation in DNA methylation, did not show 
any significant correlation either with each other, or any of the other variably 
methylated genes which demonstrated pairwise correlations with each other (Table 3.7).  
 
These results show that not only are DNA methylation levels highly variable in the 
Newcastle 85+ population, also that individuals exhibiting high DNA methylation levels 
at one loci have significantly more chance of exhibiting high levels at other loci, 
implying that the propensity to aberrantly methylate CpG islands varies within the study 
group. This pattern is reminiscent of the “CpG Island methylator phenotype” a term first 
used to describe the methylation of multiple loci simultaneously in a subset of colon 
cancer cells. Such tumours may be liable to hypermethylate several important tumour 
suppressor genes concurrently and contain numerous transcriptionally inactivated genes 
(Toyota et al., 1999). The results suggest that a similar acquisition of methylation at 
multiple loci may also be a feature of normal haematopoietic cells in an elderly 
population.
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Table 3.6: Pair-wise correlations of PBL DNA methylation levels between nine variably methylated loci from the Newcastle 85+ study 
DNA methylation data for 50 participants (25 individuals for ESR1 and APOE) was correlated at each pair of loci using Pearson test of 
correlation. The Pearson correlation coefficient (r) and corresponding p values are shown. The majority of correlations are highly significant. 
Black p value = not significant (NS), Orange p value = significant at <0.05 level, Red p value = significant at <0.0014 level after performing 
Bonferroni correction for multiple comparisons. 
 TWIST2 HOXD4 EPHA10 TUSC3 HAND2 p15 HLXB9 ESR1 
TWIST2         
HOXD4 
r = 0.51 
p = 0.0002 
       
EPHA10 
r = 0.55 
p = 0.00004 
r = 0.36 
p = 0.01 
      
TUSC3 
r = 0.49 
p = 0.0003 
r = 0.72 
p = 5.0E-09 
r = 0.31 
p = 0.03 
     
HAND2 
r = 0.43 
p = 0.001 
r = 0.64 
p = 7.0E-07 
r = 0.38 
p = 0.006 
r = 0.64 
p = 0.000002 
    
p15 
r = 0.24 
p = 0.09 
r = 0.51 
p = 0.0001 
r = 0.18 
p = 0.27 
r = 0.39 
p = 0.005 
r = 0.31 
p = 0.03 
   
HLXB9 
r = 0.60 
p = 0.00003 
r = 0.60 
p = 0.00006 
r = 0.30 
p = 0.04 
r = 0.54 
p = 0.00006 
r = 0.59 
p = 0.000007 
r = 0.28 
p = 0.05 
  
ESR1 
r = 0.58 
p = 0.002 
r = 0.77 
p = 7.7E-06 
r = 0.44 
p = 0.026 
r = 0.81 
p = 9.9E-07 
r = 0.77 
p = 5.4E-06 
r = 0.35 
p = 0.08 
r = 0.78 
p = 3.7E-06 
 
APOE 
r =  0.16 
p = 0.22 
r =  0.33 
p = 0.06 
r =  0.20 
p = 0.17 
r =  0.33 
p = 0.05 
r = -0.09 
p = 0.33 
r = 0.09 
p = 0.33 
r =  0.25 
p = 0.12 
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Table 3.7: Pair-wise correlations of HOXA4, HOXA5 and IGF2 PBL DNA 
methylation levels with other variably methylated genes in the Newcastle 85+ 
Study 
DNA methylation data for fifty participants (25 individuals for ESR1) was correlated at 
each pair of loci using the Pearson test of correlation. The Pearson correlation 
coefficient (r) and corresponding p values are shown. The results show mostly weak or 
no correlation Black p value = NS, Orange p value = significant at <0.05 level, Red p 
value = significant at <0.0019 level after performing Bonferroni correction for multiple 
comparisons. 
  
 IGF2 HOXA4 HOXA5 
IGF2    
HOXA4 r =  0.02 
p =  0.87 
  
HOXA5 r =  -0.04 
p =  0.79 
r =  -0.12 
p =  0.42 
 
TWIST2 r =  -0.19 
p =  0.18 
r =  0.12 
p =  0.40 
r =  0.21 
p =  0.15 
HOXD4 r =  -0.22 
p =  0.13 
r =  0.07 
p =  0.63 
r =  0.10 
p =  0.49 
EPHA10 r =  -0.29 
p =  0.03 
r =  0.09 
p =  0.51 
r =  0.39 
p =  0.005 
TUSC3 r =  -0.24 
p =  0.09 
r =  0.05 
p =  0.68 
r =  -0.02 
p =  0.87 
HAND2 r =  -0.27 
p =  0.05 
r =  0.07 
p =  0.59 
r =  0.22 
p =  0.13 
p15 r =  0.03 
p =  0.81 
r =  -0.007 
p =  0.96 
r =  -0.09 
p =  0.53 
HLXB9 r =  -0.26 
p =  0.06 
r =  -0.06 
p =  0.64 
r =  0.09 
p =  0.52 
ESR1 r =  -0.20 
p =  0.33 
r =  -0.06 
p =  0.75 
r =  0.02 
p =  0.91 
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3.6.2 Genes susceptible to age-related and cancer related DNA methylation 
acquisition are overlapping 
 
For the 8 loci, TWIST2, HOXD4, EPHA10, TUSC3, HAND2, HOXA4, HOXA5 and 
IGF2, which exhibit considerable susceptibility to inter-individual variation in DNA 
methylation levels, there is also evidence that these same genes become 
hypermethylated in haematological malignancies. 
 
For the four genes which showed some evidence of variability APOE, p15, HLXB9 and 
ESR1, there is some previous evidence suggesting abnormal methylation patterns of 
p15, HLXB9 and ESR1 in haematological malignancies, but none for the APOE gene.  
 
Of the remaining non variably methylated genes, RARB2, MLH1 and RASSF1A 
although there is copious evidence for either their hypermethylation status in solid 
tumours, or the presence of an age associated increase in methylation in normal tissues, 
there is limited evidence that they are subjected to aberrant methylation in leukaemia. 
The age related DNA methylation increases in these genes which have been observed in 
other studies may be tissue specific and not present in peripheral blood leukocytes. 
 
Therefore these results suggest that the targets for both age related methylation and 
aberrant DNA methylation in haematological malignancies may be overlapping. This 
finding has been supported by the outcomes from other recent studies (Rakyan et al., 
2010; Teschendorff et al., 2010), although the increased DNA methylation levels 
observed in this elderly population are less dramatic than those occurring in cancer 
cells, which typically have very high levels of methylation (>50%).  
 
3.6.3 Bisulfite sequencing reveals the presence of densely methylated alleles 
 
The results presented so far describe variable DNA methylation levels in an elderly 
population; however it is unclear from the experimental technique used, what the 
pattern of methylation is like at the allelic level. This is important with regards to how 
DNA methylation affects gene transcription and expression since DNA methylation 
functions at an allelic level. Pyrosequencing measures the average amount of 
methylation at a particular CpG site by detecting whether a methylated cytosine is 
present or not at a specific CpG site in one of the vast number of alleles and cells 
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represented within a particular DNA sample. Using this technique, it is not possible to 
determine whether consecutive CpG sites within an individual allele have the same 
methylation status (methylated or unmethylated across consecutive sites); or whether 
methylation is essentially random at any CpG site in any particular allele.  
 
This is illustrated by the simplified scenario presented in Figure 3.7. This example 
demonstrates two different samples in which 5 consecutive CpG sites are represented 
across ten individual alleles. Using Pyrosequencing analysis, both samples will measure 
30% methylation at each of the five CpG sites, but the distribution of methylation across 
the alleles is very different. In sample 1, 30% of the alleles have complete methylation 
of consecutive CpG sites, whilst the remaining 70% are free of methylation. Sample 2 
contains only partially methylated alleles, with sporadically methylated CpG sites. 
These two scenarios would likely have a very different biological consequence. An 
allele which is completely methylated will almost certainly result in transcriptional 
silencing, such as in the case of imprinted genes (Li et al., 1993), X inactivation (Kelkar 
and Deobagkar, 2010), cell type specific genes (De Smet et al., 1999) and tumour 
suppressor genes in cancer (Baylin, 2005). However, the effect of partial methylation on 
gene expression is not clear (Costello et al., 1996; Qin et al., 2004). A study examining 
the p15 promoter in leukaemia samples found that gene inactivation could be achieved 
by the presence of alleles with a methylation density of 30-40%, although samples 
comprised of alleles of lower methylation density than this still expressed p15, 
suggesting the existence of a methylation density threshold at which a gene is no longer 
expressed (Cameron et al., 1999). Therefore it is more likely that the scenario in sample 
1, with its densely methylated alleles, will produce a negative effect on gene 
transcription than sample 2, although it is possible that partial methylation could affect 
expression levels of the gene (Nile et al., 2008).  
 
In order to determine DNA methylation patterns at the allelic level in PBL DNA 
samples from the Newcastle 85+ study population, we examined the promoter region of 
two variably methylated genes, TWIST2 and HOXD4, by bisulfite sequencing of 
multiple alleles obtained from an individual with either high or low DNA methylation 
levels at these genes (determined by Pyrosequencing).  For each sample and gene, PCR 
products were cloned into a pCR®2.1 vector and transfected into competent E. coli 
cells. Each clone isolated from a growing colony contains a single PCR amplified 
sequence, which is representative of a single allele from the whole sample. TWIST2 
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methylation was analysed in one individual, DNA sample NE00000185 (20% 
methylation – high). HOXD4 methylation was analysed in three individuals, DNA 
samples NE00000185 (35% methylation – high), NE00000205 (26% methylation – 
high) and NE00000334 (8% methylation – low).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7: Allelic methylation patterns in two hypothetical samples 
Each sample is represented by ten different alleles which comprise of various 
possibilities for methylation at consecutive CpG sites. Black dots represent methylated 
CpG sites and white dots unmethylated CpG sites. The average amount of methylation 
measured by Pyrosequencing of both sample 1 and 2 would be 30%. Sample 1 is 
comprised of 30% completely hypermethylated alleles, whereas for sample 2 only 
unmethylated or partially methylated alleles exist. 
 
 
The sequencing results for the TWIST2 locus suggest that the 20% methylation observed 
in participant NE00000185 by Pyrosequencing consists of mixture of alleles which are 
either completely unmethylated/have very low levels of DNA methylation, or have very 
dense methylation in the region (Figure 3.8). 
 
The results for the HOXD4 locus suggest that the participants with high levels of DNA 
methylation at this gene (NE00000185 & NE00000205) also contain a similar 
combination of highly methylated alleles alongside those which are unmethylated 
(Figure 3.9A and B). However the highly methylated alleles are not as densely 
methylated as those observed in the TWIST2 region. There are fewer highly methylated 
alleles in participant NE00000205 than NE00000185, which was reflected by the lower 
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overall methylation DNA measurement of this individual by Pyrosequencing. In 
addition, no heavily methylated alleles were detectable in our analysis of participant 
NE00000334 and methylation was observed as a sporadic event at individual CpG sites 
(Figure 3.10).  
 
 
 
 
Figure 3.8: Bisulfite sequencing results at the TWIST2 promoter of PBL DNA 
sample NE00000185 from the Newcastle 85+ study  
Bisulfite sequencing results of 23 consecutive CpG sites within the TWIST2 promoter 
represented by 21 alleles from sample NE00000185. Methylated CpG sites are 
represented by black circles an unmethylated CpG sites by a white circles. The 
sequencing results indicate a combination of either very densely methylated or 
completely unmethylated alleles 
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Figure 3.9: Bisulfite sequencing results at the HOXD4 promoter of PBL DNA 
samples NE00000185 and NE00000205 from the Newcastle 85+ study 
Bisulfite sequencing results of 13 consecutive CpG sites within the HOXD4 promoter 
represented by (A) 16 alleles from DNA sample NE00000185. The sample was 
comprised of alleles with high levels of methylation (>50% CpGs methylated) and those 
with low levels of methylation. There are more densely methylated alleles in this 
sample than sample NE00000205; and (B) 14 alleles from DNA sample NE00000205. 
This sample again contained a mixture of alleles with either high or low levels of 
methylation but there are fewer highly methylated alleles than DNA sample 
NE00000185. Methylated CpG sites are represented by black circles and unmethylated 
CpG sites by white circles. 
 
A B 
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Figure 3.10: Bisulfite sequencing results at the HOXD4 promoter of PBL DNA 
sample NE00000334 from the Newcastle 85+ study 
Bisulfite sequencing results of 13 consecutive CpG sites within the HOXD4 promoter 
represented by 40 alleles from DNA sample NE00000334. All alleles are either 
completely unmethylated, or contain very low levels of sporadic methylation. 
Methylated CpG sites are represented by black circles and unmethylated CpG sites by 
white circles. 
 
 
Although the total number of clones sequenced in this analysis was fairly small, the 
results imply that significant numbers of alleles (10-20%) will be transcriptionally 
inactivated due to abnormal DNA hypermethylation in Newcastle 85+ study 
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participants with high methylation levels but these alleles are not present (or present at 
very low levels) in individuals with low methylation. 
 
3.7 DNA methylation levels are correlated with proportion of lymphocytes 
 
Recently published data has suggested that lymphocytes exhibit increased levels of 
methylation at differentially methylated regions compared with monocytes (Rakyan et 
al., 2010). Many of the genes examined in this study have been shown to be associated 
specifically with lymphoid and not myeloid leukaemia; therefore it was important to 
ascertain whether the proportion of lymphocytes in the Newcastle 85+ study peripheral 
blood samples was related to the DNA methylation levels observed at the five variably 
methylated genes. The percentage of lymphocytes within the total white blood cell 
population was calculated using measurements from full blood counts (Chapter 2.1) and 
was correlated to the DNA methylation levels at the TWIST2, HOXD4, EPHA10, 
TUSC3 and HAND2 promoter region for each participant. The resulting correlations are 
to some extent consistent with the idea that lymphocytes may harbour higher levels of 
methylation at the 5 variable genes, seen by a positive correlation between percentage of 
lymphocytes in an individual and methylation levels at any gene. However, the 
correlations appear to be fairly weak, are not statistically significant at most of the loci, 
only at HOXD4 (r=0.43, p=0.002) and TUSC3 (r=0.47, p=0.005) (Table 3.8 and Figure 
3.11). Therefore lymphocyte percentage appears to explain only a minority of the 
extensive variation seen in methylation levels in these 50 individuals within the 
Newcastle 85+ study population.  
 
In addition, there is extensive data within the Newcastle 85+ study including flow 
cytometry characterisation of specific leukocyte subtypes within individual blood 
samples. Calculation of the Pearson correlation coefficient indicated no relationship 
between a participants average DNA methylation level and B-cell number in the pilot 
study Newcastle 85+ study samples (r=-0.12, p=0.41). 
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 TWIST2 HOXD4 EPHA10 TUSC3 HAND2 Average 
Percentage of 
lymphocytes 
r = 0.22 
p = 0.13 
r = 0.43 
p = 0.002 
r = 0.09 
p = 0.53 
r = 0.47 
p = 0.005 
r = 0.24 
p = 0.10 
r = 0.38 
p = 0.006 
 
Table 3.8: Correlation between the DNA methylation levels of TWIST2, HOXD4, 
EPHA10, TUSC3 and HAND2 and the percentage of lymphocytes measured in the 
same individual.  
The Pearson correlation coefficient (r) and corresponding p value was calculated for 
each locus. Black p value = NS, Red p value = significant at <0.008 level after 
performing Bonferroni correction for multiple comparisons. 
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Figure 3.11: Relationship between the DNA methylation levels of TWIST2, 
HOXD4, EPHA10, TUSC3 and HAND2 and the percentage of lymphocytes 
measured in the same individual in the Newcastle 85+ study 
Methylation values of TWIST2, HOXD4, EPHA10, TUSC3, HAND2 and the overall 
average DNA methylation level of the five genes were plotted against lymphocyte 
percentage calculated from full blood counts (Chapter 2.1). The linear regression line 
and r
2
 value indicate a fairly weak relationship at most loci.  
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3.8 DNA methylation measurements are stable over 18 months 
 
In order for DNA methylation to be considered a useful measurement or biomarker to 
be analysed in relation to health outcomes, it should be relatively stable without 
fluctuations over a short space of time. In order to test this, Pyrosequencing 
measurements of TUSC3, TWIST2, HOXD4, HAND2 and EPHA10 was performed for 
37 of the 50 pilot study participants for which a DNA sample was available at phase II 
of the Newcastle 85+ study, 18 months after initial sample collection at phase I. The 
expectation was that DNA methylation measurements should have changed very little in 
such a short space of time in most individuals, as previous studies have shown stability 
of gene promoter methylation, even over a much longer period of 11-20 years (Talens et 
al., 2010). 
 
Unfortunately, although PBL DNA (i.e. total white blood cells) was analysed in phase I 
this was not available at phase II and DNA from peripheral blood mononuclear cells 
(PBMCs) was obtained instead. This led to some important differences in DNA 
methylation levels due to the differences in cell type composition. Typically a high 
percentage of cells in a PBL sample are neutrophils with the remainder being 
lymphocytes, monocytes, eosinophils and basophils, whereas PBMCs are comprised of 
the same cells but excluding neutrophils. The fact that the proportion of lymphocytes in 
the PBMC sample is increased compared to a PBL sample, in addition to recently 
published data suggesting lymphocytes exhibit increased methylation levels of 
differentially methylated regions, led us to the anticipate that DNA methylation 
measurements will be higher in samples consisting of just PBMCs compared to PBLs. 
For this reason, the methylation levels at phase I with phase II cannot be directly 
compared and instead the Pearson test of correlation was used to ascertain the 
relationship between methylation levels in the same individual at the two different 
phases. The results show that methylation levels at phase I are much lower than phase II 
as predicted based on the different cell compositions (Table 3.9), but the correlations 
between phase I and phase II measurements are strong and highly significant (Table 
3.10 and Figure 3.12). This means that DNA methylation measurements are likely to be 
stable over time, as fluctuations in DNA methylation within an individual over time 
would result in a lack of significant relationship between DNA methylation at phase I 
and phase II across the whole population.  
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Table 3.9: Comparison of DNA methylation properties at the HOXD4, EPHA10, TUSC3, TWIST2 and HAND2 promoter in the phase I PBL 
samples and Phase II PBMC samples from the Newcastle 85+ study participants 
Methylation was measured in the 37 samples for which DNA from both phases was available. The mean, minimum and maximum methylation levels 
for each gene are shown alongside standard deviation as a measure of variation 
 
 
 
 
 
 
 
Table 3.10: Correlation between DNA methylation levels at the, TWIST2, HOXD4, EPHA10, TUSC3 and HAND2 promoter in Phase I PBL 
DNA sample and Phase II PBMC samples from the Newcastle 85+ study participants 
The Pearson correlation coefficient (r) and corresponding p value is given for each locus. Correlations are strong, positive and highly significant, 
signifying a robust relationship. Red p value = significant at <0.008 level after performing Bonferroni correction for multiple comparisons. 
 Phase I (n=37) Phase II (n=37) 
Gene 
Methylation 
range (%) 
Mean 
Methylation 
(%) 
Standard 
Deviation 
(%) 
Methylation 
range (%) 
Mean 
Methylation 
(%) 
Standard 
Deviation 
(%) 
HOXD4 4-35 14.5 6.4 8-43 20.1 7.2 
EPHA10 7-31 12.0 4.1 8-35 15.0 4.7 
TUSC3 5-22 9.3 3.6 5-28 13.5 5.7 
TWIST2 3-20 8.9 3.7 4-29 9.8 6.0 
HAND2 2-18 7.4 2.8 4-22 11.0 3.9 
 Phase I 
 TWIST2 HOXD4 EPHA10 TUSC3 HAND2 Average 
Phase II 
r = 0.48 
p = 0.003 
r = 0.62 
p =  0.00006 
r = 0.82 
p =  8.2E-10 
r = 0.83 
p =  1.4E-10 
r = 0.85 
p =  3.7E-11 
r = 0.76 
p =   5.6E-08 
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Correlation of TWIST2 Methylation Levels at Phase I with Methylation 
Levels at Phase II in 37 Newcastle 85+ Study Samples  
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Correlation of TUSC3 Methylation Levels at Phase I with Methylation 
Levels at Phase II in 37 Newcastle 85+ Study Samples  
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Correlation of HOXD4 Methylation Levels at Phase I with Methylation 
Levels at Phase II in 37 Newcastle 85+ Study Samples  
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Correlation of EphA10 Methylation Levels at Phase I with Methylation 
Levels at Phase II in 37 Newcastle 85+ Study Samples  
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Figure 3.12: Correlation between DNA methylation levels in PBL DNA samples 
from Phase I and PBMC DNA samples from Phase II of the Newcastle 85+ study 
participants 
DNA methylation levels of TWIST2, TUSC3, HOXD4, HAND2, EPHA10 and the 
overall average methylation level of the five genes at Phase I and Phase II were plotted. 
The linear regression line and r
2
 value indicate a strong positive relationship between 
the two phases at all loci. 
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3.9 Discussion 
 
The purpose of the pilot study was to determine both the extent of methylation which is 
occurring in elderly individuals, and the possible presence of inter-individual variation 
in DNA methylation within this population as a potential mechanism to partly explain 
individual differences in disease susceptibility during ageing. 
 
A highly quantitative technique, Pyrosequencing, was employed for measuring DNA 
methylation with a high degree of accuracy, which was ensured by validating each 
individual assay with control samples of known methylation status. These controls were 
created by mixing in vitro methylated DNA (near to 100% methylated across the 
genome) with normal PBL DNA from young volunteers (typically unmethylated at gene 
promoters). An alternative method to validate these assays involves use of a nested PCR 
to amplify a region slightly larger than the amplicon of interest. This nested PCR 
product will be free of methylation and can be subjected to in vitro methylation using 
SSS1 methylase enzyme. Mixing differing proportions of the unmethylated and 
methylated PCR product enables the creation of known methylation standards which 
range from 0-100%. Since three of the genes in this study, HOXA4, HOXA5 and IGF2, 
are all partially methylated in normal cells, it could be argued that using a control which 
is also partially methylated is not ideal (as PBL DNA would be at these loci), as the 
assay has not demonstrated detection of methylation below the normal in vivo 
measurement (with the exception of HOXA4). A disadvantage of using a nested PCR 
approach however, is that the controls used to validate the assay (PCR product) will be 
different from the test sample (PBL DNA), whereas the method that we used ensures 
that the same kind of template is used for both validation and test samples (both PBL 
DNA). Additionally, assays may be vulnerable to contamination with amplified DNA 
from the first round of PCR due to the formation of large quantities of PCR product by 
nested PCR. 
 
The results demonstrated that methylation levels at a particular set of loci can 
accumulate both high levels of DNA methylation, and are extremely variable between 
individuals of the same age. Included within the group of genes exhibiting considerable 
levels of methylation and inter-individual variation are those which are known to be 
expressed within the haematopoietic lineage and/or have a functional role in 
haematopoietic cells, so it is possible that increased DNA methylation level at these 
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genes could have a biological consequence. For example, HOXA4 is expressed in 
haematopoietic progenitor cells, suggesting that it could play a role in control of 
differentiation. Also, HOXA5 is a key regulator of myeloid differentiation, as shown by 
altered monocytic and erthyroid cell differentiation after HOXA5 over-expression and 
inhibition experiments (Crooks et al., 1999; Fuller et al., 1999). In addition, TWIST2 is 
involved in the negative regulation of myeloid lineage development and TWIST2 
deficient mice have increased mature myeloid cell type populations including 
macrophages, neutrophils and basophils compared with WT mice (Sharabi et al., 2008). 
 
Upon investigation of the properties of these fifteen loci, we found that a significant 
proportion of these loci including TWIST2, TUSC3, HOXD4, EPHA10, HAND2, p15, 
HLXB9 and ESR1 were susceptible to increased and variable methylation in 
haematopoietic cells. For these eight loci, there is evidence in the literature that they 
exhibit aberrant hypermethylation in haematological malignancies.  
 
Previous studies have described hypermethylation of the TWIST2 promoter in chronic 
lymphoblastic leukaemia (CLL) samples which is associated with gene silencing (Raval 
et al., 2005). Bisulfite sequencing found minimal TWIST2 methylation in normal blood 
cells or CD19+ B cells, however only two samples were examined. TWIST2 
methylation status has attracted further study within our lab and we have recently shown 
that the TWIST2 promoter is frequently hypermethylated in both child and adult acute 
lymphoblastic leukaemia (ALL) which was associated with silenced expression. We 
also confirmed the methylation previously described in CLL samples, although at lower 
levels than ALL samples (Thathia et al., 2012). The re-expression of TWIST2 in ALL 
cell lines led to an inhibition of growth, induction of apoptosis as well as increasing 
susceptibility to chemotherapy, suggesting that methylation induced silencing of 
TWIST2 may confer a survival advantage for leukemic cells in vivo. 
 
DNA methylation at the TUSC3 promoter was recently identified as being 
hypermethylated in cases of adult ALL, but not AML by microarray analysis (Scholz et 
al., 2005). As far as I am aware, this remains the only published finding of TUSC3 
methylation in haematological malignancy, however our findings also indicate that 
hypermethylation of TUSC3 is frequently seen in adult and childhood ALL, where 
approximately one third of patients have methylation levels in excess of 50%. In 
contrast methylation of TUSC3 appears rarely in myeloid leukaemia. 
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Although there is no published data describing the methylation status of the HOXD4 
promoter in hematopoietic malignancies, we have found hypermethylation of this region 
in various leukaemia subtypes. In addition, a study looking for germline mutations in 
the HOX cluster which may be causal in childhood ALL samples found only three 
mutations unique to the childhood ALL cases. Of these, two were the same missense 
mutation in the HOXD4 locus which resulted in some loss of function (van 
Scherpenzeel Thim et al., 2005). This suggests that disturbing the normal function of 
HOXD4 may play a role in ALL development, therefore disruption of the gene by DNA 
methylation rather than mutation may also be functionally relevant. 
 
Hypermethylation of the Eph/ephrin family gene promoters is frequent event in ALL, 
including EPHA10, with methylation levels exceeding 60% in most ALL samples. In 
addition, this study included ten normal blood samples for which methylation levels 
were highly variable, ranging from 7.3-27.1% (Kuang et al., 2010). 
 
Abnormal DNA methylation of the HAND2 promoter was identified from a promoter 
methylation microarray of aberrantly methylated genes in CLL. Methylation density of 
the HAND2 promoter was typically in the range of 10-49% with some samples 
measuring >50% methylation. The methylation levels of blood cells from healthy 
controls were in the range of 2-8%, although this is based on a relatively small sample 
size of 10 individuals (Tong et al., 2010). Highly significant age related increases in 
Hand2 methylation have also observed in mouse tissues such as small intestine, spleen, 
kidney and liver (Maegawa et al., 2010).  
 
Hypermethylation of the p15 promoter is common in various types of leukaemia (Wong 
et al., 2000; Chim et al., 2001a; Chim et al., 2001b) and is significantly associated with 
disease progression including reduced disease free survival, lower overall survival, 
lower likelihood of achieving remission in AML (Shimamoto et al., 2005) and 
increased likelihood of relapse if p15 remains methylated in complete remission of both 
AML and ALL (Agrawal et al., 2007). Notably, p15 methylation has primarily been 
reported to be methylated in myeloid, but not lymphoid leukaemia. 
 
Hypermethylation (>50%) of the homeobox gene HLXB9 is a frequent event in adult 
and childhood ALL, although rarely appears in other leukaemia subtypes (Ferguson et 
al., 2011).  
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ESR1 promoter hypermethylation has been described in a wide range of haematopoietic 
neoplasms including both childhood and adult ALL, adult AML, chronic myeloid 
leukaemia (CML) and lymphoma samples (Issa et al., 1996b). Normal PBL samples 
examined as controls for this study of haematopoietic malignancies found fairly low 
levels of ESR1 promoter methylation (1-4%) and no association with age; however this 
conclusion was based on a small sample size of 17 individuals aged 29-67 years which 
are considerably younger than the Newcastle 85+ study population. Methylation was 
measured by southern blot analysis which is a less sensitive technique than 
Pyrosequencing, meaning some of the ESR1 promoter methylation in normal PBL 
samples may have remained undetected in previous analysis. 
 
Furthermore, we observed that methylation levels at any one of these loci, was strongly 
and positively associated with methylation levels at other genes, which could imply that 
certain individuals are predisposed to higher levels of DNA methylation. The fact that 
multiple loci across the genome are affected hints towards a general deregulation of 
methylation mechanisms with ageing. A similar co-methylation of multiple genes is 
noted in the literature as a feature of a both leukemic (Melki et al., 1999; Garcia-
Manero et al., 2002) and solid tumour cells (Bai et al., 2004; Lee et al., 2004), although 
since the levels of methylation tend to be very high in tumour cells, these studies looked 
solely for the frequency of hypermethylation at multiple genes, rather than comparing a 
quantitative level of methylation between different genes as we did in the pilot study. 
 
For the other highly methylated loci, HOXA4, HOXA5 and IGF2, which have high 
levels of inter-individual variation, there is similar evidence that they are 
hypermethylated in leukaemia. However, methylation levels at these loci are not 
correlated with any other gene, which likely is due to differences in how methylation is 
acquired and regulated at partially methylated compared to methylation free promoters. 
 
High levels of HOXA4 promoter methylation have been discovered in CLL (Strathdee et 
al., 2006), and the presence of such methylation highlighted as a possible biomarker for 
prognosis in CLL patients (Irving et al., 2011). Aberrant hypermethylation of HOXA4 is 
a feature of many leukemia subtypes including ALL, CML, where it is strongly 
associated with disease progression and AML, where is may be linked to poor prognosis 
(Strathdee et al., 2007a). 
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Very high levels of HOXA5 promoter methylation (>80%) have been described in 
numerous type of leukaemia including ALL, AML CLL and CML (Strathdee et al., 
2007a; Kim et al., 2010b) and again been linked to patient outcome. 
 
Studies have identified extensive methylation of IGF2 in leukemic cell lines and in a 
small number of primary samples examined (Issa et al., 1996a). Other studies have 
identified abnormal regulation of this gene in AML and CML leading to biallelic 
expression, but whether this is the consequence of altered DNA methylation levels is 
unclear (Wu et al., 1997; Randhawa et al., 1998).  
 
Conversely, for the loci which display low levels of methylation and a lack of 
variability including MLH1, RASSF1A, and RARB2; or a lack of correlation with 
methylation levels at other genes such as APOE, there is little or no evidence for their 
hypermethylation in leukaemia, despite these genes presenting age associated aberrant 
methylation patterns. 
 
The MLH1 gene is involved in DNA repair, specifically mismatch repair (MMR). 
Defects in the MMR pathway, due to MLH1 silencing by hypermethylation are 
associated with a microsatellite instability (MSI) phenotype in colorectal cancer (CRC) 
(Poynter et al., 2008) and endometrial cancer (Simpkins et al., 1999). However, a study 
examining MLH1 status in colorectal tissue from disease free individuals found that 
absolute methylation measurements were extremely low, around 2% in CRC samples 
and even lower in controls (Al-Ghnaniem et al., 2007). This suggests DNA methylation 
increases are small at this locus which agrees with our findings. 
 
Hypermethylation of RASSF1A has been described in numerous types of cancer 
(detailed extensively in (Dammann et al., 2005)) and partial methylation described in 
normal prostate tissue (Kwabi-Addo et al., 2007) and kidney samples, which was 
related to increasing age of the individual (Peters et al., 2007).  
 
Similarly, aberrant methylation of RARB2 is described in solid tumours of tissues such 
as the prostate (Kwabi-Addo et al., 2007), and a positive correlation between 
methylation of RARB2 and age was also described in this tissue (Kwabi-Addo et al., 
2007; Christensen et al., 2009).  
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Currently, there is no evidence for the presence of APOE methylation in haematological 
malignancies, A study found differential DNA methylation of APOE in the brains of 
Alzheimer’s disease (AD) patients compared to controls which was associated with 
advancing age, and the amount of methylation was variable within all individual 
studied. However, these findings were not observed in lymphocytes. (Wang et al., 
2008).  
 
In addition to these outcomes, we found that DNA methylation of the TWIST2 and 
HOXD4 promoter at the allelic level is represented by a mixture of alleles containing 
either densely methylated or unmethylated CpG sites in normal haematopoietic cells in 
the Newcastle 85+ study population. This again draws similarities to a cancer-like cell, 
in which genes at the allelic level are often densely, rather than partially methylated 
(Corn et al., 2000; Esteller et al., 2000b; Varley et al., 2009). 
 
Taken together, these findings led to the development of the pre-existing methylation 
hypothesis (Figure 3.13) to explain how an individual’s level of DNA methylation at 
loci which are susceptible to both hypermethylation and acquisition of methylation 
during ageing, may underlie risk of developing cancer. 
 
 
 
Figure 3.13: The pre-existing methylation hypothesis 
A 
B 
C 
D 
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Previously, it was believed that the majority genes in a normal stem cell were 
completely unmethylated. In the example shown (Figure 3.13A), four haematopoietic 
stem cells (circles, blue outline) are shown and four genes susceptible to aberrant 
methylation in cancer and ageing are represented within the cells (circles, black outline) 
which entirely lack methylation. It has since become apparent, through others and the 
observations presented here, that these types of loci are partially methylated to variable 
degrees during ageing. Figure 3.13B illustrates a possible pattern of partial methylation 
in the four stem cells whereby all four cancer-related genes are partially methylated 
(partial black colouring) in all cells a normal sample. However, we know from our 
bisulfite sequencing results of the TWIST2 and HOXD4 promoter region that partially 
methylated alleles are not common, rather the allele appears to be either densely 
methylated or completely unmethylated. In Figure 3.13C, each of the four stem cells 
have complete methylation of a one gene (black circle) which is different in each cells, 
with the others remaining unmethylated (white circles). Expression of the gene will 
likely be silenced in the cell where it is heavily methylated but the gene may be 
expressed within cells where it remains unmethylated. Furthermore, at present we know 
that co-ordinate methylation of numerous genes occurs at the level of an individual, and 
we can speculate that this may be occurring at the level of an individual stem cell. This 
is illustrated in Figure 3.13D, whereby all four loci, susceptible to both cancer and age 
associated methylation, are completely methylated in one cell (black circles), and 
unmethylated in others (white circles). This is identical to observations of tumour cells, 
in which numerous genes are hypermethylated and silenced. Consequently, if we 
hypothesise that the partial methylation measured in the PBL DNA of Newcastle 85+ 
study participants is represented by the existence of completely methylated cells such as 
those in Figure 3.13D, an individual with higher levels of methylation may likely have 
higher numbers of these abnormally methylated cells. Our hypothesis is therefore, that 
an individual, who is predisposed to acquiring abnormal methylation during ageing, 
may be more susceptible to cancer as they have an increased pool of normal cells with 
an abnormal methylation pattern from which cancer can originate via clonal expansion, 
without requiring any additional methylation changes. 
 
The relationship between methylation levels and the percentage of lymphocytes was 
suspected due to the recent observation of increased methylation of lymphocytes 
compared to monocytes (Rakyan et al., 2010). A study of haematopoietic differentiation 
in mice also revealed higher levels of global methylation in lymphocytes than myeloid 
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lineage cells (Ji et al., 2010). Although we found some evidence of an association in our 
pilot study, it was weak and not significant at most of the loci, therefore is unlikely to be 
having a substantial impact on the DNA methylation levels measured in this pilot study. 
 
A comparison between methylation levels of DNA samples taken 18 months apart at 
phase I and phase II of the Newcastle 85+ study was undertaken to confirm that DNA 
methylation measurements were relatively stable within an individual over a short space 
of time and not susceptible to day-to-day fluctuations. Fluxing levels would render 
DNA methylation an impractical measurement for relating to health outcomes. Our 
analysis was made more complicated by the different sources of DNA at the two phases, 
derived from PBLs in Phase I and PBMCs in Phase II, which affects overall levels of 
DNA methylation due to intrinsic methylation differences between cells types. In spite 
of this, methylation levels at phase I and phase II were strongly, positively correlated 
suggesting little variation of methylation over time, within the same individual. 
 
In conclusion, these results demonstrate that in elderly individuals, increased DNA 
methylation at the promoter region of multiple loci is evident but does not accumulate 
to the same level throughout the population, and instead is highly variable. In addition, 
these age-related methylation changes share similarities with those seen in tumour cells 
including the presence of densely methylated alleles and co-methylation of genes 
indicative of a “CpG island methylator phenotype”, suggesting age-associated changes 
may have a functional consequence. 
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Chapter 4 – Association between DNA methylation levels and clinical 
outcomes in the Newcastle 85+ Study 
                        
4.1 Introduction 
 
For many diseases, advancing age is a significant risk factor. According to Cancer 
Research UK, approximately 63% of all cancer (excluding non-melanoma skin cancer) 
is diagnosed in individuals aged over 65 years, and despite representing a relatively 
small proportion of the population over a third of cancers are found in those aged over 
75 (URL http://info.cancerresearchuk.org/cancerstats/incidence/age/).  
 
Numerous factors affect a person’s risk of developing a cancer. Germline mutations in 
genes such as BRCA1 are associated with a vastly increased incidence of familial breast 
or ovarian cancer (Lancaster et al., 1997), but such high penetrance germline defects  
account for only a small proportion of all cancer cases and are typically responsible for 
cancers at a younger age of onset than sporadic cancers (Brandt et al., 2008). Studies 
examining the presence of SNPs within the genome have highlighted regions which 
may be important for determining cancer risk, including the C677T SNP in MTHFR, a 
gene involved in the metabolism of folate and the provision of substrates for DNA 
synthesis and for methylation of DNA and other cell macromolecules. The TT genotype 
encodes an enzyme with reduced activity compared with the CC genotype and appears 
to decrease risk of colorectal cancer (Levine et al., 2010) and acute lymphoblastic 
leukaemia (Skibola et al., 1999). However, this effect was not observed in all analyses 
of colorectal cancer (Plaschke et al., 2003), or in myeloid leukemia (Wiemels et al., 
2001). In addition, specific environmental exposures are known to contribute to cancer 
risk. For example, the incidence of lung cancer is significantly higher in cigarette 
smokers compared with never smokers (Freedman et al., 2008). 
 
These genetic factors alone do not appear to account for all of the risk of cancer 
development. This is illustrated by MZ twins, who despite sharing an identical genetic 
background and typically very similar environments (at least early in life), often 
demonstrate discordance with regards to diseases, particularly cancer. A study of 
childhood cancer incidence in MZ twins described extremely low concordance of 
approximately 5% for leukaemia and 2% for solid tumours between pairs (Buckley et 
al., 1996). A large study of both MZ and DZ twins found that although there was some 
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evidence of genetic susceptibility, many types of cancer displayed considerable 
discordance between twin pairs (Ahlbom et al., 1997). 
 
Although stochastic events can likely explain the majority of disease discordance, 
another proposed explanation underlying such differences is DNA methylation. Indeed 
differential methylation status of genes has been implicated in the discrepancy of 
disease incidence between monozygotic twins including schizophrenia (Petronis et al., 
2003), systemic lupus erythematosus (Javierre et al., 2010) and psoriasis (Gervin et al., 
2012). In addition, a recent EWAS of MZ twins discordant for Type I diabetes 
identified a number of differentially methylated CpG sites in the affected twin, which 
were also present in singletons with the disease, even prior to disease onset, suggesting 
a potential causal role for DNA methylation in Type I diabetes (Rakyan et al., 2011).  
 
The results from the pilot study (Chapter 3) suggest strongly that DNA methylation 
levels are highly variable between individuals at age 85. The presence of such variation 
may be important when considering the dramatic differences in susceptibility to 
diseases such as cancer. In addition to the increased epigenetic variability between 
individuals with age, there are similarities between the DNA methylation patterns 
observed in peripheral blood leukocyte cells of elderly individuals and those in cancer 
cells. Such features include targeting of the same or an overlapping set of genes, the co-
methylation of genes, suggestive of a “CpG island methylator phenotype” and the 
presence of densely hypermethylated alleles. 
 
These observations led to the construction of a hypothesis that pre-existing methylation 
in normal cells may underlie an individual’s susceptibility to disease, particularly 
cancer, since the consequence of altered methylation in cancer is well described. 
Specifically I hypothesised that those 85 year olds with the highest amounts of DNA 
methylation in the promoter regions of age- and cancer-related genes may be at an 
increased risk of developing cancer, as they contain an increased pool of abnormally 
densely methylated cells, which could potentially clonally expand. To test this 
hypothesis, methylation levels of the genes HOXD4, TUSC3, TWIST2, HAND2, 
EPHA10 and HOXA5 shown to be variable methylated in the pilot study, will be used as 
surrogate loci for methylation changes occurring at genes throughout the genome and 
DNA methylation levels of individuals with a cancer diagnosis will be compared to 
those who are cancer free. 
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In addition to cancer, the prevalence of cardiovascular disease, dementia, type II 
diabetes and stroke also rises dramatically with age and altered DNA methylation has 
been proposed to play a role in the aetiology of  such diseases (Sharma et al., 2008; 
Barrachina and Ferrer, 2009; Ling and Groop, 2009; Baccarelli et al., 2010). However 
these studies primarily described associations between altered DNA methylation and 
disease status and did not demonstrate a direct biological (causal) role for the epigenetic 
changes. In addition, many of these analyses measured global DNA methylation levels 
and the functional consequences of such changes are not clearly understood 
 
To uncover potential relationships between methylation levels and the incidence of 
other diseases including cardiovascular disease, type II diabetes, stroke, and dementia, 
methylation levels were compared between individuals with and without these diseases. 
In addition, relationships between potential key confounders such as gender or smoking 
behaviour and methylation were investigated. 
 
4.2 Results – initial analysis  
 
To test our hypothesis that pre-existing methylation levels in normal haematopoietic 
cells may underlie susceptibility to cancer within the Newcastle 85+ study population, 
PBL DNA samples from all 113 participants in the study who had a previous incidence 
of any cancer (excluding non-melanoma skin cancer) prior to their recruitment onto the 
study, were selected for DNA methylation analysis. A control group consisting of PBL 
DNA from 113 participants was selected at random from all remaining study 
participants.  
 
4.2.1 Pyrosequencing Results – initial analysis 
 
DNA methylation levels were measured at six of the same genes tested in the pilot study 
including HOXD4, TUSC3, TWIST2, HAND2 and EPHA10, as these were the most 
variably methylated of the ‘normally unmethylated’ gene promoters, in addition to 
HOXA5, as this was the most extensively and variably methylated of all genes.  
 
The results for the total sample set of 226 participants confirmed the highly variable 
nature of DNA methylation which was observed in the pilot study at HOXD4 (15.3 ± 
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4.8% [mean ± SD]), TUSC3 (10.1 ± 3.8%), TWIST2 (6.8 ± 3.1%), EPHA10 (11.7 ± 
2.9%) and HAND2 (8.4 ± 2.7%). DNA methylation levels at the HOXA5 promoter 
(ranging from 31-91%) were measured in 113 participants (56 with no cancer and 57 
with previous cancers) and demonstrated extremely variable measurements within the 
85 year old population (Table 4.1 and Figure 4.1). Overall, these measurements were 
very similar to those which were observed in the pilot study at HOXD4 (14.8 ± 6.0%), 
TUSC3 (8.9 ± 3.4%), EPHA10 (12.0 ± 3.9%), HAND2 (7.3 ± 2.8%) and HOXA5 (61.5 ± 
15.1%) (Chapter 3.5). DNA methylation levels in this expanded set of participants were 
slightly lower for TWIST2 than were observed in the pilot study (6.8 ± 3.1% and 8.4 ± 
3.3% respectively). 
 
 
 
Gene n 
Methylation 
Range (%) 
Mean Methylation (%) Standard Deviation (%) 
HOXA5 113 31-91 61.9 12.7 
HOXD4 226 1-41 15.3 4.8 
TUSC3 226 4-23 10.1 3.8 
TWIST2 226 3-25 6.8 3.1 
EPHA10 226 3-24 11.7 3.9 
HAND2 226 3-27 8.4 2.7 
 
Table 4.1: Summary of methylation measurements in PBL DNA from 113 
participants with a previous cancer history and 113 cancer-free participants from 
the Newcastle 85+ study 
For each gene, the minimum and maximum methylation levels in the samples is shown, 
together with mean methylation calculated from 3-6 consecutive CpG sites for all 
participants and the standard deviation as a measure of variation. 
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Figure 4.1: Methylation levels in PBL DNA at HOXD4, TUSC3, TWIST2, HAND2 
EPHA10 and HOXA5 promoters from 113 participants with a previous cancer 
history and 113 cancer-free participants from the Newcastle 85+ study 
Samples are listed in ascending order of DNA methylation measurements at each 
particular gene. All genes exhibit highly variable DNA methylation levels between 
individuals. Lack of reproducible methylation measurements meant one sample was 
excluded from EPHA10 and HAND2 results. Only 113 samples were tested at the 
HOXA5 locus. 
 
 
4.2.2 DNA methylation levels between genes are strongly correlated 
 
Next, in order to confirm the strong positive correlations observed between genes in the 
initial 50 participants, DNA methylation levels of HOXD4, TUSC3, TWIST2, HAND2, 
EPHA10 and HOXA5 measured in 226 participants were used to calculate the Pearson 
correlation coefficient and corresponding p value for each pairwise comparison. 
 
Exceptionally strong, positive and highly significant relationships were observed 
between methylation levels at the HOXD4, N33, TWIST2, HAND2 and EPHA10 
promoter regions (Table 4.2). These correlations were both stronger and more 
significant than the correlations observed in the pilot study (see Chapter 3.6.1). Also in 
agreement with the pilot study result, there was no association of HOXA5 methylation 
levels with any other loci. 
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Table 4.2: Pair-wise correlations of methylation of TWIST2, HOXD4, EPHA10, 
TUSC3,  HAND2 and HOXA5 in DNA from 226 Newcastle 85+ Study participants 
DNA methylation data for 226 participants was correlated at each pair of loci using 
Pearson test of correlation. The Pearson correlation coefficient (r) and corresponding p 
values are shown. DNA methylation levels at TWIST2, HOXD4, EPHA10, TUSC3 and 
HAND2 are strongly positively correlated. Methylation of HOXA5 demonstrates no 
relationship with methylation at the other loci investigated. Black p value = NS, Red p 
value = significant at <0.003 level after performing Bonferroni correction for multiple 
comparisons. 
 
4.2.3 DNA methylation levels are highly correlated with proportion of lymphocytes 
 
The results from the pilot study indicated a weak relationship between DNA 
methylation levels from PBL cells and the percentage of lymphocytes in the same 
individual (Chapter 3.7). Using the data from 226 participants, correlations between 
methylation levels at the TWIST2, HOXD4, EPHA10, TUSC3, HAND2 and HOXA5 
promoter, and the proportion of lymphocytes in each individual was examined. This 
revealed very strong positive associations which were highly significant at TWIST2, 
HOXD4, EPHA10, TUSC3 and HAND2 (Figure 4.2). In contrast, there was no 
relationship between HOXA5 methylation levels and the percentage of lymphocytes.  
 
 
 
 TWIST2 HOXD4 EPHA10 TUSC3 HAND2 
TWIST2      
HOXD4 r = 0.73 
p < 1e-16 
    
EPHA10 r = 0.51 
p = 2.2e-16 
r = 0.59 
p < 1e-16 
   
TUSC3 r = 0.73 
p < 1e-16 
r = 0.66 
p < 1e-16 
r = 0.60 
p < 1e-16 
  
HAND2 r = 0.53 
p = 0 
r = 0.48 
p = 5.7e-15 
r = 0.36 
p = 2.2e-08 
r = 0.42 
p = 5.3e-11 
 
HOXA5 r = 0.04 
p = 0.62 
r = -0.03 
p = 0.72 
r = -0.002 
p = 0.98 
r = -0.02 
p = 0.77 
r = 0.003 
p = 0.97 
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Figure 4.2: Correlations between DNA methylation levels and lymphocyte 
percentage in blood samples from Newcastle 85+ study participants. 
DNA methylation values of TWIST2, HOXD4, EPHA10, TUSC3, HAND2 and HOXA5 
were plotted against lymphocyte percentage calculated from full blood counts (Chapter 
2.1). The linear regression line and r
2
 value indicate a positive relationship for all genes 
except HOXA5, for which there is no association. 
 130 
 
4.2.4 Correction of DNA methylation values to account for proportion of 
lymphocytes – initial analysis 
 
These results indicate that the percentage of lymphocytes in any individual may 
significantly affect the levels of DNA methylation at these five loci. Furthermore, a 
recent analysis of DNA methylation levels in these same five genes in isolated 
haematopoietic cell populations demonstrated that lymphocytes, particularly B-cells, 
exhibit significantly higher levels of DNA methylation than other cells types in a PBL 
sample (example in Figure 4.3 and further examples in A3.1) (Unpublished data, 
performed by Sanne van Otterdijk). B-cells typically represent approximately 5-10% of 
total lymphocyte count and consequently their numbers will increase with increasing 
lymphocytes, and subsequently raise DNA methylation levels. 
 
 
 
Figure 4.3: DNA methylation levels of TWIST2 in isolated haematopoietic cell 
populations 
DNA was isolated from PBLs (lymphocytes, neutrophils, and monocytes), PBMCs 
(lymphocytes and monocytes), B cells and monocytes and DNA methylation levels at 
the TWIST2 promoter measured by Pyrosequencing. PBMC-monocytes represent total 
lymphocytes (T cells, B cells and NK cells). DNA methylation levels are lowest in 
monocytes and highest in B cells. 
 
As data regarding the characterisation of specific leukocyte populations by flow 
cytometry was available for all Newcastle 85+ study participants, the association 
between DNA methylation levels and number of B-cells was investigated to decipher 
whether the proportion of B-cells within an individual blood sample was responsible for 
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the observed relationship between lymphocyte percentage and DNA methylation levels. 
Calculation of the Pearson correlation coefficient indicated no relationship between 
DNA methylation level and B-cell number in these Newcastle 85+ participants (r=0.07, 
p=0.12).  
 
Therefore, the DNA methylation levels measured in the Newcastle 85+ study 
participants were corrected to account for the proportion of lymphocytes in the blood 
sample. This will ensure that differences between individuals are due to genuine 
differences in cellular levels of DNA methylation and are not secondary to differences 
in cell populations. 
 
Firstly, in order to establish a single methylation measurement for each individual, the 
mean of the DNA methylation levels at TWIST2, HOXD4, EPHA10, TUSC3 and 
HAND2 would typically be calculated. However, absolute methylation measurements 
for the five genes are quite different; for example the average amount of methylation in 
the total population at the TWIST2 locus is 6.8%, whereas mean methylation of HOXD4 
is 15.3%, over 2 times greater. This would result in particular loci (such as HOXD4) 
having a greater influence on the overall methylation average than other loci. In order to 
prevent this, methylation measurements across all five loci were adjusted, such that each 
gene contributes an equal proportion to the overall mean. The average methylation level 
across five genes in all 226 participants was 10.5%; therefore, the absolute methylation 
levels of all genes were scaled such that the overall methylation percentage at each 
locus was 10.5%. The variation between individuals within the population will remain, 
as the methylation levels at each gene for each individual were corrected by multiplying 
by a factor, calculated by dividing the total population mean (10.47%) by the specific 
gene mean. 
 
Next, linear regression analysis was used to examine the relationship between the 
overall methylation mean, calculated by averaging the adjusted methylation levels at 
TWIST2, HOXD4, EPHA10, TUSC3 and HAND2 for each individual, and the proportion 
of lymphocytes in that individual (Figure 4.4). The r
2
 value of 0.33 revealed a positive 
relationship between these two variables. The equation of the regression line is shown 
below: 
 
y = 0.1811x + 5.1549  
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This can be used to determine the magnitude of the effect. If methylation is plotted on 
the y axis and lymphocytes along the x axis, the following equation states that the slope 
of the regression line is 0.1811, meaning that every 1% increase in lymphocytes (x), is 
responsible for a 0.1811% increase in methylation levels (y). 
 
 
Relationship between Overall Methylation (%) and Lymphocytes (%) 
for 226 Samples in the Newcastle 85+ Study
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Figure 4.4: Relationship between overall mean DNA methylation levels and 
percentage of lymphocytes in the blood sample of 226 Newcastle 85+ study 
participants 
Linear regression analysis was performed by plotting the overall mean methylation of 
each participant against the percentage of lymphocytes. A positive relationship is 
indicated by the r
2
 value and the equation of the regression line is also shown. 
 
 
In order to remove the influence of lymphocyte proportion on DNA methylation levels, 
measurements for all individuals were corrected to account for this effect by calculating 
by the following lymphocyte normalisation factor: 
 
( (Sample lymphocytes (%) – population mean lymphocytes (29.02%) ) * DNA 
methylation increase determined by lymphocytes (0.1811%) ) 
 
This individually calculated factor was then applied to methylation levels at all five 
genes, and either reduces or increases methylation levels according to whether that 
individual had a higher or lower than average proportion of lymphocytes. This should 
result in removing any influence of differing cell populations on methylation levels at 
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TWIST2, HOXD4, EPHA10, TUSC3 and HAND2. All analysis after this point was 
performed using the corrected methylation values. Changes to the mean, standard 
deviation and range of methylation measurements for each gene after this correction are 
shown in Table 4.3. The pairwise strong positive correlation between DNA methylation 
levels at these genes was still evident after adjusting for lymphocyte proportion 
indicating that this relationship is not driven by the relationship between increased DNA 
methylation levels and increased lymphocyte percentage (Table 4.4). No changes were 
made to the HOXA5 locus measurements since this DNA methylation at this gene 
demonstrates no relationship with the proportion of lymphocytes in the same blood 
sample. 
 
Gene Methylation Range (%) Mean Methylation (%) Standard Deviation (%) 
HOXD4 0-27 10.47 2.9 
TUSC3 2-22 10.47 3.5 
TWIST2 3-37 10.47 4.1 
EPHA10 2-20 10.47 2.4 
HAND2 3-33 10.47 3.2 
 
Table 4.3: Properties of DNA methylation measurements after correction for 
proportion of lymphocytes in the blood sample of 226 Newcastle 85+ Study 
participants 
For each gene, the corrected minimum and maximum methylation levels in the samples 
is shown, alongside the normalised average methylation level calculated as described 
above, and the standard deviation as a measure of variation. 
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Table 4.4: Pair-wise correlations of PBL DNA methylation levels at TWIST2, 
HOXD4, EPHA10, TUSC3 and HAND2 after adjusting for proportion of 
lymphocytes in 226 Newcastle 85+ Study participants 
The Pearson correlation coefficient (r) and corresponding p values are shown for 226 
participants. DNA methylation levels at TWIST2, HOXD4, EPHA10, TUSC3 and 
HAND2 are strongly positively correlated. Black p value = NS, Red p value = 
significant at <0.005 level after performing Bonferroni correction for multiple 
comparisons. 
 
4.2.5 DNA methylation levels of Newcastle 85+ study participants with a previous 
history of cancer compared to those with no cancer 
 
In order to determine whether there was a difference in DNA methylation levels 
between individuals either with no cancer, or a previous incidence of cancer, the 
difference in DNA methylation levels between these groups were compared using the 
Student’s t-test. Alongside the 226 participants, the 50 pilot study participants were also 
included, In total, 254 Newcastle 85+ study participants were analysed, as 6 of the pilot 
study individuals had a previous cancer history and 16 participants originally selected 
for the cancer free control group had developed cancer during the duration of the study; 
therefore the results for these participants were removed.  
 
The results revealed that methylation levels at the HOXD4, EPHA10, TWIST2, TUSC3 
and HAND2 promoters, as well as the overall mean, were indeed higher in participants 
with a previous history of cancer compared to those with no cancer, in accordance with 
our hypothesised relationship (Table 4.5). There was a statistically significant difference 
 TWIST2 HOXD4 EPHA10 TUSC3 
TWIST2     
HOXD4 
r = 0.61 
p < 1e-16 
   
EPHA10 
r = 0.30 
p =  5.2e-06 
r = 0.49 
p = 4.2e-15 
  
TUSC3 
r = 0.64 
p < 1e-16 
r = 0.56 
p < 1e-16 
r = 0.47 
p =  8.0e-14 
 
HAND2 
r = 0.38 
p = 2.7e-09 
r = 0.41 
p =  1.9e-10 
r = 0.29 
p =  7.8e-06 
r = 0.31 
p =  3.1e-06 
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when comparing the overall mean, as well as at two individual loci TUSC3 and 
HOXD4. At the HOXA5 promoter, no significant differences were found (Table 4.5). 
 
DNA 
methylation 
n TUSC3 TWIST2 HOXD4 HAND2 EPHA10 
Overall 
Mean 
HOXA5 
Mean no 
cancer (%) 
141 9.90 10.61 10.14 10.04 10.37 10.21 62.42 
Mean 
Previous 
cancer (%) 
113 10.78 10.77 10.79 10.48 10.72 10.71 60.40 
t-test 
p-value 
 0.021* 0.376 0.041* 0.122 0.158 0.043* 0.188 
 
Table 4.5: Comparison of PBL DNA methylation levels between individuals with a 
previous history of cancer compared to those with no cancer (excluding future 
cancers) in the Newcastle 85+ study 
Student’s t-test was used to analyse difference in methylation levels between the two 
groups. Methylation levels of TUSC3, HOXD4 and the overall mean were significantly 
different between the two groups *(p < 0.05). 
 
4.2.6 Association between DNA methylation levels with gender, smoking behaviour 
and levels of folate, vitamin B12 and homocysteine in the Newcastle 85+ Study 
The following associations were tested in the total Newcastle 85+ study sample set of 
270 individuals, to undercover relationships between DNA methylation and gender, 
smoking and levels of dietary methyl donors. Several previous publications have 
suggested such factors may impact upon levels of DNA methylation (see Chapter 1). 
 
4.2.6.1 DNA methylation and gender 
 
Several studies have suggested that DNA methylation differences exist between males 
and females, however reports are often conflicting and are dependent on the type of 
assay used for measurements (see section 1.1.9.3). The Student t-test was utilised again 
to determine the existence if significant differences between the six loci in males and 
females. As expected due to the greater life expectancy of females, there were more 
women (n=157) than men (n=113) in the Newcastle 85+ study population. At all the 
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gene promoters measured, males had higher levels of methylation than females. This 
was a statistically significant difference at TUSC3, HAND2, EPHA10 and the overall 
mean (Table 4.6). The same association was also observed at the HOXA5 promoter 
(Table 4.6). These results indicate that males have significantly increased levels of gene 
specific DNA methylation in the Newcastle 85+ study population. 
 
DNA 
methylation 
n TUSC3 TWIST2 HOXD4 HAND2 EPHA10 
Overall 
Mean 
HOXA5 
Males (%) 113 10.97 10.97 10.82 10.81 11.28 10.96 64.96 
Females (%) 157 9.92 10.76 10.27 10.02 10.08 10.21 59.79 
t-test 
p-value 
 0.007* 0.35 0.072 0.030* 0.0001* 0.008* 0.008* 
 
Table 4.6: Comparison of DNA methylation levels between males and females 
Student’s t-test was used to analyse difference in methylation levels between the sexes. 
Methylation levels of TUSC3, HAND2, EPHA10, the overall mean and HOXA5 were 
significantly different between the two groups *(p < 0.05). 
 
 
4.2.6.2 DNA methylation and smoking behaviour 
 
Smoking has been linked to aberrant DNA methylation patterns (see section 1.6.3.2.2); 
therefore we aimed to identify any differences in DNA methylation levels between 
individuals in the Newcastle 85+ study who were either never smokers, current smokers 
or former smokers.  
 
DNA methylation levels were not significantly different in current smokers than either 
former or never smokers at most loci, including the overall mean; although at the 
HOXD4 locus, never smokers had the highest level of DNA methylation (Table 4.7). 
The Student’s t-test indicated a statistically significant difference in the HAND2 
methylation levels of former compared to never smokers (Table 4.8). Also, methylation 
levels of HOXA5 were significantly higher in current compared to former smokers 
(Table 4.8). 
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Overall, the results indicate little evidence for any difference in DNA methylation levels 
between current, former or never smokers at most loci, although there was a significant 
difference at two of the loci, therefore the link between smoking and DNA methylation 
levels of the genes is not clear in the 85+ population. 
 
DNA 
methylation 
n TUSC3 TWIST2 HOXD4 HAND2 EPHA10 
Overall 
Mean 
HOXA5 
Current 
Smokers (%) 
18 10.74 12.03 10.68 10.64 10.97 11.01 66.67 
Former 
Smokers (%) 
156 10.37 10.47 10.35 10.01 10.64 10.37 60.26 
Never 
Smokers (%) 
95 10.30 11.23 10.72 10.87 10.42 10.70 62.75 
 
Table 4.7: DNA Methylation levels in PBL samples from current, former and 
never smokers in 269 Newcastle 85+ study participants 
DNA methylation levels of TUSC3, TWIST2, HOXD4, HAND2, EPHA10, the overall 
mean and HOXA5 in 269 participants. Information regarding smoking was missing for 
one sample. 
 
Student t-test TUSC3 TWIST2 HOXD4 HAND2 EPHA10 
Overall 
Mean 
HOXA5 
Current v. Never 0.32 0.28 0.48 0.41 0.19 0.35 0.11 
Current v. Former 0.33 0.06 0.32 0.19 0.32 0.18 0.04* 
Former v Never 0.44 0.08 0.18 0.02* 0.27 0.17 0.14 
 
Table 4.8: Student’s t-test for differences between DNA methylation levels in PBL 
samples from current, former and never smokers in 269 Newcastle 85+ study 
participants 
The Student’s t-test was used to analyse difference in DNA methylation levels between 
current and never smokers, current and former smokers, and former compared to never 
smokers. There was a statistically significant difference in HOXA5 methylation between 
current and former smokers, and HAND2 methylation levels of former compared to 
never smokers *(p < 0.05). 
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4.2.6.2 DNA methylation and levels of folate, vitamin B12 and homocysteine 
 
Both folate and vitamin B12 are essential for DNA methylation, as they are involved in 
the synthesis of the methyl donor S-adenosyl methionine (SAM), from methionine. 
Homocysteine is formed after the transfer of a methyl group and is converted back to 
methionine through a series of reactions requiring both folate and vitamin B12. A build-
up of homocysteine can indicate a lack of reconversion and a reduced level of SAM. 
Therefore, both folate and vitamin B12 levels have a positive impact on SAM levels, 
whilst homocysteine is negatively associated. Levels of homocysteine, vitamin B12 and 
red cell folate were measured in the Newcastle 85+ Study participants (Chapter 2.1). 
For each individual, a Z-score was calculated for these three measures combined by the 
following formula: 
 
Z-Score = (Individual measurement – Population mean) 
   Population SD 
 
A combined Z-Score was calculated by the following formula, to reflect the conflicting 
relationship between levels of homocysteine, vitamin B12 and red cell folate: 
 
Combined Z-Score = Z-Score (folate) + Z-score (vit B12) – Z-Score (homocysteine) 
The correlation between this combined Z-Score and DNA methylation levels at the six 
loci was tested by calculating the Pearson correlation coefficient which revealed no 
evidence of any association between the measures (Table 4.9). Figure 4.5 illustrates the 
lack of relationship between the overall mean methylation and the combined 
homocysteine, vitamin B12 and red cell folate Z-score. This implies that the variable 
DNA methylation levels observed in the Newcastle 85+ study participants do not appear 
to be significantly affected by differences in levels of folate, vitamin B12 and 
homocysteine. 
 
 TUSC3 TWIST2 HOXD4 HAND2 EPHA10 
Overall 
Mean 
HOXA5 
Combined 
Z – Score 
r = -0.02 
p =  0.72 
r = 0.03 
p =0.58 
r = 0.01 
p = 0.98 
r = 0.09 
p = 0.14 
r = 0.02 
p = 0.78 
r = 0.02 
p = 0.73 
r = 0.01 
p = 0.90 
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Table 4.9: Correlation between DNA methylation levels and combined 
homocysteine, vitamin B12 and red cell folate Z-score measure in blood samples 
from the Newcastle 85+ study participants (initial sample set) 
The Pearson correlation coefficient (r) and corresponding p values are shown. There 
was no association between the two measures at any gene (p<0.05). 
 
Relationship between overall mean methylation levels (%) and combined 
homocysteine, vitamin B12 and red cell folate Z score 
Combined homocysteine, vitamin B12 and red cell folate Z score 
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Figure 4.5: Relationship between overall mean DNA methylation levels and 
combined homocysteine, vitamin B12 and red cell folate Z-score in the Newcastle 
85+ study participants (initial sample set) 
There was no evidence for any association. 
 
4.2.7 Association between DNA methylation levels and the presence of age-related 
clinical outcomes in the Newcastle 85+ study population 
 
Next, possible relationships between DNA methylation levels and the presence of age 
related clinical outcomes were investigated. For comparison, the DNA methylation 
levels of participants with or without a particular clinical outcome were analysed for the 
overall mean of TUSC3, TWIST2, HOXD4, HAND2 and EPHA10, since these loci 
appear to exhibit co-methylation whereas HOXA5 was analysed separately as it does not 
fit with the similar pattern of methylation as the other five genes. The comparison of 
overall DNA methylation levels in individuals with cardiovascular disease (CVD), Type 
II diabetes (T2D), Dementia/Alzheimer’s disease (AD), stroke or who had died within 
three years can be found in Table 4.10. 
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Clinical 
Outcome 
CVD T2D 
Dementia 
(inc. AD) 
Stroke Survival 
Mean overall DNA methylation (%) 
No disease/ 
Alive  
10.35 10.55 10.50 10.49 10.46 
With disease/ 
Died  
10.87 10.34 10.82 10.70 10.90 
t-test 
p-value 
0.057 0.323 0.303 0.309 0.150 
 
Table 4.10: Comparison of PBL DNA methylation levels in association with age-
related clinical outcomes in the Newcastle 85+ study participants (initial sample 
set) 
The Student’s t-test was used to analyse differences in overall DNA methylation levels 
between participants with and without cardiovascular disease, type II diabetes, dementia 
including Alzheimer’s disease and stroke and a comparison of participants who had 
died or were still alive after the study follow up period of three years. There were no 
significant differences (p<0.05). 
 
A number of previous studies had proposed a link between DNA methylation levels of 
specific genes and CVD, although these studies typically focused on global methylation 
(Sharma et al., 2008; Kim et al., 2010a), or in mouse models of atherosclerosis (Zaina 
et al., 2005). Therefore, the potential link between DNA methylation and cardiovascular 
disease was investigated for gene specific methylation levels in the Newcastle 85+ 
population. For this analysis, a participant was defined as having CVD if they had any 
one or more of the following incidents or procedures: myocardial infarction, angina, 
coronary angioplasty/stent, coronary artery bypass graft. 
 
The results suggested no significant difference in DNA methylation levels between 
participants who have had incidents or procedures indicative of CVD (Table A3.2), 
although there was a slight trend towards higher levels of DNA methylation in 
participants with CVD (Table 4.10). Despite a relatively large number of participants 
with CVD (n=91), since absolute difference in methylation levels were small, 
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confirmation of this trend utilising independent samples is required to determine 
whether this difference in DNA methylation levels is reproducible. In contrast, 
methylation levels at HOXA5 were significantly lower in participants with 
cardiovascular events compared to those with none (CVD=58.43%, none=63.44%, 
p=0.013) (Table A3.2). 
 
Unlike Type I diabetes which is often diagnosed in childhood, or young adolescence, 
the prevalence of T2D increases with age and a possible role for differential DNA 
methylation has been proposed (Groop and Lyssenko, 2008). In this analysis diabetes 
patients exhibited a trend towards reduced methylation levels of all genes analysed 
compared to those individuals without a diagnosis of diabetes (as shown in Table A3.3), 
however these did not approach statistical significance (Table 4.10). Overall these 
results suggest no clear correlation between type II diabetes and the measured 
methylation levels, although the comparatively small number of individuals with a 
diagnosis of type II diabetes would have limited the power of the study to identify small 
differences. 
 
Dementia, including Alzheimer’s disease, is rare in the younger population, and the 
incidence increases with age, particularly over the age of 75 years (Matthews and 
Brayne, 2005).  From this analysis, there was no evidence of a significant difference 
between the overall mean DNA methylation levels of participants with and without 
dementia (Table 4.10), although there was a trend towards higher methylation of 
HOXA5 in participants with dementia (Table A3.4). Interestingly, individuals with 
dementia appeared to have significantly higher methylation of EPHA10 than those 
without the disease (Dementia=12.01%, none=10.48%, p=0.009) (Table A3.4), but the 
reliability of this observation at a single gene in a relatively small number of 
participants is unclear, and would need to be replicated in an independent set of 
samples. 
 
The risk of stroke is significantly increased in an elderly population, with a lifetime risk 
of suffering stroke estimated to be around 21% after age 55 (Hollander et al., 2003). 
Although a tendency towards higher DNA methylation levels at several loci was 
identified in participants with stroke (Table A3.5), the T-test analysis showed no 
significant difference between the overall mean DNA methylation levels at any gene 
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(Table 4.10), suggesting that altered DNA methylation in PBL DNA is not a feature of 
participants with an incidence of stroke. 
 
Finally, since the risk of dying inevitably increases with advancing age, we examined 
whether there was any differences in DNA methylation measurements between 
participants who had died prior to phase III of the study (36 months later), or those who 
were still alive. A trend towards higher DNA methylation levels was observed at most 
loci in participants who did not survive to phase III (Table A3.6) however this was not a 
significant relationship at the overall mean (Table 4.10). Again this suggests that DNA 
methylation levels are not significantly different in participants who died within three 
years of sample donation compared to those individuals who were still alive.  
 
Performing a Kaplan-Meier survival analysis could have been used as an alternative 
method for analysing the relationship between DNA methylation levels and survival. 
Participants could be grouped based on their overall methylation level (high or low) and 
combined with survival data, to uncover any significant differences between those 
participants with high DNA methylation compared to those with low levels of DNA 
methylation in terms of survival over 36 months. This may possibly be a more powerful 
analysis as it may identify significant differences in the length of time survived between 
individuals with differential DNA methylation levels. 
 
 
4.3 Validation analysis 
 
To further test our hypothesis that individuals with higher levels of methylation may be 
more susceptible to cancer, participants who developed cancer during the study period, 
after DNA samples were taken at phase I, were selected for analysis of their DNA 
methylation levels. In total 72 participants were diagnosed with cancer within the 3 
years after sample collection (future cancer). Nineteen of these individuals also had a 
previous history of cancer so were included in the initial comparison of methylation 
levels in participants who had a previous cancer. Seventeen individuals were 
unknowing tested as part of the initial control group but were excluded from analysis. A 
total of 36 participants with a future cancer were tested. 
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A number of factors were identified as demonstrating potential associations with 
methylation levels in the initial analysis of 270 Newcastle 85+ study participants 
including gender, smoking behaviour, cardiovascular events, type II diabetes, dementia, 
stroke and survival. Such associations may have arisen by chance due to multiple 
testing, so an additional group of Newcastle 85+ study participants were tested as a 
validation sample set, in an attempt to confirm the findings using independent group. 
Often, the trends observed were not statistically significant so testing additional samples 
may increase the strength of the association. 
 
The validation sample set was comprised of all 24 current smokers, 36 dementia 
patients, and 57 participants diagnosed with Type II diabetes. This represents a total of 
103 unique participants due to an overlap of participants in more than one group, for 
example individuals with both Type II diabetes and dementia. In addition, the 36 
participants with future cancer were included alongside a control group comprised of 71 
participants randomly selected from all remaining participants. In total, the number of 
DNA samples analysed in the validation sample set was 210. 
 
4.3.1 Pyrosequencing results – validation analysis 
 
DNA methylation levels were once more measured at the six same genes; HOXD4, 
TUSC3, TWIST2, HAND2, EPHA10 and HOXA5. For the 210 participants in the 
validation set, the results again demonstrated highly variable DNA methylation levels at 
all loci and the range of DNA methylation measurements, mean and standard deviation 
was very similar at all gene promoters to those observed in the previous 226 participants 
used for the initial analysis (Table 4.11 and Figure 4.6). 
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Gene Methylation Range (%) Mean Methylation (%) Standard Deviation (%) 
HOXA5 30-95 62.8 13.5 
HOXD4 8-33 16.3 4.0 
TUSC3 3-24 9.3 3.3 
TWIST2 2-21 6.3 2.6 
EPHA10 6-24 12.3 3.3 
HAND2 4-17 9.0 2.1 
 
Table 4.11: Properties of PBL DNA methylation measurements in the validation 
sample set of 210 participants in the Newcastle 85+ study 
For each gene, the minimum and maximum methylation level in the DNA samples is 
shown for all participants, together with the mean methylation calculated from 3-6 
consecutive CpG sites and the standard deviation as a measure of variation. 
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Methylation of TWIST2 in 210 PBL DNA Newcastle 85+ Study Samples
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Methylation of HAND2 in 206 PBL DNA Newcastle 85+ Study Samples
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Figure 4.6: PBL DNA methylation levels of HOXD4, TUSC3, TWIST2, EPHA10, 
HAND2 and HOXA5 in the validation sample set of 210 participants from the 
Newcastle 85+ Study 
Samples are shown in ascending order of DNA methylation measurements at each 
particular gene. All genes exhibit highly variable DNA methylation levels between 
individuals. Seven results from HOXD4 and four results at the HAND2 promoter were 
excluded due to a lack of reproducible methylation measurements. 
 
4.3.2 Pairwise correlations of DNA methylation measurements, correlation with 
lymphocyte percentage and correction of measurements to account for lymphocyte 
percentage – validation analysis 
 
As in all previous analysis, calculation of the Pearson correlation coefficient and 
corresponding p value for each pairwise comparison of DNA methylation levels 
revealed strong positive correlations between methylation levels of HOXD4, TUSC3, 
TWIST2, HAND2 and EPHA10 in the 210 participants, which were highly significant 
(Table A3.7). Similarly, there was no association between methylation levels of 
HOXA5 and those at any other gene. 
 
Additionally, the calculated Pearson correlation coefficient again indicated a highly 
significant relationship between the proportion of lymphocytes and DNA methylation 
levels at TWIST2, HOXD4, EPHA10, TUSC3 and HAND2, but not HOXA5 in 210 
participants (Figure A3.8 and Table A3.9).  
 
Once more, DNA methylation measurements for each individual across all five loci 
were adjusted so that each gene contributes an equal proportion to the overall mean. The 
average methylation level across five genes in the validation set of 210 participants was 
10.63%. Linear regression analysis indicated that every 1% increase in lymphocytes 
was responsible for a 0.1947% increase in methylation levels in this validation sample 
set (Figure A3.10) and a specific lymphocyte normalisation factor (Figure A3.11) was 
applied to the DNA measurements of TWIST2, HOXD4, EPHA10, TUSC3 and HAND2 
for each individual participant, to account for the contribution of lymphocytes to DNA 
methylation levels. All analysis performed after this point used the lymphocyte 
corrected DNA methylation values. Changes to the mean, standard deviation and range 
of methylation measurements for each gene after this correction can be found in Table 
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A3.12. As for previous participants, HOXA5 results remained unchanged as DNA 
methylation measurements at this gene are not associated with lymphocytes percentage. 
 
4.3.3 DNA methylation levels of Newcastle 85+ study participants diagnosed with 
cancer throughout the three year study duration, compared to those with no 
cancer 
 
The participants who had a previous incidence of cancer had higher levels of DNA 
methylation compared to cancer-free individuals, which was statistically significant at 
several loci including TUSC3 and HOXD4, as well as the overall sample mean. Next, 
DNA methylation levels measurements from the 72 participants who developed cancer 
during the 3 year follow up of the study (future cancer cases) were compared to the 71 
control group participants in the validation sample set, in addition to the 141 cancer free 
participants from the first analysis, using the Student’s t-test. DNA samples were taken 
prior to cancer diagnosis.  
 
The results revealed that methylation levels at individual loci, TUSC3, TWIST2, 
HOXD4, EPHA10, HAND2 and the overall mean DNA methylation were higher in 
those participants with a subsequent diagnosis of cancer compared to those who 
remained cancer free, reflecting the trend observed in the initial analysis comparing 
previous cancer incidence this no cancer (Table 4.12).  
 
The differences were statistically significant when analysing the overall mean DNA 
methylation at these genes, as well as at HAND2 and EPHA10 individually. Similarly, 
HOXA5 promoter methylation was also increased in participants with a future diagnosis 
of cancer (Table 4.12). These results are intriguing, as it suggests that DNA methylation 
increases may be evident before the onset of clinically detectable disease in the 
Newcastle 85+ study participants. 
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DNA 
methylation 
n TUSC3 TWIST2 HOXD4 HAND2 EPHA10 
Overall 
Mean 
HOXA5 
No cancer 
(%) 
141 9.90 10.61 10.14 10.04 10.37 10.21 62.42 
Previous 
cancer (%) 
113 10.78 10.77 10.79 10.48 10.72 10.71 60.40 
t-test 
p-value 
 0.021* 0.376 0.041* 0.122 0.158 0.043* 0.188 
No cancer 
(%) 
212 10.20 10.75 10.29 10.23 10.32 10.36 62.02 
Future 
cancer (%) 
72 10.82 10.99 10.75 11.18 11.11 10.96 64.19 
t-test 
p-value 
 0.076 0.337 0.128 0.016* 0.014* 0.034* 0.152 
 
Table 4.12: PBL DNA methylation levels of participants with a previous or 
subsequent diagnosis of cancer, compared to cancer-free individuals in the 
Newcastle 85+ study. 
Student’s t-test was used to analyse difference in mean methylation levels between the 
two groups. In the first analysis, TUSC3, HOXD4 and the overall mean were more 
highly methylated in participants with a previous cancer incidence. In the validation 
sample set, there was a statistical significance in HAND2, EPHA10 and the overall 
mean methylation level (*p < 0.05). 
 
 
4.3.3.1 Participants with subsequent diagnosis of haematological cancer had highly 
increased DNA methylation levels 
 
Only 2 of the total 72 participants who were subsequently diagnosed with any cancer 
during the study had a haematological cancer. Participant NE00000472 was diagnosed 
with lymphoma and participant NE00001741 was diagnosed with leukaemia 
approximately one year and two and a half years after DNA samples were obtained, 
respectively. Participant NE00000472 had the highest overall DNA methylation 
(average of TUSC3, TWIST2, HOXD4, EPHA10 and HAND2) and participant 
NE00001741 had the third highest overall DNA methylation of all 480 participants 
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analysed. Although this is based on a very small number of individuals, it suggests that 
high methylation levels of these specific gene loci in PBL DNA samples could predict 
individuals at risk from a haematological based cancer before the onset of clinically 
detectable disease. Methylation levels of all six loci are detailed in Table 4.13, alongside 
the population average measurements. 
 
However, further analysis showed that these two participants had two of the three 
highest measurements of B-cell number measured by flow cytometry within the total 
Newcastle 85+ study population. Although at a population level in the Newcastle 85+ 
study, DNA methylation levels were not associated with B-cell number, previous 
analysis has suggested that B-cells harbour particularly high levels of methylation 
compared to other haematopoietic cell populations (see chapter 4.2.4). This means that 
the high methylation levels in these two individuals may simply be reflecting an 
abnormally increased level of B-cells. 
 
 
Sample TUSC3 TWIST2 HOXD4 HAND2 EPHA10 
Overall 
Mean 
HOXA5 
Mean (%) 
(n=480) 
10.4 8.7 13.1 9.5 11.2 10.6 62.5 
NE00000472  
(rank) 
22.6 
(2) 
25.4 
(2) 
41.1 
(1) 
27.5 
(1) 
23.6 
(1) 
28.0 
(1) 
- 
NE00001741 
(rank)       
20.0 
(8) 
18.2 
(12) 
19.3 
(40) 
18.7 
(5) 
19.1 
(9) 
19.1 
(3) 
88.8 
(6) 
 
Table 4.13: Methylation levels measured in PBL DNA samples from two 
participants with subsequent diagnosis of haematological cancer in the Newcastle 
85+ study 
At each gene, the methylation measurements for participants NE00000472 and 
NE00001741 alongside the Newcastle 85+ study population average measurement. At 
each locus, the rank position of the participant when all 480 participants were sorted 
based on highest to lowest DNA methylation level is shown in brackets after the 
measurement. HOXA5 methylation was not measured for individual NE00000472. 
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4.3.4 Association between DNA methylation levels with gender, smoking behaviour 
and levels of folate, vitamin B12 and homocysteine in the Newcastle 85+ study – 
validation analysis 
 
The same associations made in the first analysis were re-analysed using the validation 
set of 210 participants, in an attempt to confirm any significant findings in an 
independent sample set. 
 
4.3.4.1 DNA methylation and gender – validation analysis 
 
Previous analysis indicated a significant difference in methylation levels at several loci 
such that males had higher levels of DNA methylation than females. The validation 
analysis confirmed this trend at most loci, however only the increased methylation 
levels of males at TUSC3 and the HOXD4 loci reached statistical significance (Table 
4.14). When examining the overall mean, the difference between genders was close to 
statistical significance (p=0.09). These results combined with the first analysis add 
support to previous observations of higher levels of gene specific DNA methylation in 
males. 
 
DNA 
methylation 
n TUSC3 TWIST2 HOXD4 HAND2 EPHA10 
Overall 
Mean 
HOXA5 
Initial sample set 
Males (%) 113 10.97 10.97 10.82 10.81 11.28 10.96 64.96 
Females (%) 157 9.92 10.76 10.27 10.02 10.08 10.21 59.79 
t-test 
p-value 
 0.007* 0.35 0.072 0.030* 0.0001* 0.008* 0.008* 
Validation sample set 
Males (%) 85 11.06 10.64 11.18 10.91 10.64 10.88 63.02 
Females (%) 125 10.34 10.62 10.30 10.48 10.63 10.49 62.64 
t-test 
p-value 
 0.044* 0.480 0.003* 0.110 0.491 0.094 0.420 
 
Table 4.14: Comparison of methylation levels in PBL DNA samples between male 
and female participants in the initial and validation sample sets in the Newcastle 
85+ study 
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Student’s t-test was used to analyse difference in methylation levels between the sexes. 
In the validation analysis, methylation levels of TUSC3 and HOXD4 were significantly 
different between the two groups *(p < 0.05). The overall mean methylation level failed 
to reach significance. 
 
4.3.4.2 DNA methylation and smoking behaviour – validation analysis 
 
In the validation analysis, DNA methylation levels of current smokers were lower than 
both former and never smokers at many loci, which is the opposite trend to that in the 
first analysis (Table 4.15). Although several significant difference between current, 
former and never smokers were implied, the majority of these were not evident in the 
first analysis and so are unlikely to represent real associations. 
 
However, both HAND2 and HOXA5 demonstrated the same relationship in both the 
previous and validation analysis suggesting these loci could be worthy for further 
investigation of their altered methylation levels in smokers. The Student’s t-test analysis 
showed significantly increased methylation of current smokers compared to former 
smokers at HOXA5, and reduced methylation at the HAND2 locus in both current and 
former smokers compared never smokers (Table 4.16).  
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DNA 
methylation 
n TUSC3 TWIST2 HOXD4 HAND2 EPHA10 
Overall 
Mean 
HOXA5 
Initial sample set 
Current 
Smokers (%) 
18 10.74 12.03 10.68 10.64 10.97 11.01 66.67 
Former 
Smokers (%) 
156 10.37 10.47 10.35 10.01 10.64 10.37 60.26 
Never 
Smokers (%) 
95 10.30 11.23 10.72 10.87 10.42 10.70 62.75 
Validation sample set 
Current 
Smokers (%) 
24 9.64 9.44 10.29 10.12 10.53 9.99 67.13 
Former 
Smokers (%) 
122 10.82 10.60 10.95 10.47 10.68 10.71 62.21 
Never 
Smokers (%) 
64 10.64 11.14 10.19 11.12 10.57 10.77 62.28 
 
Table 4.15: Methylation levels in PBL DNA from current, former and never 
smokers in the initial and validation sample sets of Newcastle 85+ Study 
participants 
Methylation levels of TUSC3, TWIST2, HOXD4, HAND2, EPHA10, the overall mean 
and HOXA5. There was a lack of consistent trend between participants in the initial and 
validation sample sets. 
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Student’s t-test TUSC3 TWIST2 HOXD4 HAND2 EPHA10 
Overall 
Mean 
HOXA5 
Initial sample set 
Current v. Never 0.32 0.28 0.48 0.41 0.19 0.35 0.11 
Current v. Former 0.33 0.06 0.32 0.19 0.32 0.18 0.04* 
Former v Never 0.44 0.08 0.18 0.02* 0.27 0.17 0.14 
Validation sample set 
Current v. Never 0.084 0.027* 0.423 0.041* 0.471 0.062 0.078 
Current v. Former 0.039* 0.079 0.104 0.263 0.403 0.060 0.046* 
Former v Never 0.347 0.179 0.020* 0.025* 0.390 0.424 0.486 
 
Table 4.16: Significance of Student’s t-test for differences between PBL DNA 
methylation levels of current, former and never smokers in the initial and 
validation set of Newcastle 85+ study participants 
Student’s t-test was used to analyse difference in DNA methylation levels between 
current and never smokers, current and former smokers, and former versus never 
smokers. Significant associations *(p < 0.05). 
 
 
4.3.4.3 DNA methylation and levels of folate, vitamin B12 and homocysteine – 
validation analysis 
 
As for the previous analysis, individual Z-scores were calculated for each of participants 
in the validation set of 210 participants to examine the relationship between levels of 
homocysteine, vitamin B12 and red cell folate. Initial analysis revealed no relationship 
between levels of folate, vitamin B12 and homocysteine and DNA methylation. The 
Pearson correlation coefficient was calculated for the validation sample set and there 
was a weak but statistically significant positive relationship between the two variables 
at the HAND2 locus, suggesting a higher folate, vitamin B12 and homocysteine score 
may be weakly associated with increased methylation at this gene (Figure 4.7), however 
this is likely to be coincidental, since no relationship was observed in the first analysis, 
and none of the other genes show a similar association (Table 4.17). 
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Relationship between HAND2 methylation (%) and the 
Combined Folate, Vitamin B12 andHomocysteine Z score
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Figure 4.7: Relationship between HAND2 PBL DNA methylation levels and 
combined homocysteine, vitamin B12 and red cell folate Z-score in the validation 
sample set of the Newcastle 85+ study participants 
There is a weak but statistically significant positive correlation between the two 
variables. 
 
 TUSC3 TWIST2 HOXD4 HAND2 EPHA10 
Overall 
Mean 
HOXA5 
Initial sample set 
Combined 
Z – Score 
r = -0.02 
p =  0.72 
r = 0.03 
p =0.58 
r = 0.01 
p = 0.98 
r = 0.09 
p = 0.14 
r = 0.02 
p = 0.78 
r = 0.02 
p = 0.73 
r = 0.01 
p = 0.90 
Validation sample set 
Combined 
Z – Score 
r = -0.10 
p =  0.16 
r = -0.06 
p =0.38 
r = -0.12 
p = 0.10 
r = 0.15 
p = 0.03* 
r = 0.08 
p = 0.24 
r = -0.02 
p = 0.78 
r = -0.05 
p = 0.52 
 
Table 4.17: Relationship between PBL DNA methylation levels and combined 
homocysteine, vitamin B12 and red cell folate Z-score in the initial and validation 
sample sets of the Newcastle 85+ study participants 
The Pearson correlation coefficient (r) and corresponding p values are shown. There 
were no associations in the first analysis but a weak positive association between the 
combined homocysteine, vitamin B12 and red cell folate Z-score and methylation of 
HAND2 in the validation sample set, which was statistically significant *(p<0.05). 
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4.3.5 Validation of observed relationships between DNA methylation 
measurements and clinical outcomes measured in the Newcastle 85+ Study 
 
Once again, overall DNA methylation levels in individuals with CVD, T2D, 
Dementia/Alzheimer’s disease, stroke or participants who had died within three years 
was compared to disease free individuals (Table 4.18). 
 
The validation analysis revealed no significant differences in DNA methylation 
measurements between overall mean DNA methylation levels of participants with CVD 
compared to those with no disease. This was unlike the initial analysis which suggested 
increased overall DNA methylation in participants with CVD compared to those 
without, which was close to statistical significance (p=0.057) (Table 4.18). At several 
individual loci, including HOXA5, the trends observed in the first analysis were 
reversed in validation analysis (Table A3.13), implying that differences in gene specific 
DNA methylation patterns cannot separate individuals with and without CVD. 
 
The DNA methylation levels of 58 pre-selected participants with Type II diabetes (T2D) 
were compared to the control group of 71 in the validation sample set. In the first 
analysis, a trend for lower levels of DNA methylation was observed in participants 
diagnosed with Type II diabetes compared to those who did not have the disease, 
however this association was reversed in the validation sample set (Table 4.18) DNA 
methylation levels at all six gene loci were either no different, or higher in participants 
with Type II diabetes than those without the disease (Table A3.14), implying no clear 
relationships between Type II diabetes and levels of DNA methylation. 
 
For the validation analysis, DNA methylation levels of the 36 pre-selected participants 
with dementia or Alzheimer’s disease were compared to the control group of 71 
participants. In the first analysis, there was no evidence for differential methylation in 
participants with and without dementia with the exception of significantly increased 
EPHA10 promoter methylation in dementia. In this analysis, there was little difference 
in overall mean DNA methylation levels in participants with and without dementia 
(Table 4.18), however, the significantly higher methylation of EPHA10 in participants 
with dementia was replicated (dementia = 11.13%, none = 10.23, p=0.043) (Table 
A3.15). These results suggest that although overall patterns of methylation are not 
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affected, EPHA10 demonstrates consistently higher methylation in PBL DNA samples 
from participants with dementia.  
 
Clinical 
Outcome 
CVD T2D 
Dementia 
(inc. AD) 
Stroke Survival 
Mean overall DNA methylation (%) 
Initial sample set 
No disease/ 
Alive  
10.35 10.55 10.50 10.49 10.46 
With disease/ 
Died 
10.87 10.34 10.85 10.70 10.90 
t-test 
p-value 
0.057 0.323 0.301 0.309 0.150 
Validation sample set 
No disease/ 
Alive 
10.65 10.65 10.68 10.67 10.66 
With disease/ 
Died  
10.64 10.93 10.46 10.46 10.62 
t-test 
p-value 
0.479 0.240 0.305 0.318 0.456 
 
Table 4.18: Comparison of methylation levels in PBL DNA samples in association 
with age-related clinical outcomes in the initial and validation set of Newcastle 85+ 
study participants 
The Student’s t-test was used to analyse differences in overall DNA methylation levels 
between participants with and without cardiovascular disease, type II diabetes, dementia 
including Alzheimer’s disease, stroke and survival. There were no significant 
differences in overall DNA methylation in any analysis of either the initial or validation 
set of samples (p<0.05). 
 
Despite initial results indicating a tendency towards higher methylation levels in 
participants with stroke, subsequent validation analysis indicated no significant 
differences of the overall mean of DNA methylation between participants (Table 4.18).  
 159 
 
At most gene loci, DNA methylation levels were either lower or not different in 
participants with stroke (Table A3.16), again suggesting that DNA methylation patterns 
are not altered by stroke in this population. 
 
Initial indications suggested that the methylation levels at the majority of gene loci were 
higher in participants who did not survive to phase III compared to survivors, although 
this was not a significant association. In the validation analysis however, there was no 
difference between the overall mean DNA methylation level of survivors or non-
survivors (Table 4.18). Mean DNA methylation levels of non-survivors in the validation 
sample set were significantly higher than survivors at HOXA5 (non-survivors = 66.66%, 
survivors = 61.88%, p=0.022) (Table A3.17), although there was only a small 
methylation difference at this gene in the initial analysis which was not statistically 
significant (non-survivors = 62.63%, survivors = 61.68%, p=0.37). 
 
4.4 Construction of a linear regression analysis model 
 
For all the analysis described above, all associations were tested individually. 
Performing the analysis in this manner was useful for generating an initial hypothesis of 
associations which may be related to DNA methylation levels. The reproducibility of 
these associations was tested in a separate set of participants from the 85+ study. One 
issue caused by examining a number of associations individually is that of multiple 
testing, which increases the likelihood of identifying a seemingly significant association 
purely by chance. In addition, individual testing fails to account for the fact that 
associations may be dependent on another factor in the analysis. 
 
In order to perform a more robust analysis, a linear regression analysis model was 
constructed using non-lymphocyte corrected data from all 480 participants tested, to 
identify any variable which had a significant effect on DNA methylation levels at 
HOXD4, TUSC3, TWIST2, HAND2, EPHA10, the overall mean of these 5 genes and 
HOXA5. Variables included lymphocyte percentage, previous history of cancer, 
subsequent diagnosis of cancer, gender, smoking behaviour, CVD, T2D, dementia, 
stroke and survival, which were built into a step-down model. Non-significant 
associations were removed (exclusion criteria p>0.10) and only the effects of significant 
associations on methylation levels were retained (retention criteria p<0.05). This 
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removes seemingly significant associations which are likely caused by additional 
factors. 
 
Each individual locus was analysed in turn as the dependent variable, whilst all other 
variables were input as independent variables. Many associations which were 
significant in individual analysis, such as the increased methylation in participants with 
a previous incidence of cancer, were no longer significantly different when all variables 
were built into the step-down model. The percentage of lymphocytes had a clearly 
significant effect on methylation levels (p<0.000) at TUSC3 (Table 4.19), TWIST2 
(Table 4.20), HOXD4 (Table 4.21), HAND2 (Table 4.22), EPHA10 (Table 4.23) and the 
overall mean of these five loci (Table 4.24), which was previously recognised in the 
correlation analysis and methylation levels were corrected in an attempt to account for 
this. In addition, gender had a significant influence on methylation levels at TUSC3 
(p=0.001, Table 4.19), HOXD4 (p=0.02, Table 4.21) the overall mean (p=0.006, Table 
4.24), and a borderline association at EPHA10 (p=0.057, Table 4.23). At the HAND2 
locus, other associations which remained significant in the model included increased 
methylation in participants with a future cancer diagnosis (p=0.033) and the presence of 
reduced methylation levels in current or former smokers (p=0.005). An association with 
stroke at this gene did not reach statistical significance, but was just outside of the 
exclusion criteria (p=0.092) (Table 4.22). Increased methylation of EPHA10 in 
participants with dementia retained significance (p=0.024), although the increased 
levels of methylation associated with a future cancer diagnosis at this gene 
demonstrated borderline statistical significance (p=0.088) (Table 4.23). The model 
revealed no variables with a significant effect on levels of HOXA5 methylation (Table 
4.25).  
 
These results indicate that affect of many associations which were significantly 
associated with differential DNA methylation levels when analysed alone, such as 
previous or future incidence of cancer, gender and smoking behaviour, may be mediated 
by the presence of other factors within the population, since they lose significance in a 
combined analysis. 
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Coefficients
a
 
Model 
Unstandardized Coefficients 
Standardized 
Coefficients 
t Sig. B Std. Error Beta 
9 (Constant) 3.901 .524  7.447 .000 
 
Lymphocytes_Percent .250 .017 .563 14.440 .000 
 
Gender -1.071 .307 -.136 -3.490 .001 
 a. Dependent Variable: TUSC3 
 
Table 4.19: Significant associations with TUSC3 methylation levels after 
construction of a step-down linear regression model 
All 480 participants were included in this analysis. Independent variables built into the 
model include lymphocyte percentage, previous history of cancer, subsequent diagnosis 
of cancer, gender, smoking behaviour, history of cardiovascular events, type II diabetes, 
dementia, stroke and survival. The magnitude of the effect on DNA methylation levels 
is indicated by the coefficient B. Significant associations (p<0.05). 
 
 
 
Coefficients
a
 
Model 
Unstandardized Coefficients 
Standardized 
Coefficients 
t Sig. B Std. Error Beta 
10 (Constant) 2.595 .629  4.127 .000 
 
Lymphocytes_Percent .273 .021 .518 13.082 .000 
 a. Dependent Variable: TWIST2 
 
Table 4.20: Significant associations with TWIST2 methylation levels after 
construction of a step-down linear regression model  
Independent variables built into the model include lymphocyte percentage, previous 
history of cancer, subsequent diagnosis of cancer, gender, smoking behaviour, history of 
cardiovascular events, type II diabetes, dementia, stroke and survival. The magnitude of 
the effect on DNA methylation levels is indicated by the coefficient B. Significant 
associations (p<0.05). 
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Coefficients
a
 
Model 
Unstandardized Coefficients 
Standardized 
Coefficients 
t Sig. B Std. Error Beta 
9 (Constant) 5.923 .445  13.321 .000 
 
Lymphocytes_Percent .172 .015 .485 11.667 .000 
 
Gender -.610 .261 -.097 -2.335 .020 
 a. Dependent Variable: HOXD4 
 
Table 4.21: Significant associations with HOXD4 methylation levels after 
construction of a step-down linear regression model 
All 480 participants were included in this analysis. Independent variables built into the 
model include lymphocyte percentage, previous history of cancer, subsequent diagnosis 
of cancer, gender, smoking behaviour, history of cardiovascular events, type II diabetes, 
dementia, stroke and survival. The magnitude of the effect on DNA methylation levels 
is indicated by the coefficient B. Significant associations (p<0.05). 
 
Coefficients
a
 
Model 
Unstandardized Coefficients 
Standardized 
Coefficients 
t Sig. B Std. Error Beta 
7 (Constant) 7.524 .518  14.529 .000 
 
Lymphocytes_Percent .114 .016 .320 7.254 .000 
 
Smoking -.375 .132 -.126 -2.849 .005 
 
Future_Cancer .812 .378 .095 2.144 .033 
 
Stroke .658 .390 .074 1.688 .092 
 a. Dependent Variable: HAND2 
 
Table 4.22: Significant associations with HAND2 methylation levels after 
construction of a step-down linear regression model 
All 480 participants were included in this analysis. Independent variables built into the 
model include lymphocyte percentage, previous history of cancer, subsequent diagnosis 
of cancer, gender, smoking behaviour, history of cardiovascular events, type II diabetes, 
dementia, stroke and survival. The magnitude of the effect on DNA methylation levels 
is indicated by the coefficient B. Significant associations (p<0.05). 
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Coefficients
a
 
Model 
Unstandardized Coefficients 
Standardized 
Coefficients 
t Sig. B Std. Error Beta 
7 (Constant) 6.912 .434  15.920 .000 
 
Lymphocytes_Percent .128 .014 .396 9.130 .000 
 
Dementia .883 .390 .098 2.268 .024 
 
Gender -.478 .251 -.084 -1.905 .057 
 
Future_Cancer .584 .342 .074 1.709 .088 
a. Dependent Variable: EPHA10 
 
Table 4.23: Significant associations with EPHA10 methylation levels after 
construction of a step-down linear regression model 
All 480 participants were included in this analysis. Independent variables built into the 
model include lymphocyte percentage, previous history of cancer, subsequent diagnosis 
of cancer, gender, smoking behaviour, history of cardiovascular events, type II diabetes, 
dementia, stroke and survival. The magnitude of the effect on DNA methylation levels 
is indicated by the coefficient B. Significant associations (p<0.05). 
 
 
Coefficients
a
 
Model 
Unstandardized Coefficients 
Standardized 
Coefficients 
t Sig. B Std. Error Beta 
9 (Constant) 5.369 .374  14.361 .000 
 
Lymphocytes_Percent .190 .012 .589 15.398 .000 
 
Gender -.602 .219 -.105 -2.748 .006 
 a. Dependent Variable: OVERALL_MEAN 
 
Table 4.24: Significant associations with overall mean methylation levels after 
construction of a step-down linear regression model 
All 480 participants were included in this analysis. Independent variables built into the 
model include lymphocyte percentage, previous history of cancer, subsequent diagnosis 
of cancer, gender, smoking behaviour, history of cardiovascular events, type II diabetes, 
dementia, stroke and survival. The magnitude of the effect on DNA methylation levels 
is indicated by the coefficient B. Significant associations (p<0.05). 
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Excluded Variables
k
 
Model Beta In t Sig. 
Partial 
Correlation 
Collinearity 
Statistics 
Tolerance 
11 Type2Diabetes .014 .268 .789 .014 1.000 
Dementia .031 .590 .556 .031 1.000 
Survival .040 .762 .447 .040 1.000 
Cardiovascular -.044 -.835 .404 -.044 1.000 
Stroke .045 .846 .398 .045 1.000 
Future_Cancer .067 1.278 .202 .067 1.000 
Lymphocytes_Percent .038 .728 .467 .038 1.000 
Gender -.060 -1.146 .252 -.060 1.000 
Smoking .068 1.294 .196 .068 1.000 
Previous_Cancer -.076 -1.453 .147 -.076 1.000 
k. Dependent Variable: HOXA5 
 
Table 4.25: No significant associations with HOXA5 methylation levels after 
construction of a step-down linear regression model 
All 480 participants were included in this analysis. Independent variables built into the 
model include lymphocyte percentage, previous history of cancer, subsequent diagnosis 
of cancer, gender, smoking behaviour, history of cardiovascular events, type II diabetes, 
dementia, stroke and survival. There were no significant associations (p<0.05), so all 
variables were excluded from the model. 
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4.5 Discussion  
 
In total, 436 Newcastle 85+ study participants were tested in this part of the analysis, 
but results were combined with those from the initial pilot study creating a total of 480 
individuals.  In the initial analysis, 226 DNA were from participants with and without a 
previous history of cancer were compared and also utilised for generating hypotheses of 
associations of DNA methylation levels with other diseases. The remaining 210 
participants formed a validation sample set and were comprised of individuals with a 
future diagnosis of cancer, individuals with specific age-related diseases and a disease 
free control group to enable confirmation of associations from the first analysis. 
 
The Pyrosequencing results for this expanded set of Newcastle 85+ study participants 
revealed that DNA methylation levels at HOXD4, TUSC3, TWIST2, HAND2, EPHA10 
and HOXA5 were highly variable within the 85 year old population, comparable to the 
observations from the pilot study. Furthermore, DNA methylation levels at the HOXD4, 
TUSC3, TWIST2, HAND2 and EPHA10 promoter regions demonstrated strong positive 
correlations with each other, with exceptionally high statistical significance. Again this 
co-methylation of genes suggests certain individuals are more susceptible to increased 
methylation at numerous gene promoters throughout the genome. An alternative 
explanation for the strong correlation between DNA methylation levels of multiple 
promoters may be reflecting a shifting proportion of a specific lymphocyte cell sub 
fraction in certain individuals at an elderly age. This seems unlikely however, given the 
magnitude of DNA methylation levels at some of these promoters which means that the 
proportion of such a specific leukocyte subtype would have to become significantly 
larger in order to contribute towards such an increase in DNA methylation levels. 
 
Additional analysis of correlation revealed that the proportion of lymphocytes within a 
particular individual has a small but highly significant effect on the levels of DNA 
methylation at the HOXD4, TUSC3, TWIST2, HAND2 and EPHA10 promoters. The 
strength of these relationships was significantly greater than in the pilot study, possibly 
due to an increased sample size. In order to avoid the possibility of identifying 
methylation differences between individuals which were solely reflecting differences in 
haematopoietic cell populations, methylation levels at all five genes for all participants 
were corrected to account for the effect caused by differing lymphocyte percentages 
between individuals 
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The main hypothesis under investigation this part of the study was that pre-existing 
methylation may underlie susceptibility to disease, particularly cancer where aberrant 
methylation patterns are frequently observed. Therefore, it was expected that an 
individual with either a previous history of any cancer, or a subsequent diagnosis of 
cancer within the Newcastle 85+ study duration would have higher levels of DNA 
methylation than participants who were free of cancer, This may be particularly at the 
five loci, HOXD4, TUSC3, TWIST2, HAND2 and EPHA10 as we believe these genes 
might acts as ‘sensors’ for similar methylation changes which are occurring throughout 
the genome, since they show a very similar pattern of DNA methylation acquisition.. 
 
All forms of cancer were examined together, since categorising participants based on 
type of cancer could not yield groups with large enough sample sizes to make 
convincing comparisons. Cases of non-melanoma skin cancer were not included as 
either a previous or future occurrence of cancer as it typically has a specific 
environmental cause (sunlight exposure), is relatively common and has a very good 
prognosis, a high cure rate and rare metastasis. Types and frequency of cancer in the 
Newcastle 85+ study participants are detailed in Table 4.26. Some participants had 
more than one diagnosis of cancer at different times. Individuals with non-melanoma 
skin cancer were only included if they had an additional cancer diagnosis at a different 
site. 
 
When performing the individual analysis of incidences of any previous cancer 
compared to a control group with no history of cancer (excluding non-melanoma skin 
cancer), a trend for increased DNA methylation of HOXD4, TUSC3, TWIST2, HAND2 
and EPHA10 in the group of participants with a previous cancer was observed 
(statistically significant difference at TUSC3, HOXD4 and the overall mean), which 
agrees with our hypothesis that individuals with increased levels of DNA methylation 
may be at increased risk of cancer. However, this increased methylation may not 
necessarily be pre-existing and may arise as a consequence of the cancer itself or 
treatment with chemotherapy drugs which can trigger hypermethylation and resistance 
(Nyce, 1997). These concerns can be avoided by examining a DNA sample taken from 
participants before their cancer diagnosis, and so not subjected to treatment. This was 
possible for 72 individuals in the Newcastle 85+ study. All gene loci (HOXD4, TUSC3, 
TWIST2, HAND2, EPHA10 and HOXA5) again show the same trend. Mean methylation 
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levels were higher in the group of participants who subsequently developed cancer, 
which was a statistically significant difference at HAND2, EPHA10 and the overall 
mean. Again, these results are in agreement with our initial hypothesis and suggest that 
increased methylation may exist prior to the development of cancer. It is possible that 
since the source of DNA is PBL cells, if a haematopoietic malignancy is present, 
neoplastic transformation may have already commenced and initiated altered 
methylation changes, although the frequency of haematological malignancy is very low 
in the Newcastle 85+ study population (Table 4.26). Even if such DNA methylation 
changes are triggered by cancer initiation but are evident before the onset of clinically 
detectable cancer, then differential DNA methylation levels at these specific genes may 
still prove a useful marker for possible early diagnosis of the disease in the elderly. 
 
There are several caveats to the analysis presented here. Firstly, the DNA samples were 
taken from peripheral blood and the majority of cancer is occurring in other tissues 
(Table 4.26). However, if the inter-individual differences in DNA methylation have 
underlying genetic basis, then this may well affect DNA on methylation of genes 
similarly across multiple tissues. Thus the increased DNA methylation we observed in 
peripheral blood may also be associated with increased DNA methylation in other 
tissues. Additionally, if inter-individual DNA methylation differences are caused by an 
environmental exposure then blood will be a good surrogate for the likely exposure 
levels of other exposed tissues. Also, blood is a more widely available tissue for study 
as it can be retrieved in a non-invasive manner, unlike other tissue samples.   
 
Secondly the absolute difference in DNA methylation levels between the groups was 
small. For this reason it is important to consider where such differences arise. The 
absolute methylation levels may not be particularly important, but instead may highlight 
differences in methylation patterns (e.g. at the allelic level of methylation density) in the 
participants who are at risk for developing cancer. For example, a recent specific case 
detailing the effect of differential DNA methylation on cancer risk described an MZ 
twin pair discordant for childhood lymphoblastic leukaemia with secondary cancer of 
the thyroid. Analysis revealed differential methylation of BRCA1 in the affected twin 
compared to unaffected twin (12% and 3% respectively). Closer inspection of the allelic 
pattern of methylation found that this was comprised of 13% of alleles which were 
completely hypermethylated, whereas the unaffected twin had no dense methylation and 
only single CpG sites methylated. This was associated with reduced BRCA1 protein 
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levels in the affected twin (Galetzka et al., 2012). This study highlights the impact that 
such relatively small increases can have on DNA methylation levels. The amount of 
BRCA1 methylation in the affected twin is similar, if not lower than some levels 
observed in the Newcastle 85+ study participants, and has a clear impact on protein 
production, and possibly cancer risk. 
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Site of Cancer 
Previous Incidence (n) Future Diagnosis (n) 
1st 2nd 3rd 4th 1st 2nd 3rd 
Lip, oral cavity or pharynx 1       
Oesophagus     1   
Stomach 2 1   3   
Colon 11 2   10   
Recto-sigmoid junction 1       
Rectum 7    3   
Liver  1   2  1 
Pancreas     1   
Bile duct/Gall bladder     1   
Lung 5 2 2 1 9 3 1 
Non-melanoma skin cancer 10 30 17 8 1 1  
Melanoma skin cancer 11 1 1     
Breast 16 2   5   
Cervix 4       
Uterus 3       
Ovary 2    3   
Prostate 14 2   8 1  
Kidney 4    1 1  
Bladder 13 2   12 2  
Thyroid 2       
Lymphoma 5    1 1  
Leukaemia     1   
Multiple myeloma   1     
Brain  1   2   
Eye  1      
Secondary metastatic, ill-defined 1    5 8 1 
Other 1    1  1 
 
Table 4.26: Types of cancer in the Newcastle 85+ Study participants 
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Since there was a large amount of clinical information accompanying the Newcastle 
85+ study participants, associations between DNA methylation levels and factors such 
as gender and smoking behaviour or the presence of age related diseases were 
investigated to generate new hypotheses concerning the role of DNA methylation in 
disease. An attempt to validate these initial associations was then attempted in a further 
set of Newcastle 85+ study participants. 
 
There appeared to be a significant effect of gender on DNA methylation levels. All loci 
were more methylated in males than females (statistically significant at TUSC3, 
HAND2, EPHA10 and HOXA5), and the same trend was confirmed in an additional 
sample set (statistically significant at TUSC3 and HOXD4), suggesting this could be a 
real relationship. Higher levels of methylation at specific genes in males have also been 
reported by others (Sarter et al., 2005; El-Maarri et al., 2007). This association is 
particularly interesting given the differential life expectancy and discordance in disease 
rates between males and females. Could differential DNA methylation in the sexes 
underlie such differences? 
 
There were conflicting effects on DNA methylation levels in current, former or never 
smokers in the two separate sample sets analysed. The first analysis indicated higher 
DNA methylation levels in current smokers at except HAND2, where current smokers 
appeared to have the lowest level of methylation. In addition, former smokers displayed 
the least mean methylation most loci. The validation analysis revealed that HAND2 
methylation was still lowest in current smokers compared to never smokers. The only 
other association which was replicated in both sample sets was the increased 
methylation of HOXA5 in current compared to former smokers. 
 
Previous studies have linked both hypermethylation and hypomethylation of specific 
genes to current smoking behaviour. For example, frequent methylation of several genes 
including RARCDH13, p16 and RASSF1A was noted in the upper aerodigestive tract 
epithelia of healthy current heavy smokers compared to non-smokers (Zochbauer-
Muller et al., 2003). A recent comprehensive genome wide analysis of over 27,000 CpG 
sites in peripheral blood identified a highly significant single site in the F2RL3 locus 
which was methylated at a lower level in smokers than non-smokers (Breitling et al., 
2011). 
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Overall, this analysis suggests there is little effect of smoking behaviour on DNA 
methylation levels, except perhaps at the HAND2 or HOXA5 locus. However, this 
analysis may complicated by reported observations that the quantity of cigarettes 
smoked by current smokers may alter DNA methylation levels. Also, for former 
smokers, time since quitting appears to have a significant impact on DNA methylation. 
A recent genome wide analysis described two loci, F2RL3 and GPR15, which were 
hypomethylated in current smokers. Increased smoke exposure (number of pack years) 
in current smokers was significantly associated with progressively reducing methylation 
of CpG sites in these genes; whereas for former smokers, increasing time since quitting 
was linked to increasing levels of methylation (Wan et al., 2012). This suggests that 
aberrant methylation patterns caused by smoking may be reversible. Neither of these 
factors is considered in our analysis but may be important for determining methylation 
levels within the groups of current and former smokers, and explain why we were 
unable to identify more significant associations. 
 
Nutritional intake, particularly of methyl donors is known to impact upon DNA 
methylation (see section 1.6.3.1). Previous examination has linked folate deficiency to 
genomic hypomethylation of DNA (Rampersaud et al., 2000) and increased levels of 
homocysteine (Jacob et al., 1998), whilst folate supplementation may correct such 
changes by increasing DNA methylation levels (Jacob et al., 1998), although this has 
not been replicated by all studies (Rampersaud et al., 2000). Our analysis of methyl 
donor levels in the Newcastle 85+ study population revealed no relationship between 
the combined folate, vitamin B12 and homocysteine score and DNA methylation; 
although a weak but significant positive correlation was observed at the HAND2 locus 
in the validation sample set. These observations suggest that differential nutritional 
intake of methyl donors is unlikely to be significantly contributing towards variable 
DNA methylation in the Newcastle 85+ study participants. 
 
Analysis of participants with dementia revealed significantly increased methylation 
levels at the EPHA10 promoter, which was confirmed in the validation sample set, 
suggesting that this loci could be worthy of further investigation in dementia. Previous 
examination of altered DNA methylation in dementia has mostly focused on brain tissue 
from Alzheimer’s disease patients (Siegmund et al., 2007), although a recent study has 
suggested that differential methylation of specific genes such as SIRT1 and APP is 
evident in PBL DNA samples taken from Alzheimer’s disease patients compared to 
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controls, which impacts upon expression levels (Hou, 2012). Since no other gene we 
examined demonstrated differential DNA methylation in participants with dementia, it 
is unlikely that a general deregulation of DNA methylation is associated with the 
disease. The difference in EPHA10 methylation could potentially be driven by a nearby 
SNP which affects the methylation state of this specific gene in all tissues, and it may be 
the SNP rather than altered DNA methylation patterns, which is associated with 
dementia. 
 
In the first analysis, trends of either increased or decreased DNA methylation were 
associated with clinical outcomes such as cardiovascular disease, type II diabetes, stroke 
and survival. However we were unable to confirm these same trends in the validation 
sample set. For this reason, it is likely that there is no real effect of these outcomes on 
DNA methylation levels at the specific loci examined. For some outcomes, although the 
same direction of methylation change was observed with disease in both the initial and 
validation sample sets, DNA methylation levels were not significantly different from 
those of individuals without the disease, possibly due to the relatively small number of 
participants diagnosed with many of these age-related diseases. Although trends were 
implied, the sample size is not large enough for a statistically significant association to 
be established. 
 
One problem with the analysis presented here is that of multiple testing. The association 
between DNA methylation levels and the presence of clinical outcomes were analysed 
individually using a standard significance level of p=0.05, however since multiple 
outcomes were analysed in the same sample set, this increases the likelihood that 
significant associations may appear by chance at the level of p=0.05. Therefore, a 
Bonferroni correction may have been appropriate to improve the stringency of the 
statistical tests. As an alternative, a linear regression model was constructed which 
reduced the number of comparisons being made in multiple tests to a single model. 
 
Once all variables were built into the linear regression model, several associations 
retained a significant effect on DNA methylation levels, including proportion of 
lymphocytes at all loci, higher methylation in males at TUSC3, HOXD4 and the overall 
mean, increased methylation of HAND2 in participants with a subsequent diagnosis of 
cancer, reduced methylation of HAND2 in current or former smokers and increased 
methylation of EPHA10 in individuals with dementia, which suggests that these 
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relationships are not dependent on other confounding factors. This significance of these 
relationships requires further investigation. 
 
There was no longer a significant relationship between previous incidences or future 
occurrence of cancer and increased DNA methylation levels at most loci except 
HAND2. One possible explanation for this in case of future cancer is that there are more 
males (58%) than females (42%), and males have been shown to have increased levels 
of DNA methylation. When gender is factored into the model, the association of 
increased methylation in participants with a subsequent diagnosis of cancer is lost. 
However, this is likely to be a relatively small effect. A more likely explanation is that 
in the linear regression analysis model, comparisons are made between participants with 
either a previous history of cancer compared to all other individuals, or a future 
incidence of cancer compared to all other participants, therefore both future and 
previous cancers would be included in the respective control groups and lessen apparent 
associations. This is clearly different to the way the data was analysed in the first 
instance, with two strict control groups, containing no participants with either a 
previous cancer, or a diagnosis of cancer within 3 years of DNA sample donation. 
 
Another possibility is that although DNA methylation increases are evident in blood, 
they are more apparent in the tissue in which the cancer originates. This is well 
illustrated by the only two subsequent diagnoses of haematological cancer (leukaemia 
and lymphoma) which occurred in individuals with some of the highest methylation 
levels of the total population (Table 4.13). Since the majority of both previous and 
future incidences of cancer in this study are occurring in other tissues, it is possible that 
a stronger association between increased DNA methylation and cancer would be 
observed in these tissues rather than blood. However, it is often impractical to obtain 
normal tissue samples, thus for a large study such as this, blood remains the best source 
of DNA for analysis. 
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Chapter 5 – Genome wide methylation analysis of lymphoma cell lines 
to identify genes susceptible to aberrant methylation in both cancer 
and ageing 
 
5.1. Introduction 
 
The number of genes with reports of abnormally increased levels of DNA methylation 
in the cancer epigenome is vast (Costello et al., 2000). Since recently published data has 
indicated that genes which become hypermethylated in cancer are also susceptible to 
altered methylation during ageing, this implies that a large number of genes may be 
susceptible to such aberrant methylation in an elderly individual.  
 
The results presented so far were based on a panel of genes which were pre-selected due 
to either their known hypermethylation in leukaemia, or their age-associated acquisition 
of methylation, and these genes also demonstrated highly variable DNA methylation in 
a population of 85 year olds. These genes also display a strong co-methylation, 
suggesting that the propensity to methylate promoter associated CpG islands varies 
between individuals, and that methylation levels of these genes could act as a “sensor” 
for methylation changes which are occurring at promoter associated CpG islands 
throughout the genome.  
 
However, since these genes were pre-selected, it is possible that some features may be 
related to this non-random selection and not applicable more generally to a larger set of 
genes. Therefore, our aim was to identify hypermethylated genes from an unbiased 
screen of a haematological cancer and examine whether these loci were methylated in a 
similar manner to those loci already examined in normal haematopoietic cells. 
 
In order to identify potentially novel methylation changes in haematological 
malignancies, a genome wide analysis was performed. This was achieved by isolating 
the methylated fraction of DNA using a methyl-binding domain (MBD) based method. 
DNA fragments containing methylated cytosines are recognised and bound by the MBD 
protein component of MeCP2, whilst unmethylated fragments remain unbound. DNA 
fragments were then subjected to high-throughput sequencing for identification of these 
hypermethylated regions.  
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For our analysis, four lymphoma cell lines: DB, HT, Karpas-442 and SUDHL8 were 
selected. DNA from all four cell lines was pooled to form a single sample rather than 
examined individually in order to detect aberrant methylation which is present in 
multiple cell lines. This increases the likelihood that the identified DNA methylated 
changes are truly cancer associated, rather than being unique to a single cell line, as 
such changes may be less relevant in terms of disease and possibly due to cell type 
specific variation. Furthermore, although malignant cell lines generally have more 
frequent methylation than primary samples, this appears to be largely due to an 
increased frequency of methylation of the same set of genes found to be methylated in 
primary samples, as opposed to the existence of large numbers of cell line specific 
methylated loci (Toyota et al., 1999). 
 
Finally, the methylation levels of genes identified by this method will be tested in a 
subset of the Newcastle 85+ study participants, to confirm that genes susceptible to both 
age-related and cancer associated methylation are overlapping. Further examination will 
reveal whether these loci also show a similar pattern of co-methylation to genes in the 
pilot study, suggesting a shared mechanism for the propensity to methylate CpG island 
sequences at numerous loci throughout the genome. 
 
5.1.1 Enrichment of methylated regions by MBD binding 
 
After DNA was prepared from the four individual lymphoma cell lines by standard 
phenol chloroform extraction, DNA was combined to form a single sample and 
fragments of DNA were generated firstly using the Bioruptor® Plus sonication system; 
however gel electrophoresis and the fragment profile generated by Bioanalyzer analysis 
suggested that some of the fragments may be too large, ranging from 150-650bp with a 
mean length of approximately 550bp (Figure 5.1A and B). The optimum fragment size 
for enrichment with MBD protein ranges from 200-500bp, whereas the ideal size for 
Illumina GAIIx sequencing is around 100-300bp, including the additional sequencing 
adapters. For this reason, the Covaris system was also used for DNA shearing which 
allowed the breakdown of DNA fragments which were too large without causing 
addition fragmentation to sections of DNA which were the correct size. The fragmented 
DNA was used to prepare a sequencing library involving the ligation of distinct 
sequences to the 5’ and 3’ ends of the fragments. After the library preparation, the 
fragment profile was again checked using the Bioanalyzer and the mean fragment length 
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was 241bp (Figure 5.2), an ideal length for performance of both MethylCap enrichment 
for DNA fragments containing methylated CpG sites and subsequent sequencing. The 
adapter ligated DNA was subjected to methylated DNA precipitation by MBD protein 
binding, using the MethylCap method. Using this technique, DNA can be precipitated 
on the basis of CpG methylation density by increasing the concentration of salt in the 
elution buffer. 
 
 
 
 
Figure 5.1: (A) gel electrophoresis image and (B) Bioanalyzer analysis of sonicated 
DNA to determine fragment size 
(A) 500ng (5μl) of sonicated DNA was run on a 1% agarose gel with 1 Kb Plus DNA 
Ladder. The smear indicates fragmented DNA in the range of 150-650bp. 
(B) 100ng (1μl) of sonicated DNA was examined by Bioanalyzer analysis. This allows 
more accurate determination of fragment sizes then electrophoresis, and quantitation of 
DNA by examination of the area under the curve, which indicated a fragment range 
from 150-620bp with a mean length of 552bp. Accuracy was determined by inclusion of 
internal controls at 15bp and 1500bp. 
 
 
 
 
A B 
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Figure 5.2: Bioanalyzer analysis of sonicated DNA to determine fragment size after 
ligation of sequencing adapters 
1μl of sonicated DNA was analysed by the Bioanalyzer allowing accurate determination 
of fragment size and quantity of DNA by examination of the area under the curve, 
which indicated a mean fragment size of 241bp and a DNA concentration of 172ng/μl. 
Accuracy was determined by inclusion of internal controls at 15bp and 1500bp. 
 
5.1.2 Validation of enrichment by quantitative PCR (qPCR) analysis of known 
methylated and unmethylated genes 
 
In order to validate the MethylCap technique for isolating methylated regions of the 
genome, successful enrichment was determined by qPCR analysis of a known 
methylated gene, HOXA5; and a known unmethylated gene, GAPDH. Each sample was 
tested in triplicate, and an average Ct value was calculated from three values. In order to 
determine the amount of methylated gene template relative to unmethylated gene 
template in the input DNA as well as the low, medium and high salt concentration 
elution, the delta ( Ct value was calculated by the following formula: 
 
Ct = Ct (GAPDH) - Ct (HOXA5) 
 
As the salt concentration of elution buffers was increased, the amount of HOXA5 
template relative to GAPDH template also increased (demonstrated by an increasing 
Ct value) (Figure 5.3); confirming that HOXA5, a methylated gene, is enriched after 
the MBD protein based precipitation of DNA. In the high salt elution, this typically 
resulted in an enrichment equivalent to 10 cycles, which represents approximately 1000-
fold enrichment for a known methylated region, compared to the input fraction 
containing DNA which has not been subjected to MBD enrichment. The DNA obtained 
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from the high salt fraction was used for high throughput sequencing on the Illumina 
GAIIx platform as this fraction demonstrated the largest fold enrichment for a known 
methylated sequence. 
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Figure 5.3: Validation of the MethylCap technique for methylated DNA 
enrichment by qPCR analysis 
The Ct Value of HOXA5 and GAPDH were compared in each of the different salt 
concentration precipitation fractions, plus input DNA. The Y axis represents the delta 
( Ct value of HOXA5 Ct values compared to GAPDH Ct values as this represents the 
magnitude of HOXA5 enrichment (A higher delta ( Ct value indicates the presence of 
more of the methylated target compared to unmethylated). In the input fraction, no 
enrichment of methylated DNA is expected and there is more GAPDH template than 
HOXA5 (shown by a negative Ct value). HOXA5 enrichment is enhanced by 
increasing salt concentrations (shown by progressively higher Ct values). 
 
5.1.3 Sequencing and Bioinformatics analysis 
 
Once enrichment for methylated CpG containing sequences was confirmed by PCR 
analysis, the DNA fragments were subjected to 75 cycles of paired end sequencing on 
the Illumina GAIIx platform, generating two 75bp sequencing reads (forward and 
reverse). 
 
Bioinformatic analysis was executed by Dr Simon Cockell. Quality control analysis 
removed unreliable sequencing reads prior to mapping onto the human reference 
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genome for identification of enriched fragments peaks from the 4 lymphoma cell lines. 
A gene list was created based on the 10,000 sequencing peaks which either crossed the 
transcriptional start site, or were within 300bp of annotated genes. In order to restrict 
the number of potential target genes for validation, two additional gene lists were 
created containing the top 10% and bottom 10% of peaks which mapped near genes, 
based on the accompanying p-value. The gene list featuring the top 10% of peaks still 
contained over 800 genes, whereas the bottom 10% of peaks mapped near just over 350 
genes since a greater proportion of these peaks matched pseudo genes which were not 
included in the analysis (for further explanation see section 2.15). Genes were selected 
from list of the bottom 10% to compare to those from the top 10% to determine whether 
there was any differences in methylation status of the genes associated with peaks with 
more significant p-values. It was expected that peaks with more strongly significantly p-
values (top 10%) have greater confidence and may be better candidates for true 
hypermethylated cancer-associated genes than those with lower p-values (bottom 10%). 
 
5.2 Validation of methylation status of specific genes in lymphoma cell lines by 
COBRA 
 
Genome wide analysis provided a large list of possible target genes for further analysis, 
therefore a reduced list from which to the select target genes for validation of their 
methylation status in primary samples was required. Consequently, the methylation 
status of genes contained within the top 10% and bottom 10% of all sequencing peaks 
based on p-value were compared using an alternative technique for determining DNA 
methylation (COBRA).  
From the gene list representing the top 10% of peaks, seven genes were selected at 
random for further validation and analysis. These genes were APP, CACNA1B, CELF4, 
CYGB, ERN2, HAP1 and SH2D4A. Additionally, four genes were chosen from the gene 
list featuring the bottom 10% of peaks, which were EBF4, HCK, PDCD5 and TCL1B. 
 
Initially, the DNA methylation status of target genes in the individual cells lines was 
established by COBRA analysis of the promoter regions. This involved restriction 
enzyme digestion of each PCR amplified amplicon with enzymes specifically targeting 
sequences containing a CpG site. The sequence change (CT conversion) induced by 
bisulfite modification at unmethylated sites means that the enzyme cutting site is no 
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longer recognised and the amplicon remains undigested. Methylated sequences are 
recognised and cut into smaller fragments which can be detected by agarose gel 
electrophoresis. 
Of the genes within the top 10%, the COBRA results indicated that all four cell lines 
were highly methylated at the promoter regions of the CANA1B, CELF4 and CYGB 
genes. Both the HT and SUDHL8 cell lines were unmethylated at the APP locus whilst 
DB and Karpas-442 were both hypermethylated. The Karpas-442 cell line demonstrated 
only partial methylation at the ERN2 promoter, whilst the remaining cell lines were 
highly methylated at this gene. The HT cell line was unmethylated at the HAP1 
promoter, whilst the other three cell lines were highly, although not completely, 
methylated. Finally, whilst the DB, HT and Karpas-442 lines were completely 
hypermethylated at the SH2D4A promoter, SUDHL8 was only partially methylated 
(Figure 5.4). These results demonstrate that all of these seven randomly selected genes 
are highly methylated in multiple cell lines. 3/7 were hypermethylated in all four cell 
lines, 3/7 were highly methylated in three of the cell lines and just 1 gene was only 
methylated in two of the cell lines.  
Conversely, of the genes selected from the gene list representing the bottom 10% of 
sequencing peaks, none of the cell lines were methylated at the PDCD5 locus. HCK was 
unmethylated in the SUDHL8 cell line, and showed only partial methylation in both the 
DB and Karpas-442 line whilst HT was only partially methylated at BstUI digested sites 
at this locus. The Karpas-442 cell line showed hypermethylation of EBF4 however only 
partial methylation of specific sites was detected in DB and SUDHL8 whilst HT was 
largely unmethylated. TCL1B was hypermethylated in all four cell lines; however it is 
also highly methylated in peripheral blood making it an uninformative candidate for 
hypermethylation in leukaemia (Figure 5.5). These results suggest that genes within the 
bottom 10% of identified peaks are methylated at a lower frequency in the cell lines 
compared to those in the top 10%, therefore may be more representative of cell specific 
methylation changes as opposed to cancer specific changes. 
Consequently, the genes featured in the top 10% of sequencing peaks may represent 
better candidates for hypermethylated loci in primary leukaemia samples, than those in 
the bottom 10%, and these gene targets identified by our genome wide methylation 
analysis are representative of methylation changes occurring in the majority of the cell 
lines. 
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Figure 5.4: COBRA analyses of seven genes selected from the top 10% of 
sequenced peaks in the individual lymphoma cell lines: DB, HT, Karpas-442 and 
SUDHL8 
Restriction enzyme digestion of the APP, CACNA1B, CELF4, CYGB, ERN2, HAP1 and 
SH2D4A amplicons in the four individual cell lines, alongside methylation standards of 
0%, 33%, 66% and 100%. Restriction enzymes used for DNA digestion are shown and 
detailed in chapter 2 (Table 2.6). Only the TaqI digest is shown at the APP locus. (L) = 
left, (R) = right 
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Figure 5.5: COBRA analyses of four genes selected from the bottom 10% of 
sequenced peaks in the individual lymphoma cell lines: DB, HT, Karpas-442 and 
SUDHL8 
Restriction enzyme digestion of the EBF4, HCK, PDCD5 and TCL1B amplicons in the 
four individual cell lines are shown, alongside known methylation standards of 0%, 
33%, 66% and 100%. Restriction enzymes used for DNA digestion are shown and 
detailed in chapter 2 (Table 2.6) (L) = left, (R) = right. 
 
5.3 Validation of methylation status of specific genes in primary lymphoma/ALL 
samples by COBRA 
 
Once the methylation status of APP, CACNA1B, CELF4, CYGB, ERN2, HAP1 and 
SH2D4A was confirmed by COBRA analysis in the cell lines, a panel of primary adult 
acute lymphoblastic leukaemia (ALL) samples were selected for analysis of their 
methylation status. It is important to confirm that methylation exists in primary samples 
and therefore may be cancer associated, rather than being an artefact of cell culture. We 
did not have sufficient primary lymphoma samples to test, however lymphoid 
leukaemias are closely related to lymphomas as both affect cells of the lymphoid 
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lineage (Swisher et al., 1991) and previous analysis in the lab had suggested a strong 
overlap in the genes methylated in lymphoid leukaemia and lymphoma. The four genes 
selected from the bottom 10% of identified targets were not taken forward for further 
analysis due to the lack of frequency with which they were methylated in the individual 
cell lines. A total of eighteen primary ALL samples were amplified and digested with 
restriction enzymes for each gene, alongside 0%, 33%, 66% and 100% controls (Figure 
5.6). A sample was defined as hypermethylated by the presence of greater than 50% 
methylation. A sample containing >10% but <50% was categorised as partially 
methylated, whilst a sample with <10% methylation was unmethylated.  
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Figure 5.6: DNA methylation of APP, CACNA1B, CELF4, CYGB, ERN2, HAP1 
and SH2D4A in primary acute lymphoblastic leukaemia samples by COBRA 
Restriction enzyme digestion of the APP, CACNA1B, CELF4, CYGB, ERN2, HAP1 and 
SH2D4A amplicons in primary ALL samples alongside methylation standards of 0%, 
33%, 66% and 100%. Only one restriction enzyme digestion is shown for each locus as 
an example. 
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The results demonstrated that methylation of the CACNA1B locus appeared to be a very 
frequent event in ALL, with hypermethylation of all samples evident. Likewise, the 
majority of ALL samples were highly methylated at SH2D4A. At both the CELF4 and 
ERN2 genes partial or hypermethylation was common. In contrast, methylation was 
much less frequent at the CYGB promoter and furthermore, there was no detectable 
methylation of the any of the APP or HAP1 promoter in any of the adult ALL samples 
digested with both restriction enzymes (Table 5.1).  
 
 
 
Gene 
Restriction 
Enzymes 
Hypermethylated 
(n) 
Partial 
methylation (n) 
Unmethylated 
(n) 
APP 
TaqI 0 0 18 
HpyCH4IV 0 0 18 
CACNA1B 
HinFI 16 1 0 
BstUI 17 0 0 
CELF4 
BsiEI 7 8 3 
TaqI 4 13 1 
CYGB 
TaqI 1 4 13 
BstUI 1 4 13 
ERN2 
RsaI 8 6 4 
BsiEI 4 7 7 
HAP1 
HhaI 0 0 18 
RsaI 0 0 18 
SH2D4A 
BstUI 11 4 2 
TaqI 10 5 2 
 
Table 5.1: Results of COBRA assay digestion of APP, CACNA1B, CELF4, CYGB, 
ERN2, HAP1 and SH2D4A in primary ALL samples 
Each gene was digested with two restriction enzymes. The number of samples which 
were defined as being hypermethylated (>50%), partially methylated (>10% and <50%) 
and unmethylated (>10%) with each digest are shown in the Table.  
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5.4 Measuring the methylation status of APP, CACNA1B, CELF4, CYGB, ERN2, 
HAP1 and SH2D4A in the Newcastle 85+ Study by Pyrosequencing 
 
In order to contribute to the hypothesis that age associated and cancer associated 
methylation changes are overlapping, we examined whether these genes which are 
hypermethylated to differing degrees in lymphoid malignancies, also exhibit age 
associated variability in DNA methylation. DNA methylation levels were measured in a 
subset of the Newcastle 85+ study participants by Pyrosequencing.  
 
5.4.1 Pyrosequencing assay design 
 
Suitable forward, reverse and sequencing primers corresponding to the region 
surrounding transcriptional start site were designed using PSQ assay design software as 
previously described (see section 2.2). 
 
5.4.2 Validation of Pyrosequencing assays 
 
Previous COBRA analysis demonstrated that all seven genes were largely unmethylated 
in normal peripheral blood from young volunteers (0% methylated control – see Figure 
5.6). Validation of the Pyrosequencing assays was performed by mixing unmethylated 
normal peripheral blood with varying quantities of in vitro methylated DNA, to create 
known methylation standards of 0%, 5%, 10%, 15%, 20%, 30%, 50%, 60%, 70% and 
100%. This known methylation was plotted against methylation values obtained by 
Pyrosequencing measurements. For all genes, average methylation was calculated 
across 3-5 consecutive CpG sites and all samples were tested in duplicate. Successful 
assay validation was achieved for the APP, CYGB, ERN2, HAP2 and SH2D4A genes, 
shown by the strong, positive correlation between observed and expected methylation 
measurements (Figure 5.7). Unfortunately, validation of CACNA1B and CELF4 was not 
possible, despite numerous redesigns of sequencing primers and forward and reverse 
primer sequences. Therefore the DNA methylation status of these two genes in the 
Newcastle 85+ population remains undetermined. 
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APP Assay Validation: Expected and Measured Methylation
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CYGB Assay Validation: Expected and Measured Methylation
Expected Methylation (%)
0 20 40 60 80 100
M
e
a
s
u
re
d
 M
e
th
y
la
ti
o
n
 (
%
)
0
20
40
60
80
100
r ²	0.966
 
 
ERN2 Assay Validation: Expected and Measured Methylation
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HAP2 Assay Validation: Expected and Measured Methylation
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SH2D4A Assay Validation: Expected and Measured Methylation
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Figure 5.7: Validation of Pyrosequencing assays for APP, CYGB, ERN2, HAP2 and 
SH2D4A genes identified from genome wide methylation analysis of lymphoma cell 
lines 
Linear regression analysis was performed by plotting the expected methylation of each 
sample against the methylation levels at the APP, CYGB, ERN2, HAP2 and SH2D4A 
loci measured by the PyroMark MD instrument, with all assays demonstrating a robust 
positive relationship between these measurements (respective r
2
 values shown on each 
graph). All samples were tested in duplicate and an average of 3-5 CpG sites calculated.  
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5.4.3 Pyrosequencing results of APP, CYGB, ERN2, HAP2 and SH2D4A 
methylation levels in PBL DNA samples from the Newcastle 85+ study population 
 
A sample size of 50 participants was selected for the methylation analysis of APP, 
CYGB, ERN2, HAP2 and SH2D4A in the Newcastle 85+ study, as this quantity of 
participants was successful in the pilot study analysis for both identifying the extent of 
methylation levels at individual loci, and to make an assessment of inter-individual 
variation in methylation at specific genes.  
 
The Pyrosequencing results are presented in Table 5.2, and show the most highly 
methylated and most variable of these five genes was ERN2 (11.8 ± 3.6% [mean ± SD] 
– Figure 5.8), which is similar to the mean methylation and considerable variability seen 
for the most variably methylated genes in the pilot study which were; HOXD4 (14.8 ± 
6.0%), EPHA10 (12.0 ± 3.9%), TUSC3 (8.9 ± 3.4%), TWIST2 (8.4 ± 3.3%) and HAND2 
(7.3 ± 2.8%).   
 
The other four genes: HAP (5.1 ± 3.0%), APP (4.0 ± 2.1%), SH2D4A (4.6 ± 1.7%), and 
CYGB (4.1 ± 1.4%), exhibited lower average DNA methylation measurements, although 
some variation was apparent (Figure 5.8). These methylation patterns at four genes were 
comparable to HLXB9 (3.3 ± 2.1%), APOE (8.4 ± 1.9%), p15 (4.9 ± 1.9%) and ESR1 
(5.5 ± 1.6%) from the pilot study which showed some evidence of moderate variability. 
 
The Pyrosequencing results indicate that the APP, CYGB, ERN2, HAP2 and SH2D4A 
promoter regions, identified from a genome wide analysis of hypermethylated regions 
in lymphoma cell lines and ALL primary samples, also show some evidence of 
becoming methylated in normal elderly PBL DNA samples, suggesting that they may 
also be susceptible to acquiring DNA methylation during ageing as well as in cancer. 
However, the levels of methylation are not as high as several of the genes tested during 
the pilot study. 
 
 
 
 
 
 
 189 
 
Gene Methylation range (%) Mean Methylation (%) Standard Deviation (%) 
ERN2 6-24 11.8 3.6 
HAP1 1-13 5.1 3.0 
APP 1-14 4.0 2.1 
SH2D4A 2-11 4.6 1.7 
CYGB 1-8 4.1 1.4 
 
Table 5.2: DNA methylation properties of APP, CYGB, ERN2, HAP2 and SH2D4A 
analysed by Pyrosequencing in 50 PBL samples from the Newcastle 85+ study 
participants 
For each gene, the minimum and maximum methylation levels in the samples is shown, 
alongside average methylation calculated from 3-5 consecutive CpG sites and the 
standard deviation as a measure of variation. 
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Methylation of ERN2 in 50 PBL DNA Newcastle 85+ Study Samples 
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Methylation of APP in 49 PBL Samples in the Newcastle 85+ Study
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Methylation of SH2D4A in 49 PBL DNA Newcastle 85+ Study Samples
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Figure 5.8: DNA Methylation levels of ERN2, HAP2, APP, SH2D4A and CYGB in 
50 PBL DNA samples from the Newcastle 85+ study measured by Pyrosequencing 
The five genes demonstrate variable methylation levels. One sample was excluded from 
HAP1, APP and SH2D4A results due to a lack of reproducible methylation 
measurements. 
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5.4.4 Correlation of ERN2, HAP2, APP, SH2D4A and CYGB methylation levels 
with methylation levels of genes measured in the pilot study of Newcastle 85+ study 
participants 
 
Finally, the methylation levels of APP, CYGB, ERN2, HAP2 and SH2D4A were 
assessed to determine whether these genes displayed co-methylation, in a similar 
manner to those genes displaying variable methylation in the pilot study. As well as the 
pairwise correlation between APP, CYGB, ERN2, HAP2 and SH2D4A DNA 
methylation levels, a correlation was assessed with the eight genes which were strongly 
correlated with each other in the pilot study. The purpose of this was to further test the 
hypothesis that certain individuals are more susceptible to acquiring methylation at 
numerous loci throughout the genome, which may explain why methylation levels are 
extremely variable within the population. The Pearson correlation coefficient was 
calculated based on methylation levels for all fifty participants at each pair of loci 
(Table 5.3). This analysis revealed that, ERN2 methylation levels were positively 
correlated with methylation levels of TUSC3, HOXD4, HAND2, HLXB9, ESR1 and p15 
with high significance, and the association with TWIST2 was borderline statistically 
significant. Likewise, methylation of SH2D4A demonstrated a significant and positive 
relationship with methylation of HOXD4, HLXB9 and ESR1, and also a positive 
correlation with TWIST2, TUSC3 and p15 although these failed to reach the significance 
level required to compensate for multiple testing. Correlations concerning CYGB 
methylation and TWIST2, HOXD4 and HLXB9 methylation were suggested but did not 
reach statistical significance. Conversely, there was no indication of any relationships 
between APP and HAP1 methylation levels with any other gene.  
 
Both ERN2 and SH2D4 were frequently methylation in primary ALL samples and the 
ERN2 promoter demonstrated the most extensive variability in the 85+ population out 
of the five gene targets identified by genome wide DNA methylation analysis. In 
contrast neither the APP or HAP1 promoter was hypermethylated in any of the primary 
ALL samples; suggesting aberrant methylation of these genes is not common in 
leukaemia. 
 
This suggests that two of the genes, ERN2 and SH2D4, identified by the genome wide 
methylation analysis for cancer associated loci are also methylated in an aged 
population, and similarly fit the pattern of a “CpG island methylator phenotype” 
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observed in the pilot study  whereby certain individuals are predisposed to methylate a 
large number of loci in normal haematopoietic cells. 
 
 
 
 
Table 5.3: Pair-wise correlations between PBL DNA methylation levels of genes 
identified from genome wide analysis and genes analysed in the pilot study of 
Newcastle 85+ study participants 
DNA methylation data for fifty participants (25 individuals for ESR1) was correlated at 
each pair of loci using Pearson test of correlation. The Pearson correlation coefficient (r) 
and corresponding p values are shown. Methylation levels at ERN2 and SH2D4A are 
highly significantly correlated with methylation at several other loci. Black p value = 
NS, Orange p value = significant at <0.05 level, Red p value = significant at <0.0010 
level after performing Bonferroni correction for multiple comparisons. 
 
 
 
 
 APP CYGB ERN2 HAP1 SH2D4A 
APP      
CYGB r = -0.11 
p = 0.44 
    
ERN2 r = 0.21 
p = 0.14 
r = -0.01 
p = 0.90 
   
HAP1 r = 0.18 
p = 0.22 
r = -0.15 
p = 0.29 
r = 0.17 
p = 0.23 
  
SH2D4A r = 0.19 
p = 0.19 
r = 0.03 
p = 0.82 
r = 0.26 
p = 0.07 
r = 0.16 
p = 0.28 
 
TWIST2 r = -0.02 
p = 0.86 
r = 0.36 
p = 0.01 
r = 0.34 
p = 0.01 
r = 0.13 
p = 0.36 
r = 0.38 
p = 0.006 
TUSC3 r = 0.04 
p = 0.74 
r = 0.21 
p = 0.14 
r = 0.48 
p = 0.0004 
r = -0.06 
p = 0.68 
r = 0.41 
p = 0.003 
HOXD4 r = -0.003 
p = 0.97 
r = 0.31 
p = 0.03 
r = 0.47 
p = 0.0006 
r = 0.08 
p = 0.56 
r = 0.48 
p = 0.0004 
HAND2 r = 0.05 
p = 0.71 
r = 0.10 
p = 0.48 
r = 0.71 
p = 5.5e-09 
r = 0.18 
p = 0.22 
r = 0.38 
p = 0.007 
EPHA10 r = -0.04 
p = 0.74 
r = 0.24 
p = 0.09 
r = 0.21 
p = 0.15 
r = 0.08 
p = 0.59 
r = 0.28 
p = 0.08 
HLXB9 r = 0.015 
p = 0.92 
r = 0.44 
p =  0.002 
r = 0.51 
p = 0.0002 
r = 0.001 
p = 0.98 
r = 0.46 
p = 0.001 
ESR1 r = 0.04 
p =0.84 
r = 0.36 
p =0.08 
r = 0.68 
p =0.0002 
r = 0.20 
p =0.34 
r = 0.67 
p =0.0006 
p15 r = -0.01 
p = 0.94 
r = 0.11 
p = 0.41 
r = 0.50 
p = 0.0004 
r = 0.004 
p = 0.97 
r = 0.30 
p = 0.04 
 193 
 
5.5 Discussion 
 
The aim of this part of the study was to strengthen the previously noted overlap between 
genes which are susceptible to hypermethylation in both cancer and ageing. Initially, a 
genome wide DNA methylation analysis of lymphoma cell lines was undertaken. 
 
The use of cell lines in this analysis has disadvantages, such as the propensity for cell 
lines to exhibit exceptionally abnormal methylation profiles, more so than their 
counterpart primary cancer cells (Smiraglia et al., 2001). However, a consequence of 
this high number of aberrantly methylated genes is increased frequency of potentially 
cancer associated loci, which is beneficial for the identification of novel targets. Cell 
lines are also useful for providing an almost infinite source of DNA, as opposed to 
primary samples for which abundant DNA can be difficult to obtain. 
 
A possible problem caused by the use of cancer cell lines is that of ploidy. Although 
normal human cells are diploid, immortalised cell lines and cancer cells often exhibit 
aneuploidy (Pellman, 2007). This can result in certain genes being present at a different 
copy number to the usual two per cell. When cell lines are mixed such as in the analysis 
presented here, the enrichment for hypermethylated genes and subsequent identification 
by genome wide sequencing may be artificially enhanced due to multiple copies of the 
same gene caused by an increased number of chromosomes in certain cell lines. The 
possible bias caused by aneuploidy could be avoided by controlling for copy number 
alterations. Aneuploidy could be identified by sequencing the input genomic DNA of 
the cell lines without any enrichment for DNA methylation to identify whether the 
signal for certain chromosomes was significantly different to the average signal across 
the genome. 
 
The captured of methylated DNA fragments by MBD proteins; in combination with 
high throughout sequencing has many advantages over other techniques for methylation 
analysis. This method required no sodium bisulfite conversion of the DNA as the 
protein acts directly on 5’methylcytosine, which removes potential over-estimation of 
DNA methylation levels due to incomplete modification of DNA. De novo sequencing 
for the identification of methylated regions of the genome was determined to be the 
most informative analysis since there is no preference towards certain gene targets, 
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unlike an array for example, where a limited number of genes or individual CpG sites 
are represented.  
 
The validation of hypermethylated targets identified from the genome wide methylation 
analysis of lymphoma cell lines was performed in primary samples of acute 
lymphoblastic leukaemia origin. Similarities exist between lymphomas and 
lymphoblastic leukaemia as both originate in lymphoid cells, and they share expression 
of some cell surface markers (Swisher et al., 1991), therefore it is likely that many 
genes exist which are susceptible to aberrant methylation in both malignancies. In 
accordance with this, it has been demonstrated that the genes subjected to 
hypermethylation in cases of lymphoma and lymphoid leukaemia can be overlapping 
(Corn et al., 1999; Takahashi et al., 2004). However, more recent and comprehensive 
microarray analysis of over 700 genes in 367 haematopoietic neoplasms of different 
subtypes found important differences in the methylation profiles of all subtypes 
including lymphoblastic leukaemia and lymphomas (Martin-Subero et al., 2009). Also, 
gene expression arrays have revealed differential transcriptional profiles of 
lymphoblastic leukaemia and lymphoma, suggesting that distinctive gene regulatory 
mechanisms, including DNA methylation levels, may be responsible for such 
differences between the two types of malignancy (Raetz et al., 2006). This may explain 
why some of the genes identified as being hypermethylated in the lymphoma cell lines, 
were not methylated in primary leukaemia samples. None of the ALL samples showed 
evidence of any methylation at the APP or HAP1 loci, and only one sample was 
hypermethylated at the CYGB locus. Either using primary samples for the initial 
genome wide methylation analysis, or validating the genes hypermethylated in 
lymphoma cell lines using primary lymphoma tissues may have increased the specificity 
of identified targets, but sensitivity for new targets would be reduced unless a large 
number of primary samples could be analysed for recurring DNA methylation changes. 
 
The Pyrosequencing results of 50 participants from the Newcastle 85+ study showed 
variation at all loci, although overall DNA methylation levels were quite low at most 
loci. The methylation levels were highest at ERN2, which was one of the genes for 
which several ALL samples were hypermethylated. Even the three loci, APP, HAP1 and 
CYGB which were unmethylated or methylated very infrequently in the ALL samples, 
showed some evidence of variable methylation in the 85 year old population. 
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Out of the seven genes, only four (CACNA1B, CELF4, ERN2 and SH2D4A) were 
methylated with a high degree of frequency in primary leukaemia samples. 
Unfortunately, no assessment of CACNA1B and CELF4 could be made in the Newcastle 
85+ study participants, but pair-wise correlation analysis of ERN2 and SH2D4A 
revealed strong positive and highly significant correlations between both ERN2 and 
SH2D4A, and the methylation levels at several of the loci measured in the pilot, as well 
as a positive relationship between methylation levels of these two loci although this was 
of borderline statistical significance. 
 
This is similar to the observation made in the pilot study whereby genes which are 
methylated in leukaemia/lymphoma, exhibit variable methylation in the elderly and a 
pattern of methylation acquisition which is similar at multiple loci across the genome. 
The fact that methylation levels of the loci which were confirmed to be frequently 
methylated in leukaemia in our analysis, were correlated with methylation levels at 
other loci in normal cells, suggests a mechanism affecting the acquisition of methylation 
which could potentially be affecting hundreds of loci simultaneously (an age-related 
“CpG island methylator phenotype”). Some individuals may be more susceptible to 
acquiring methylation, explaining their high methylation levels of numerous loci. 
Further validation and testing of other gene targets identified from the genome wide 
methylation analysis could confirm whether this is the case. My results also suggest the 
existence of a second type of increased methylation during ageing, of those genes which 
are infrequently methylated in leukaemia. The methylation levels at these genes do not 
correlate with each other, so DNA methylation at these promoters may be sporadic. 
 
For the SH2D4A gene, there is some reported evidence of altered expression in 
malignancies, which could potentially be mediated by hypermethylation. Although there 
is no direct evidence in the literature regarding the presence of hypermethylation of 
SH2D4A in leukaemia; however the number of reports of activity of this gene is low. 
The SH2D4A protein has a high level of homology to two other proteins, TSAd and 
ALX, which function in the regulation of T cell receptor signalling. Both the generation 
of SH2D4A deficient mice, and the knockdown of SH2D4A by RNA interference in 
human T cells appeared to have no effect of normal functioning, suggesting a non-
essential role in signalling (Lapinski et al., 2008). As well as being expressed in T cells, 
SH2D4A is universally expression in numerous tissues and has been suggested to be 
involved in estrogen receptor alpha signalling pathways, acting as an inhibitor of 
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proliferation (Li et al., 2009). In addition to this, a region on chromosome 8p containing 
the SH2D4A gene is deleted in incidences of hepatocellular carcinoma (HCC) with poor 
prognosis. Re-expression of SH2D4A in HCC cell lines inhibited cell growth and 
injection of SH2D4A into nude mice reduced tumour incidence (Roessler et al., 2012). 
This evidence suggests a tumour suppressive role for SH2D4A, which could be 
potentially silenced by hypermethylation. 
 
For the ERN2, a role in cancer remains to be elucidated. However, overexpression of 
Ern2 in mice is associated with activation of the unfolded protein response, a stress 
response of the endoplasmic reticulum, which could also trigger apoptosis (Kaufman, 
1999). This observation proposes a possible hypothesis whereby silencing expression of 
ERN2 by a mechanism such as hypermethylation could be beneficial for survival of a 
tumour cell. 
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Chapter 6 – Biological significance of DNA methylation levels 
in the 85+ study participants 
 
One of the key advantages of performing this analysis within the context of the 85+ 
study is that numerous other analyses were also being performed on the same or 
overlapping sample sets, thus allowing additional opportunities for assessing the 
potential biological significance of identified variation in methylation, both at a 
molecular and a clinical level. 
 
6.1 Identification of candidate genes which may control the differential 
development of age related CpG island methylation. 
 
6.1.1 SNPs and DNA methylation 
 
In an attempt to uncover a possible explanation for variable DNA methylations levels in 
this population, the role of genetic variation was assessed by integration of SNP 
genotyping data and methylation data to determine which, if any, SNPs or genomic 
regions correlate with DNA methylation levels in the Newcastle 85+ study participants. 
The primary purpose of this analysis was to identify candidate genes which may control 
global levels of CpG island methylation. 
 
In order to examine the possibility that allelic variants caused by SNPs are associated 
with particular traits in the Newcastle 85+ study, a genome wide association study 
(GWAS) analysis was undertaken by Dr Kristin Ayers and Dr Heather Cordell.  
 
Genotyping of 733,202 SNPs in 642 Newcastle 85+ study participants was performed 
using an Illumina OmniExpress array at the Estonian Genome Center, University of 
Tartu, Estonia. This was combined with DNA methylation data set, providing a total of 
411 participants with both measurements available. 
 
Since methylation measurements at TWIST2, HOXD4, TUSC3, EPHA10 and HAND2 
are correlated with each other, and levels at these genes seem to act as a sensor for 
methylation changes at multiple loci, the overall mean methylation of these five genes 
was used to represent a single DNA methylation value for each participant, which was 
then correlated with the SNP data. 
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Since only a fraction of all potential SNPs were assayed by genotyping in this analysis, 
information about additional SNPs was inferred using the presence linkage 
disequilibrium (LD) within the local region, using the International Haplotype Map 
Project (HapMap) as a reference data set, as it contains a large number of genotyped 
SNPs. This enabled the likely alleles of SNPs which were not directly genotyped to be 
determined and these are referred to as imputed SNPs. 
 
The large number of variables in GWAS can lead to the identification of false 
relationships due to multiple testing. Because of this, previous GWAS analyses have 
typically applied a very stringent level of significance for associations with genotype at 
around 5 × 10
-8 
(corrected from p<0.05) (Risch and Merikangas, 1996; Pearson and 
Manolio, 2008; Johnson et al., 2010), although the exact threshold varies depending on 
the exact number of SNPs in an individual study. However, for this analysis a less strict 
level of significance was used (p<1 × 10
-5
). This allowed a preliminary identification of 
SNPs which were suggested to be associated with DNA methylation levels, whilst 
reducing the likelihood of identifying false associations. Further validation of such 
associations will be required 
 
6.1.2 Relationship between SNPs and DNA methylation levels – results 
 
The negative logarithm of the significance level for associations between both 
genotyped and imputed SNPs and levels of DNA methylation was calculated and are 
displayed using a Manhattan plot (Figure 6.1). Strongly related SNPs have the smallest 
p values and therefore highest negative logarithm of the p value. 
 
The results showed that several genotyped SNPs on chromosomes 1, 4, 7, 11, 14 and 21 
and imputed SNPs on chromosomes 1, 4, 6, 7, 11, 14 and 21, may be associated with 
DNA methylation levels with genome wide significance. Table 6.1 details the position 
and allele frequencies of identified SNPs.  
 
Next, in order to further characterise the genomic location of methylation-associated 
SNPs, the LocusZoom tool (URL http://csg.sph.umich.edu/locuszoom/) (Pruim et al., 
2010) was utilised to identify genes within the region. The genotyped SNP with the 
smallest p-value on chromosomes 1, 4, 11, 14 and 21 was designated as the central SNP 
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from which linkage disequilibrium of other SNPs was determined (r
2
 value). The SNPs 
on chromosomes 1, 4 and 14 were not located either within or nearby to genes (>50kb 
away from nearest gene) (Figure 6.2). Interestingly, SNPs located on chromosome 11 
and 21 were both positioned within the 3’ end of the genes, Down syndrome cell 
adhesion molecule like 1 (DSCAML1) (Figure 6.3) and Down syndrome cell adhesion 
molecule (DSCAM) (Figure 6.4) respectively. Further investigation of these two loci 
revealed that they are highly related. An analysis of protein similarity using NCBI 
BLAST (Basic Local Alignment Search Tool) revealed a homologous protein structure 
between DSCAM and DSCAML1 (59% similarity) with no other strongly similar 
proteins (maximum similarity was only 33% over relatively small portions of DSCAM). 
The high level of homology between these two proteins suggests that they will likely 
have similar functions. 
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Figure 6.1: Manhattan plots displaying significance of associations between 
individual SNPs and DNA methylation levels in the Newcastle 85+ study 
The plots show the association between methylation and both genotyped SNPs (A) and 
imputed SNPs (B). Genomic location is displayed along the X-axis and negative 
logarithm of the p value for the association with methylation at each SNP shown on the 
Y-axis. SNPs showing potentially significant association are indicated by an arrow (p-
value>negative logarithm 1 × 10
-5
).
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Chr. rsID Position A B Frequency (A) p-value Genotyped 
1 
rs1116438 112551210 C T 0.316 4.84E-06 No 
rs12564809 112580127 G A 0.292 9.72E-06 Yes 
rs12033004 112581191 G A 0.293 8.64E-06 Yes 
rs2788420 112585128 A G 0.293 5.69E-06 No 
rs2119192 112585504 A C 0.293 5.68E-06 No 
rs7534975 112586441 C T 0.297 4.19E-06 No 
4 
rs7669062 175328361 A G 0.332 7.15E-06 No 
rs13102070 175329014 C T 0.334 5.76E-06 No 
rs7657652 175330825 C A 0.347 7.80E-06 Yes 
6 rs708017 37104751 C G 0.460 8.43E-06 No 
7 rs10237793 146069234 A G 0.022 5.22E-06 Yes 
11 
rs11216542 117155935 C T 0.469 7.71E-06 No 
rs7940750 117158560 A G 0.402 5.76E-06 Yes 
rs7124184 117160273 C T 0.390 8.52E-06 No 
14 
rs8020379 93385069 A G 0.394 1.99E-06 No 
rs8021173 93385453 C T 0.394 1.93E-06 No 
rs11160147 93386595 A G 0.406 1.87E-06 No 
rs1956661 93388655 G A 0.396 9.96E-07 Yes 
rs753642 93390339 C T 0.394 1.93E-06 No 
rs910784 94964112 A G 0.458 1.02E-04 No 
rs1187751 94964331 A G 0.458 1.04E-04 Yes 
21 
rs1001972 41069632 C G 0.190 3.36E-07 No 
rs1571724 41070706 G A 0.191 2.45E-07 Yes 
 
Table 6.1: GWAS identification of SNPs potentially associated with DNA 
methylation levels in the Newcastle 85+ study participants. 
For each SNP, the chromosomal position, allelic variants, minor allele frequency and p-
value for the association with DNA methylation level are shown. Information about 
non-genotyped (imputed) SNPs was inferred by the presence of LD within the local 
region. The local genomic regions of genotyped SNPs highlighted in bold font were 
investigated. Chr. = Chromosome. 
 
 202 
 
 
 
 
 
 
 
 
 
 
A 
B 
 203 
 
 
 
 
 
 
Figure 6.2: LocusZoom plots of DNA methylation associated SNPs on 
chromosomes 1, 4 and 14 
The genotyped SNP with the smallest p value was allocated as the central SNP (purple 
square) from which linkage disequilibrium was calculated (r
2
 value). Genotyped SNPs 
are represented by squares and imputed SNPs by circles. SNPs on chromosome 1 (A), 
chromosome 4 (B) and chromosome 14 (C) were not located nearby to genes (>50kb 
distance from nearest gene). 
 
 
 
 
 
C 
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Figure 6.3: LocusZoom plot of methylation associated SNPs on chromosome 11 
The genotyped SNP with the smallest p value was allocated as the central SNP (purple 
square) from which linkage disequilibrium was calculated (r
2
 value). Genotyped SNPs 
are represented by squares and imputed SNPs by circles. SNPs were located within the 
DSCAML1 gene. 
 
Figure 6.4: LocusZoom plot of methylation associated SNPs on chromosome 21 
The genotyped SNP with the smallest p value was allocated as the central SNP (purple 
square) from which linkage disequilibrium was calculated (r
2
 value). Genotyped SNPs 
are represented by squares and imputed SNPs by circles. SNPs were located within the 
DSCAM gene. 
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6.1.3 Discussion of the association between SNPs and DNA methylation levels 
 
A recent analysis of human cell lines examined the differential methylation status of 
specific alleles caused by the presence of a heterozygous SNP by bisulfite sequencing. 
There were two categories of SNP identified by this study. Firstly were those which 
affected methylation only at the site which was overlapping the SNP, since the 
nucleotide change resulted in a loss of potential to methylate that particular site. This 
appeared to be the most frequent consequence of SNPs. Secondly were examples of 
SNPs which despite only affecting a single site, were associated with similar pattern of 
methylation at nearby CpG sites, suggesting these SNPs may be located in regions 
involved in the regulation of DNA methylation levels (Shoemaker et al., 2010), possibly 
affecting CpG sites within 2Kb of the most strongly SNP-associated CpG site (Bell et 
al., 2011). 
Alternatively, SNPs may cause differential expression of a gene or genes involved in 
determining methylation patterns. This would have consequences for methylation levels 
at loci throughout the genome as opposed to only those genes with a nearby SNP. An 
examination of approximately 3 million SNPs and 27,000 CpG sites in lymphoblastoid 
cell lines from HapMap individuals found that genotype associated methylation was 
mostly due to nearby SNPs within 50Kb. A SNP (rs10876043) located in DIP2B, a gene 
previously implicated in DNA methylation as it contains binding sites for DNA 
methyltransferase 1 – associated protein 1, which in turn interacts with DNMT1, was 
seemingly related to overall DNA methylation levels; however this was a fairly weak 
association (Bell et al., 2011). 
 
SNPs in two genes, DSCAM and DSCAM1 were identified from the GWAS as being 
potentially associated with DNA methylation levels in the Newcastle 85+ study 
population. Whilst the role of proteins involved in cell adhesion in determining DNA 
methylation patterns is not clear, the fact that the only two SNPs within genes which 
were significantly associated with methylation levels were located in two highly 
homologous genes of the same family suggests that this observation may well be 
functionally significant, although confirmatory studies in other sample sets will be 
required. 
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Additionally, there is evidence that the DSCAM enhancer is bound by FOXA1 (Carroll 
et al., 2005). FOXA1 is a forkhead DNA binding protein and has been recently 
identified in our lab as a possible candidate for mediating the altered DNA methylation 
patterns observed in undifferentiated and differentiated cells (Strathdee and Thathia, 
unpublished data). 
 
6.2 Association between mitochondrial haplogroups and DNA methylation levels in 
the Newcastle 85+ study participants 
 
6.2.1 Mitochondria, reactive oxygen species and DNA methylation 
 
Reactive oxygen species (ROS) are often a by-product of normal cellular processes, 
including mitochondrial oxidative phosphorylation (Cooke et al., 2003). However, ROS 
can damage cellular macromolecules including DNA, triggering a DNA damage 
response which is typically repaired by base excision repair (Cooke et al., 2003). 
 
Several publications have suggested that DNA methylation patterns could be influenced 
by oxidative stress (reviewed in (Franco et al., 2008)). A recent study described a 
possible mechanism for this association. Treatment of cell lines with hydrogen peroxide 
to induce oxidative damage led to the formation of large multi-protein silencing 
complexes containing DNMT1, DNMT3B, SIRT1 and members of the PRC4, which 
are recruited to chromatin at sites of oxidative DNA damage, particularly those in 
promoter associated CpG islands (O'Hagan et al., 2011). A reduction in the active 
chromatin mark (H3K4me3), increased DNA methylation specifically at genes 
containing CpG island promoters and reduced expression was detected. Additionally, a 
link was observed between the genes which exhibit this oxidative damage response and 
those susceptible to hypermethylation and silencing in cancer (O'Hagan et al., 2011). 
This study suggested that different levels of exposure to oxidative stress could mediate 
differential DNA methylation levels. 
 
Mitochondrial haplogroups reflect SNP differences in mitochondrial DNA (mtDNA) 
sequences which represent different lineages from a single common ancestor and there 
is evidence linking mtDNA variants with ageing, longevity and disease (De Benedictis 
et al., 1999; Takasaki, 2009; Nishigaki et al., 2010), however the mechanisms 
underlying such relationships was not determined. 
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It is thought that mtDNA haplotype may influence mitochondrial function via effects on 
oxidative phosphorylation capability. For example, haplogroup J has been suggested to 
have lower oxygen consumption and ATP production than haplogroup H (Gomez-
Duran et al., 2012). Analysis suggests that individuals with haplogroup H have the 
greatest maximum oxygen consumption and highest levels of mitochondrial oxidative 
damage, a sign of increased ROS production (Martinez-Redondo et al., 2010).  
 
The possibility that the mtDNA genome can influence DNA methylation of the nuclear 
genome was emphasised by the disrupted DNA methylation patterns observed in Rho
0
 
cells, which lack a mitochondrial genome. Such changes could be partially reversed by 
the replacing mtDNA in these cells (Smiraglia et al., 2008), which suggests that 
mtDNA is somehow involved in regulating epigenetic mechanisms. 
 
As both the mtDNA genome and oxidative stress have been linked to the establishment 
of DNA methylation, and differing mtDNA haplogroups appear to exhibit functional 
differences, it is possible that the differing ROS levels generated by specific 
haplogroups can lead to differential DNA methylation levels between individuals. 
 
6.2.2 Association between mitochondrial haplogroups and DNA methylation levels 
– results 
 
In order to investigate the association between DNA methylation levels and mtDNA, 
DNA methylation measurements from the Newcastle 85+ study participants were 
compared dependant on their mtDNA haplogroup. MtDNA haplogroups were 
determined by Dr Angela Pyle and were available for 444 Newcastle 85+ study 
participants whose DNA methylation levels were known. Average overall DNA 
methylation measurements of participants sharing the same haplogroups are shown in 
Table 6.2. 
 
A step-down linear regression analysis model was constructed using non-lymphocyte 
corrected data from all 480 participants tested, to identify any mtDNA haplogroup 
which had significantly different DNA methylation levels at HOXD4, TUSC3, TWIST2, 
HAND2, EPHA10 and the overall mean of these 5 genes. Other variables included in the 
model were lymphocyte percentage and gender. Non-significant associations were 
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removed (exclusion criteria p>0.10) and only mtDNA haplogroups significantly 
associated with DNA methylation levels were retained (retention criteria p<0.05). 
 
There were no significant associations between overall DNA methylation level and any 
of the mtDNA haplogroups remaining in the step-down model, only the proportion of 
lymphocytes and gender were related to DNA methylation levels, which was expected 
based on previous results (Table 6.3).   
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MtDNA Haplogroup 
Number of 
individuals 
TWIST2 TUSC3 HOXD4 HAND2 EPHA10 Overall mean (%) 
H 196 10.75 10.23 10.43 10.57 10.48 10.50 
I 8 10.40 9.27 11.01 9.38 9.5 9.92 
J 47 9.78 10.80 10.59 10.45 9.98 10.32 
K 29 10.76 10.75 10.57 10.31 11.2 10.73 
T 51 9.37 9.49 10.08 9.72 10.57 9.84 
U 70 11.02 11.20 10.77 10.56 10.88 10.90 
V 17 11.55 11.13 11.91 12.02 11.33 11.58 
W 14 10.44 11.71 10.87 11.03 10.30 10.87 
X 12 8.98 9.96 9.62 9.25 9.56 9.48 
No haplogroup 36       
 
 
Table 6.2: Mitochondrial DNA haplogroups and DNA methylation levels in the Newcastle 85+ study participants 
DNA methylation levels of TWIST2, TUSC3, HOXD4, EPHA10, HAND2 and the overall mean in Newcastle 85+ study participants with different 
mtDNA haplogroups. 
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Coefficients
a
 
Model 
Unstandardized Coefficients 
Standardized 
Coefficients 
t Sig. B Std. Error Beta 
 (Constant) 6.818 .387  17.620 .000 
Lymphocytes .141 .013 .466 10.859 .000 
Gender -.451 .248 -.078 -1.817 .070 
a. Dependent Variable: OVERALL_MEAN 
 
Table 6.3: Significant associations with overall mean DNA methylation levels from 
the step-down linear regression model analysis of mtDNA haplogroups. 
None of the mtDNA haplogroups were associated with overall DNA methylation levels. 
Both gender and lymphocyte percentage was related to levels of DNA methylation 
which was expected based on previous analysis. The magnitude of the effect on DNA 
methylation levels is indicated by the coefficient B. Significant associations (p<0.05). 
 
 
 
In addition, the relationship between mtDNA haplogroup and DNA methylation levels 
of each of the genes was tested individually by the linear regression analysis model. 
Added to the expected link with lymphocytes and gender, individuals with haplogroup 
T had significantly lower levels of DNA methylation at TUSC3 (p=0.049) (Table 6.4). 
Individuals with the mtDNA haplogroup V demonstrated significantly higher 
methylation at the HAND2 locus (p=0.031) (Table 6.5). At all other loci there were no 
associations between DNA methylations levels and mtDNA haplogroup.  
 
Based on such results however, there is little evidence to support the hypothesis that 
specific mtDNA haplogroups may exhibit differential methylation patterns in the 
Newcastle 85+ study population, at least for the set of loci analysed in this study. 
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Coefficients
a
 
Model 
Unstandardized Coefficients 
Standardized 
Coefficients 
t Sig. B Std. Error Beta 
 (Constant) 5.989 .544  11.012 .000 
Lymphocytes .185 .018 .441 10.174 .000 
Gender -.892 .347 -.112 -2.575 .010 
hap_T -1.041 .528 -.084 -1.972 .049 
a. Dependent Variable: TUSC3 
 
Table 6.4: Significant associations with TUSC3 methylation levels from the step-
down linear regression model analysis of mtDNA haplogroups  
The mtDNA haplogroup T was associated with lower levels of TUSC3 DNA 
methylation. The magnitude of the effect on DNA methylation levels is indicated by the 
coefficient B. Significant associations (p<0.05). 
 
 
Coefficients
a
 
Model 
Unstandardized Coefficients 
Standardized 
Coefficients 
t Sig. B Std. Error Beta 
9 (Constant) 8.235 .458  17.965 .000 
Lymphocytes .074 .016 .219 4.746 .000 
hap_V 1.647 .762 .100 2.161 .031 
a. Dependent Variable: HAND2 
 
Table 6.5: Significant associations with HAND2 methylation levels from the step-
down linear regression model analysis of mtDNA haplogroups 
The mtDNA haplogroup V was associated with increased HAND2 DNA methylation. 
The magnitude of the effect on DNA methylation levels is indicated by the coefficient 
B. Significant associations (p<0.05). 
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6.2.3 Discussion of the association between mitochondrial haplogroups and DNA 
methylation levels 
 
The results of the linear regression analysis suggested that mitochondrial haplogroups 
are unlikely to be associated with the highly variable DNA methylation patterns 
observed in the Newcastle 85+ study population. A link was suggested between altered 
DNA methylation levels of two specific loci, TUSC3 and HAND2 with the T and V 
mtDNA haplotype respectively, however, these associations were not strongly 
significant, and the same significance could not be achieved at other loci. Participants 
with the V haplogroup actually had increased levels of methylation at all five loci 
compared to participants in all other haplogroups (Table 6.2), but the very small number 
of individuals with this haplogroup (n=17), make it hard to assess the potential 
significance of this observation. Thus while this study presents little evidence of a link 
to mitochondrial haplotypes, a link between methylation and some of the rarer 
haplotypes, particularly the V haplotype, cannot be excluded. 
 
A recent study examining levels of global methylation in peripheral blood from elderly 
individuals with different mitochondrial haplogroups, found that people with the J 
haplogroup appeared to have a significantly higher global level of DNA methylation 
than those individuals with other haplogroups (Bellizzi et al., 2012a). Analysis was also 
performed by in vitro experiments using cybrid cells, containing identical nuclear 
genomic DNA but mtDNA from different haplogroups (H, J, U, X and T). Methylation 
levels were variable between the haplogroups and once again, the J haplogroup was 
associated with the highest levels. The J cybrids also exhibited lower levels of ROS, 
ATP and increased expression of MAT1A, a gene involved in the synthesis of SAM, 
This  suggests that increased SAM availability may be a possible mechanism for the 
higher DNA methylation status linked with carriers of this mtDNA variant (Bellizzi et 
al., 2012a). We did not observe the same trend for high DNA methylation associated 
with the J haplogroup in the specific genes examined in Newcastle 85+ study 
participants.  
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6.3 Association between frailty and DNA methylation levels in the Newcastle 85+ 
study participants 
 
6.3.1 Frailty and DNA methylation 
 
Frailty encompasses a multitude of symptoms associated with declining function and 
increasing vulnerability to disability and death in the elderly (Weiss, 2011). There is no 
universally accepted method to define frailty, and many means of classifying frailty 
have been suggested. Two of the foremost methods applied to characterise frailty in 
elderly individuals are those proposed by Fried and Rockwood. 
 
Fried applies a fairly simplistic estimation of frailty considering few variables. Frailty is 
defined as a clinical syndrome comprised of three or more of the following 
characteristics: weight loss, exhaustion, low physical activity, muscle weakness or slow 
walking speed (Fried et al., 2001). 
 
The Rockwood approach is more focused on an accumulation of health defects, 
measured by the presence of disease-related and clinical symptoms and abnormal 
clinical test results (Rockwood et al., 2005). A standardised protocol was developed to 
determine a consistent measure of frailty, the Rockwood frailty index (RFI) (Searle et 
al., 2008).  
 
In an attempt to uncover the consequences of inter-individual variability of DNA 
methylation in the elderly, a recent study examined the relationship between global 
DNA methylation levels and the presence of frailty in 318 individuals aged 65-105 
years (Bellizzi et al., 2012b). Frailty was assessed using a cluster analysis applied by 
Montesanto et al (2010), using a combination of physical (activities of daily living, hand 
grip strength), cognitive (mini mental state exam (MMSE) score) and psychological 
(depression) markers to develop a frailty phenotype. Individuals were categorised as 
frail, pre-frail or non-frail (Montesanto et al., 2010). Frail individuals had significantly 
decreased levels of global DNA methylation compared to those who were pre-frail or 
non-frail. In addition, progressively deteriorating frailty after a 7 year follow up was 
associated with further reductions in global DNA methylation (Bellizzi et al., 2012b). 
This suggests a link between altered DNA methylation and functional decline in the 
 214 
 
elderly; however the importance of global DNA methylation changes is largely 
uncertain. 
 
6.3.2 Association between frailty and DNA methylation levels – results 
 
Therefore, an analysis investigating the association between gene specific DNA 
methylation levels (which have a role in gene regulation) and frailty in the Newcastle 
85+ study population was undertaken. Analysis of frailty in the Newcastle 85+ study 
population using both the Rockwood and Fried approaches was performed by Dr Joanna 
Collerton. 
 
For the Newcastle 85+ study participants, Fried frailty characteristics were determined 
by BMI measurement (<18.5, underweight), questionnaires (negative responses to 
questions regarding energy levels), hand grip strength and a timed “up and go” test (rise 
from chair, walk short distance). Participants with stroke, Parkinson’s disease or a 
MMSE score <18 were excluded, as these disease states may affect frailty variables. 
The Fried frailty status (FFS) for each individual was calculated as: 3 or more 
characteristics = frail, 1-2 = pre-frail, 0 = non-frail. A total of 321 Newcastle 85+ study 
participants had both DNA methylation data and FFS measurement. 
 
For Rockwood frailty, a total of 40 deficit variables were measured individually in the 
Newcastle 85+ study population with scores ranging from 0 (no deficit) to 1 (full 
deficit) and partial deficiencies scored within this range. The RFI represents the score of 
combined deficits divided by total deficits measured (e.g. 20 deficits present, 20/40 = 
0.5 RFI). Examples of deficit variables included activities of daily living (e.g. washing, 
feeding), presence of disease (e.g. CVD, cancer), geriatric symptoms (e.g. incontinence, 
impaired hearing), cognitive function and other symptoms (chronic pain, depression). A 
total of 471 participants had both RFI scores and DNA methylation measurements 
available. 
 
6.3.2.1. Relationship between FFS and DNA methylation levels 
 
An ordinal linear regression model was utilised to analyse the possible relationship 
between FFS and DNA methylation levels in the Newcastle 85+ participants. FFS was 
the dependent variable, overall DNA methylation was the independent variable and the 
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output was an odds ratio representing the risk of being in a frailer FFS category. The 
model was adjusted for the effects of gender and percentage of lymphocytes, since these 
variables are known to influence DNA methylation measurements (model 1). A second 
model was adjusted for gender, percentage of lymphocytes, smoking behaviour, 
education and disease count (model 2). DNA methylation values were either categorised 
into quartiles, or log transformed methylation values used as a continuous variable. 
 
The results show evidence of an association between DNA methylation levels and 
frailty as determine by Fried using both the adjusted ordinal linear regression models 
(Table 6.6). When the lowest quartile was used as a reference category, the calculated 
odds ratios demonstrate that individuals in higher quartiles (increased methylation) had 
a greater risk of being in a frailer FFS category, although this was only statistically 
significant for the 2
nd
 and 4
th
 quartiles. Similarly, when the middle 2 quartiles were used 
as a reference, those participants with the lowest quartile of DNA methylation levels 
had a significantly reduced risk of being in a more frail category. With DNA 
methylation as a continuous variable, there was also a significant association between 
increasing level of DNA methylation and worsening frailty in model 1, although this 
was just outside the level of significance for model 2. 
 
Overall, this analysis suggests that in the Newcastle 85+ study, elderly individuals with 
increased DNA methylation levels at the specific gene loci investigated are more likely 
to be in a frailer category as classified by FFS, than those with lower levels of DNA 
methylation. 
 
6.3.2.2. Relationship between RFI and DNA methylation levels 
 
Since RFI is measured as a continuous variable, the relationship between Rockwood 
frailty scores and DNA methylation levels were firstly examined by Spearman’s rank 
correlation. This revealed no association (Spearman’s rho -0.038; p-value 0.415).  
 
Next, a linear regression model was constructed with RFI values, subjected to square 
root transformation in order to best fit the model, as the dependent variable. As for 
previous analysis, DNA methylation either as quartiles or a continuous variable was the 
independent variable. The outcome of the model, the unstandardized regression 
coefficient, represents the difference between the mean square root RFI for a particular 
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category compared to that of the reference category. The model was adjusted for the 
effects of gender and percentage of lymphocytes. The results revealed no significant 
association between DNA methylation levels and frailty as classified by Rockwood 
frailty scores (Table 6.7), although there was a trend towards increased frailty in those 
individuals with higher level of DNA methylation. 
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Overall DNA methylation (%) 
Model 1 odds ratio (95% 
CI) 
p-value 
Model 2 odds ratio 
(95% CI) 
p-value 
Quartiles – lowest 
quartile as reference 
≤ 8.50 Reference  Reference  
8.51-10.14 2.39 (1.27 to 4.50) 0.007* 2.42 (1.24 to 4.74) 0.010* 
10.15-11.95 1.83 (0.94 to 3.56) 0.076 1.86 (0.91 to 3.79) 0.090 
≥ 11.96 3.32 (1.55 to 7.12) 0.002* 3.17 (1.38 to 7.26) 0.006* 
Quartiles – middle 
quartiles as reference 
≤ 8.50 0.47 (0.27 to 0.83) 0.009* 0.46 (0.25 to 0.85) 0.013* 
8.51-11.95 Reference  Reference  
≥ 11.96 1.63 (0.89 to 2.97) 0.113 1.54 (0.80 to 2.95) 0.198 
Continuous variable  3.19 (1.06 to 9.62) 0.039* 3.21 (0.98 to 10.51) 0.054 
 
Table 6.6: Ordinal linear regression model analysis of FFS and DNA methylation 
Odds ratios represent the risk of being in a frailer FFS category. Model 1 was adjusted for gender and percentage of lymphocytes, model 2 was 
adjusted for gender, percentage of lymphocytes, smoking behaviour, education and disease count. Significant associations *(p<0.05) 
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Overall DNA methylation (%) 
Unstandardized regression 
coefficient (95% CI) 
p-value 
Quartiles – lowest 
quartile as reference 
≤ 8.50 Reference  
8.51-10.14 0.009 (-0.022 to 0.041) 0.564 
10.15-11.95 0.033 (0.000 to 0.067) 0.052 
≥ 11.96 0.033 (-0.004 to 0.070) 0.077 
Quartiles – middle 
quartiles as reference 
≤ 8.50 -0.020 (-0.048 to 0.009) 0.169 
8.51-11.95 Reference  
≥ 11.96 0.010 (-0.019 to 0.040) 0.490 
Continuous variable  0.003 (-0.002 to 0.008) 0.245 
 
Table 6.7: Linear regression model analysis of RFI and DNA methylation 
The unstandardized regression coefficient, represents the difference between the mean square root RFI for a particular category compared to that of the 
reference category. The model was adjusted for gender and percentage of lymphocytes. There were no significant associations (p<0.05) 
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6.3.3 Discussion of the association between frailty and DNA methylation levels 
 
The results of this analysis suggested that DNA methylation levels were significantly 
increased in Newcastle 85+ participants who were categorized as being more frail by 
the definition proposed by Fried. However, there was no significant relationship using 
the Rockwood definition of frailty. This suggests that the approach used to define frailty 
is of great importance and investigations of frailty in relation to other biomarkers could 
either miss associations or lack reproducibility if different definitions are used.  
 
Although there was a significant association between DNA methylation level and Fried 
frailty score, but not between methylation and the Rockwood frailty index, this may be 
due to the different sample sets used for both analyses. A total of 150 Newcastle 85+ 
study participants were excluded from the Fried frailty analysis due to certain pre-
existing medical conditions such as stroke, Parkinson’s disease or dementia. An 
additional analysis could be performed to examine the relationship between DNA 
methylation and Rockwood frailty index in the same participants who were included in 
the Fried analysis. If this analysis resulted in a significant association, it would indicate 
that DNA methylation is associated with frailty in people without stroke, Parkinson or 
dementia.  
 
An additional problem is that a number of criteria often used to define frailty are self-
reported, for example using questionnaires meaning responses can be subjective, 
making it more difficult to establish consistent associations with other biomarkers. 
 
From this investigation, it is impossible to decipher causation i.e. whether individuals 
with higher DNA methylation are more susceptible to becoming frail, or whether DNA 
methylation changes are induced subsequent to this. However, it is certainly possible 
that increased DNA methylation may silence gene expression in a number of cells to a 
level which is detrimental to normal tissue functioning, affecting multiple systems and 
this manifests itself as frailty. 
 
To my knowledge there is only one previous study detailing a link between frailty and 
global DNA methylation (Bellizzi et al., 2012b). However, the method applied by this 
study, which depends on HpaII digestion, only assessed a small fraction of all CpG 
sites. In addition, the results seem to indicate extremely variable levels of global 
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methylation, which seem unlikely to be biologically accurate. Previous studies of global 
DNA methylation levels using HPLC have identified much lower amounts of variability 
in the normal population (Fuke et al., 2004). Therefore, it would be interesting to 
attempt to confirm the Bellizzi et al. findings using an alternative assay for global 
methylation and the Fried and Rockwood definitions for frail individuals in the 
Newcastle 85+ study population. Ageing is typically associated with increased 
methylation at CpG islands within a background of reduced global methylation and so 
the direction of the associations identified; that is increased frailty in those with reduced 
global methylation (Bellizzi et al., 2012b) and increased CpG island methylation (this 
study) is consistent with the idea that increased disruption of methylation patterns is 
associated with detrimental effects on healthy ageing. 
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Chapter 7 – Final Discussion 
 
The role of DNA methylation in the regulation of gene expression is well established 
and the silencing of tumour suppressor genes by hypermethylation is now known to be a 
major mechanism behind the altered gene expression profiles evident in tumour cells 
(Esteller, 2007). It is also apparent that similar DNA methylation changes are accrued 
with increasing age but the consequences are not well understood, since such changes 
are not as dramatic as those observed in cancer. 
 
Methylation changes are typically less widespread during ageing, as some genes appear 
to be uniquely methylated in cancer tissue (Toyota et al., 1999). In addition, the extent 
of methylation is often lower, since genes are often completely methylated in cancer 
tissues. The underlying cause of such differences is likely to be differences in cellular 
composition between tumours and ageing tissue. Tumours are typically composed of a 
clonally expanded cell (monoclonal), therefore if the original cancer stem cell had a 
particular tumour suppressor gene inactivated by methylation, then all progeny cells 
will similarly by methylated at that site. Consequently, a quantitative measure of 
methylation at that site in tumour DNA will reveal 100% methylation. 
 
Ageing tissues are derived from many different stem cells, and so a sample of cells from 
the tissue represents many genomes with differing patterns of methylation. Such 
patterns are likely to be the result of effects of “damage” and stochastic methylation 
changes. Detection of 20% methylation at a tumour suppressor gene in ageing tissues 
means that around 20% of cells are methylated at that site. The number of cells in which 
expression of the gene is silenced by hypermethylation may reach a level which is 
detrimental for normal tissue function without being completely methylated in all cells. 
 
According to the Office for National Statistics (ONS), the greatest increase in 
population growth over the next 20 years will be represented by individuals aged over 
75 years old, particularly the 85 and over category (Figure 7.1). Therefore, identification 
of factors underlying health at an elderly age is of great importance to prevent an 
overwhelming burden on health service providers and ensure a good quality of life as 
the elderly population grows. 
 222 
 
 
Figure 7.1: Projected population change by age group in the United Kingdom 
2010-2035 
For each age group and time point, change in population was calculated compared to 
2010 population measurements. Greatest population growth is predicted in individuals 
aged over 75. Data obtained from the ONS National Population Projections, 2010-based 
projections (URL http://www.ons.gov.uk/ons/rel/npp/national-population-
projections/2010-based-projections/index.html) 
 
The Newcastle 85+ study is a unique resource as it is one of the largest longitudinal 
based studies of the very elderly available for analysis. In addition to the investigation 
of DNA methylation levels in this population, a number of other biomarkers of health 
status have been measured in an effort to identify the features underlying healthy ageing 
in this population of the oldest old. 
 
In an attempt to more clearly understand age-related patterns of DNA methylation, we 
quantified methylation levels in normal PBLs from individuals aged 85 years, at the 
promoter region of genes either known to be hypermethylated in leukaemia, or 
exhibited age-related methylation increases in tissues rather than blood (See Chapter 
3.1).  These genes were not chosen due to a particular functional role but selected as 
likely candidates for demonstrating some degree of methylation in normal aged DNA, 
since an age-associated effect had already been demonstrated in other tissues, or they 
were susceptible to methylation increases in a malignancy of the same cell type. We 
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found that those genes which were known to be hypermethylated in leukaemia exhibited 
highly variable methylation levels in PBL DNA from individuals aged 85, suggesting 
that similar genes acquire methylation during ageing and cancer. However, we did not 
detect any appreciable level of DNA methylation of non-leukaemia associated genes in 
PBL DNA from the elderly, suggesting that these genes are only methylated in solid 
tissues during ageing. 
 
7.1 Critique of the Pyrosequencing technique 
 
The analysis of DNA methylation levels in the Newcastle 85+ study participants was 
performed by Pyrosequencing, which is one of the best techniques available for 
quantification of site specific DNA methylation, even allowing small methylation 
changes to be accurately measured. In addition, several consecutive CpG sites can be 
measured within the same region and there is no sequence bias for which sites can be 
analysed, unlike other techniques such as COBRA where only sites incorporated within 
a restriction enzyme cut site can be examined (Shen and Waterland, 2007). One 
disadvantage of using this method was that specific genes had to be targeted for 
analysis. It is not possible to look at large number of genes due to the time consuming 
nature of validating each assay before use. A genome wide approach such as 
methylation arrays would possibly have identified a greater number of candidate genes 
with altered methylation during ageing, but genome wide techniques are unlikely to be 
sensitive enough to detect the small inter-individual differences in DNA methylation 
which we were able to distinguish by Pyrosequencing in the Newcastle 85+ study (Shen 
and Waterland, 2007). Another disadvantage of Pyrosequencing is that information 
regarding allele specific DNA methylation cannot be gained, although this was 
overcome by performing sodium bisulfite sequencing of individual sequences to allow 
an assessment of allele specific methylation patterns in the Newcastle 85+ study 
participants. 
 
7.2 Critique of Newcastle 85+ study samples 
 
The Newcastle 85+ study is an excellent resource for studying people of a very elderly 
age. Presently, people who survive beyond age 85 are a minority but with increasing life 
expectancy, a greater proportion of people will reach 85 years of age and soon they may 
be the majority. However, as we want to know about changes during the ageing process, 
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we want to ensure that such changes are evident throughout ageing, and not unique to 
this very elderly group of individuals. Therefore, we need to study people of different 
ages Thus, to test whether increased and variable DNA methylation levels were also 
evident in younger age groups, DNA methylation levels of TWIST2, TUSC3, HOXD4, 
HAND2 and EPHA10 were measured in samples of cord blood from newborns, PBLs 
from their mothers (aged 17-42) and a separate population of 50 year olds by Sanne van 
Otterdijk (Figure 7.2). The results revealed that at all loci; there is a clear increase in 
DNA methylation levels with advancing age although a significant amount of 
methylation can also be detected at birth. There is also a lot of variation in DNA 
methylation measurements within each age group; although it does become more 
pronounced with increasing age (Unpublished data from van Otterdijk, Mathers and 
Strathdee). These results suggest that increasing DNA methylation is evident all 
throughout life not just at very elderly ages. 
 
A recent study examined DNA methylation levels in peripheral blood at over 27,000 
CpG sites in boys aged 3-17 and discovered over 2000 loci which exhibit age-related 
methylation changes in this young population. In addition, a comparison with adult 
populations (24-85 years) suggested a high degree of overlap between those loci which 
accrued methylation in both populations (Alisch et al., 2012). Interestingly, there did 
not appear to be a direct linear accumulation of DNA methylation at these loci 
throughout life, suggesting that some regions of the genome may be particularly 
sensitive to changeable methylation during childhood or adolescence with smaller 
changes during adulthood. A similar finding was observed in an analysis of 300 CpG 
sites flanking the TSS of genes in mouse brain, muscle and kidney. DNA methylation 
changes occurred more rapidly in the period prior to adulthood, than during adulthood 
to old age (Takasugi, 2011). 
 
For the purposes of our analysis, the very old age of the Newcastle 85+ study 
participants was a benefit as they have had more time to accumulate DNA aberrant 
methylation meaning it is easier to detect. Secondly, the higher incidence of age-related 
disease in this population increased the ability to detect associations between disease 
and DNA methylation levels with lower participant numbers than would be required 
with younger cohorts. For example, as the incidence of cancer increases rapidly with 
advancing age (Cancer Research UK, URL 
http://info.cancerresearchuk.org/cancerstats/incidence/age/), it is likely that there would 
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be fewer incidences of cancer in younger aged population both prior to study 
recruitment and during the study follow up of three years. 
 
For all Newcastle 85+ volunteers, PBL was used as a DNA source. This can complicate 
the interpretation of results due to the presence of different cell types within the sample. 
A recent genome wide analysis examined the methylation status over 450 thousand 
CpG sites in whole blood, as well as specific cell populations such as mononuclear 
cells, granulocytes, monocytes, neutrophils, eosinophils, natural killer (NK), B and T 
cells. This revealed extensive differential methylation of CpG sites between cell 
lineages; although the methylation states of cells types within the same lineage (i.e. 
lymphoid or myeloid cells) are most similar. Differential DNA methylation was 
particularly evident in genes with an immune-related cell type specific function (Reinius 
et al., 2012). Our results should therefore be interpreted with caution, as the inter-
individual differences in DNA methylation levels of specific genes which we observed 
in PBL DNA may be reflecting differences in NK, B and T cell numbers between 
individuals. We attempted to counteract such effects by accounting for the proportion of 
overall lymphocyte cells in the Newcastle 85+ study PBL DNA sample, but not specific 
types of lymphocyte. The isolation of specific cell types requires cell sorting typically 
by flow cytometry or using antibodies against cell surface markers, however samples 
suitable for such cell isolations were not available and analysing multiple samples from 
each individual would have significantly reduced the total number of individuals who 
could have been screened. Furthermore the study was based on the hypothesis that 
methylation levels in PBL samples would, at least in part, reflect methylation levels in 
other tissues (as this would be influenced by shared genetic and environmental factors). 
This would be especially likely to be the case for different cells in the same tissue (i.e. 
PBL). This is further supported by the relatively consistent effect of ageing on DNA 
methylation levels seen at different loci (see Figure 7.2). Additionally, examination of 
multiple cell types increases the likelihood of identifying universal changes in DNA 
methylation, rather than cell type specific alterations of DNA methylation. 
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Figure 7.2: DNA methylation levels of TWIST2, TUSC3, HOXD4, EPHA10 and 
HAND2 in different age groups 
DNA methylation in the promoter region of TWIST2, TUSC3, HOXD4, EPHA10 and 
HAND2 were measured by Pyrosequencing in 50 newborn cord blood samples and PBL 
DNA from their respective mothers aged 17-42 (average age 27) from the North 
Cumbrian Community Genetics Project and 50 PBL DNA samples from the Newcastle 
Thousand Families study (Unpublished data from van Otterdijk, Mathers and 
Strathdee), together with the 50 pilot study PBL DNA samples from the Newcastle 85+ 
study. DNA methylation levels, as well as inter-individual variability are clearly 
increased with advancing age. 
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7.3 Role of DNA methylation in ageing and development of cancer 
 
Observations that the same types of genes are susceptible to increased and variable 
methylation during ageing and in cancer cells have been made by others since this study 
began (Rakyan et al., 2010; Teschendorff et al., 2010), and we were able to identify the 
same overlap at specific genes in the Newcastle 85+ study population (see Chapter 
3.5.2). Although these specific genes were initially chosen as they were known to be 
hypermethylated in leukaemia, a genome wide analysis for identification of novel gene 
targets in haematological malignancies also showed a similar overlap when their 
methylation levels were investigated in the 85 year old individuals (see Chapter 5.4.3). 
This proposes a hypothesis that cancer-associated aberrant DNA methylation may 
directly originate from the age-related methylation which accumulates to variable 
degrees in normal individuals, and may partly explain why cancer risk is greater with 
increasing age, and why certain individuals are more susceptible than others. DNA 
methylation is usually much more dramatically increased in cancer than in ageing and 
this may because tumour tissue is typically monoclonal whereas ageing tissue is 
comprised of numerous cells. Cancer may originate by clonal expansion of an already 
abnormally methylated stem cell, and this may be more likely in an individual who has 
a greater proportion of abnormally methylated cells (higher level of methylation 
quantified by Pyrosequencing) than in a person with lower levels. 
 
The co-methylation of genes in the Newcastle 85+ population is suggestive of a 
mechanism such that multiple genes are simultaneously affected by aberrant DNA 
methylation (see Chapter 3.5.1 and 5.5.4). Although not all of these targets may be 
expressed in haematopoietic cells, it is likely that for some genes, their expression 
would be detrimentally affected by the presence of promoter associated DNA 
methylation increases. Silenced expression may result in cells where DNA methylation 
appears to be particularly dense in individual alleles (see Chapter 3.5.3). 
 
Interestingly, our results revealed a small but significant increase in DNA methylation 
measurement, in Newcastle 85+ participants with either a previous history, or future 
incidence of cancer, at the overall mean of five genes (TWIST2, TUSC3, HOXD4, 
EPHA10 and HAND2) which are known by exhibit increased and variable methylation 
in ageing (as well as being hypermethylated in leukaemia) (see Chapter 4.2.5 and 4.3.3). 
Greater methylation was apparent in the 2 participants who went on to be diagnosed 
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with lymphoma or leukaemia (see chapter 4.3.3.1). However, since there were such few 
incidences of haematological cancer, care should be taken in concluding that higher 
methylation is a predictor of imminent risk of haematological cancer. It will be 
important to attempt to replicate this finding in other prospective analysis of leukaemia 
or lymphoma incidence, to provide further evidence of the possible predictive value of 
methylation of these genes a marker of individuals at high risk of haematological 
malignancy. 
 
This prospective study has shown that differences in DNA methylation are evident 
before cancer can be diagnosed; therefore methylation changes may exist prior to cancer 
onset and subsequent treatment. Understanding how such DNA methylation differences 
arise in apparently normal samples could be vital to uncovering the role of pre-existing 
methylation in risk of cancer. If these small increases are due to an increased proportion 
of densely methylated alleles for example, the consequence is a greater number of cells 
with abnormal methylation patterns and altered gene transcription. However, it is not 
just densely methylated promoters which are associated with loss of expression. Recent 
results from the ENCODE project analysing over 1 million CpG sites in cells lines and 
tissue found the most variably methylated sites were located outside of promoter 
regions and also revealed DNA methylation located at some distance from the gene may 
be important in regulating transcription (Bernstein et al., 2012). The early appearance of 
methylation abnormalities, prior to clinical disease development, would be consistent 
with a direct functional role for altered methylation in early stages of cancer 
development. 
 
The absolute DNA methylation differences at the five loci measured were quite small 
between the groups of participants with previous cancer, future cancer or no cancer. The 
genes known to be hypermethylated leukaemia which were investigated in the 85 year 
old population, appeared to be co-ordinately methylated within an individual. This 
suggests the existence of a mechanism which controls the acquisition of DNA 
methylation across the genome within an individual and could therefore affect other loci 
similarly. The mechanism responsible for determining individual DNA methylation 
levels could be due to underlying genetic sequence, activity of the methylation 
machinery such as DNMTs or differential environmental exposures (See section 1.9). 
Therefore it is possible that the genes which were originally selected for analysis were 
not the most optimal. Other genes may have demonstrated similar, but more dramatic 
 230 
 
DNA methylation differences between previous cancer, future cancer and individuals 
with no cancer, but were not investigated as part of this study.  
 
Also, we chose to measure CpG sites within the promoter region of genes, as 
methylation covering the TSS is most well understood to cause transcriptional silencing 
(Eckhardt et al., 2006; Bell et al., 2011). However there are several reports that DNA 
methylation in alternative genomic regions, such as introns and exons, could control 
expression of an associated gene, particularly in a tissue specific manner (Strathdee et 
al., 2004a; Wu et al., 2010; Brenet et al., 2011). Therefore, differential DNA 
methylation at different genomic locations could play an important role in gene 
expression. 
 
7.4 Role of DNA methylation in age-related clinical outcomes 
 
Our analysis revealed no evidence for any association between DNA methylation levels 
and CVD, T2D, dementia, stroke, smoking status or the 3 year survival of participants 
in the Newcastle 85+ study. This suggests that the mechanism underlying altered DNA 
methylation levels in this population may not be related to these clinical factors. 
However, we may have failed to identify the effect for several reasons, such as too few 
observations, failure to examine the right genes or the most informative regions in the 
genome.  
 
Although altered DNA methylation patterns have been proposed to impact upon 
markers of healthy ageing (Liu et al., 2011) and a role for aberrant methylation 
suggested in many age-related diseases (Barrachina and Ferrer, 2009; Ling and Groop, 
2009; Baccarelli et al., 2010; Kim et al., 2010a), the significance of such changes in 
diseases other than cancer is not clearly understood. Thus it is not known whether 
aberrant DNA methylation may increase susceptibility to certain diseases, or whether 
DNA methylation changes may be triggered after the disease has initiated, for example 
inflammation is often present in CVD, T2D and stroke and has been implicated in 
causing altered DNA methylation (Stenvinkel et al., 2007). 
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7.5 Future studies 
 
We observed that genes which are methylated in leukaemia/lymphoma, exhibit variable 
methylation in the elderly. This was found in our pilot study analysis based on a panel 
of genes known to be methylated in leukaemia, and in two new targets identified by 
genome wide DNA methylation analysis of haematological malignancies. The level of 
DNA methylation across these loci was highly correlated within the 85 year old 
individuals.  
 
The supposed presence of a mechanism affecting the acquisition of DNA methylation at 
genes susceptible to both age and cancer associated methylation would be further 
strengthened by examining other genes hypermethylated in haematological 
malignancies. This would require investigation of the other gene targets from the 
genome wide DNA methylation screen either by establishing successful Pyrosequencing 
assays for the other 2 genes known to be methylated in ALL samples by COBRA 
analysis (CACNA1B and CELF4); or alternatively by picking new targets from the 
genome wide methylation study, confirming their methylation status in primary 
leukaemia samples and establishing new Pyrosequencing assays to test DNA 
methylation levels in the Newcastle 85+ study participants. 
 
An important finding from our pilot study analysis was the presence of densely 
methylated alleles in apparently normal samples. The majority of previous studies 
investigating the role of altered DNA methylation in malignancies, or during ageing 
have utilised techniques for measuring average methylation across all cells in a sample. 
However, methylation is known to act at the level of individual alleles and thus, the 
presence of different allelic patterns of methylation at individual alleles in both ageing 
and cancer should be investigated, as these patterns are likely to have different 
biological consequences. The cloning and bisulfite sequencing technique used in this 
study is time consuming and only allowed investigation of a relatively small number of 
alleles, which is unlikely to reveal the true complexity of allelic methylation patterns. A 
new procedure is currently being developed within our laboratory, combining 
multiplexed gene specific amplification of sodium bisulfite modified DNA with ultra-
deep DNA sequencing allowing potentially thousands of alleles to be simultaneously 
characterised (Unpublished data from van Otterdijk and Strathdee). Subsequently, 
changes to the allelic patterns of methylation during ageing or in malignancies could be 
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examined to possibly identify particular types of methylation patterns associated with 
cancer, or age related disease risk. 
 
It has been acknowledged that methylation covering the promoter region of a gene will 
result in transcriptional silencing, particularly evident at tumour suppressor genes in 
cancer. However, as the dense methylation we observed in normal elderly PBL DNA 
did not affect all alleles in the sample, it is not known to what extent expression of the 
gene would be affected. Certainly, not all the genes we examined in the pilot study 
would be expected to be expressed in normal haematopoietic cells, but since the 
methylation pattern we observed at these genes appears to be affecting numerous loci it 
is likely that some of these would normally be expressed. At least two of set of five 
genes used in most of the studies, TWIST2 and TUSC3, are known to be expressed in 
PBL cells. Measuring gene expression levels in samples with differing proportions of 
densely methylated alleles could be performed to characterise the biological 
consequence of the variable DNA methylation levels in the Newcastle 85+ study 
population. 
 
Our results have suggested co-methylation of genes in the Newcastle 85+ study 
participants is occurring at the levels of an individual and we hypothesise this is because 
multiple loci are hypermethylated in same cell, rather than different genes being 
hypermethylated in different cells. Experiments to confirm this hypothesis of 
concordant methylation would involve analysis of a single cell. Single cells can be 
isolated by flow cytometry, laser capture microdissection or by performing limiting 
dilutions, but subsequent analysis is technically difficult due to the low concentration of 
DNA in the starting material and high sensitivity to contamination with foreign DNA. 
This can possibly be overcome by clonal expansion of a single cell in vitro to a density 
which would generate enough DNA for accurate quantification of DNA methylation 
levels. However, this runs the risk of acquisition of inter-cell methylation differences as 
demonstrated by Kim and Shibata (2002) (Kim and Shibata, 2002). A recent publication 
described a technique allowing high-throughput methylation analysis of a single cell 
without the need for clonal expansion involving cleavage of DNA with methylation 
sensitive restriction enzymes and subsequent gene specific amplification utilising two 
forward primers either side of the enzyme cut site. Methylation status can be determined 
by the size of products formed depending on whether the site was methylated/uncleaved 
or unmethylated/cleaved (Kantlehner et al., 2011). A criticism of this approach is that 
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analysis of CpG sites is limited to those which lie within a methylation sensitive 
enzyme recognition sequence, and it is not possible to examine multiple genes in the 
same cell. If single gene methylation analysis confirmed that numerous genes are 
hypermethylated in a single cell, it would strengthen the hypothesis that clonal 
expansion from these types of cells may be responsible for the abnormal methylation 
patterns seen in cancer, without requiring any additional methylation alterations. 
 
This study focused entirely on methylation gains at gene promoter regions, although the 
presence of global DNA hypomethylation is frequently associated with both advancing 
cancer and advancing age (Ehrlich, 2002; Jintaridth and Mutirangura, 2010). Therefore 
it would be interesting to measure global DNA methylation levels in the Newcastle 85+ 
study participants, and look for any significant associations between global DNA 
methylation levels and the incidence of cancer or other clinical outcomes in the elderly 
age group. A study measuring LINE-1 and Alu repetitive elements in an elderly 
population as a surrogate for global methylation found that individuals with low LINE-1 
methylation appeared to be at increased risk of cancer, with greater mortality (Zhu et 
al., 2011). 
 
Genome wide SNPs were characterised in the Newcastle 85+ study participants which 
allowed us to perform a hypothesis generating GWAS for identification of SNPs which 
may be associated with determination of DNA methylation levels. This analysis 
revealed several SNPs which were related to DNA methylation although the level of 
significance for the associations was not particularly stringent since there are a huge 
number of comparisons being made in genome wide analysis, therefore these 
associations require replication in an independent population to confirm the effect of 
these particular SNPs in driving DNA methylation differences within the population. 
Two of the identified SNPs were each located within two genes, DSCAM and 
DSCAML1, which encode highly related protein products. In an attempt to characterise 
the effects of these SNPs on DNA methylation levels, the relationship between the 
presence of these SNPs at DSCAM/DSCAML1 and the accumulation of abnormally high 
levels of DNA methylation will be examined in leukaemia patients. 
 
In addition, Fried frailty status appeared to be significantly related to DNA methylation 
levels in the Newcastle 85+ study participants. However, an alternative definition of 
frailty (Rockwood) was unrelated to DNA methylation levels in the same individuals. 
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Further investigation could uncover which specific frailty characteristics are linked to 
differential DNA methylation. Replication of the relationship between DNA 
methylation in additional population, perhaps with differing definitions of frailty would 
strength this finding.  
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Chapter 8 – Appendices 
Appendix 1 – Methodology 
 
A1.1 Epigentek Methylamp™ One-Step DNA Modification Kit Protocol 
 
Before starting, add 15 ml of 100% ethanol to G5 to make final cleaning buffer. Prepare 
90% ethanol. 
 
1. Add 1.1ml of G2 (DNA modification solution) to 1 vial of G1 (DNA modification 
powder). Vortex until solution is clear or saturated (about 2 min). Add 40μl of G3 
(balance solution) to the solution, lightly vortex. 
 
2. Add 110μl of the mixed G1/G2/G3 solution to 10μl of DNA sample (200ng). Vortex 
and place the vial in a thermal cycler with a program of 99°C for 6 min followed by 
65°C for 90 min. 
 
3. Place a spin column into a 2ml collection tube. Add 300μl of G4 (modified DNA 
capture buffer) to the column, and then transfer the sample (from step 2) to the column 
containing G4. Centrifuge at 12,000 rpm for 30 sec. Remove the column from the 
collection tube and discard the flow through. Replace column to the collection tube. 
 
4. Add 200μl of G5 solution (modified DNA cleaning buffer) to the column, and 
centrifuge at 12,000 rpm for 30 sec. 
 
5. Add 10μl of G3 to 1.1ml of 90% ethanol, mix. Add 50μl of the mixed G3/ethanol to 
the column. Sit for 8 min at room temperature, then centrifuge at 12,000 rpm for 20 sec. 
 
6. Add 200μl of 90% ethanol to the column, centrifuge at 12,000 rpm for 30 sec., 
remove the column from the collection tube and discard the flow through. Replace 
column to the collection tube. Add 200μl of 90% ethanol to the column again and 
centrifuge at 12,000 rpm for 1 minute. 
 
7. Place the column in a new 1.5 ml vial. Add 15μl of G6 (modified DNA elution 
buffer) directly to the column filter, centrifuge at 12,000 rpm for 30 sec to elute 
modified DNA. 
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A1.2 Recipe for TAE (Tris base, acetic acid and EDTA) DNA Electrophoresis 
Buffer (50x and 1x) and EDTA (Ethylenediaminetetraacetic acid) 0.5 M (pH 8) 
 
TAE (50 X) (500ml) 
121g Tris base  
28.6ml acetic acid 
50ml 0.5M EDTA (Ethylenediaminetetraacetic acid) pH 8 
Add ddH2O (double deionized water) to 500ml 
 
TAE (1X) (10 Litres) 
200 ml TAE (50x) buffer  
Add 9800ml ddH2O. 
 
EDTA 0.5 M (pH8.0) (1 litre) 
148 g EDTA  
~30-40 g NaOH (Sodium hydroxide) to adjust to pH 8 
Add ddH2O to 1000ml 
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A1.3 Pyrosequencing Protocol  
Materials 
Ethanol (70%) 
Streptavidin Sepharose beads (GE Healthcare) 
Binding buffer (Qiagen) 
Annealing buffer (Qiagen) 
Denaturation buffer (BDH) 
Wash buffer (Tris acetate buffer) (10x) (Qiagen) 
18.2 mΩ ddH2O 
Sequencing primer (MWG Eurofins) 
Pyro gold SQA reagents (Qiagen) 
96-well PCR plate 
96-well Pyrosequencing plate 
Pipettes 
Pipette tips 
Heat block 
Plate shaker 
 
Buffer Solutions 
 
Wash buffer (1x) (1 litre) 
100ml (10x) wash buffer 
900ml 18.2 mΩ ddH2O 
 
Ethanol (70%) (1 litre) 
700ml 100% Ethanol 
300ml 18.2 mΩ ddH2O 
 
Denaturing buffer (1 litre) 
8g NaOH (Sodium hydroxide) 
1000ml 18.2 mΩ ddH2O 
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Set up Pyro work station as follows 
 
 
Probe block 
18.2 mΩ ddH2O 
Denaturing buffer 
(NaOH) 
18.2 mΩ ddH2O 
70% Ethanol Wash buffer (1x) 
PCR plate Pyrosequencing plate 
 
Remove reagents from fridge and allow solutions to reach room temperature. 
 
Heat block set to 80ºC 
 
Immobilisation of PCR products 
Biotinylated PCR products are immobilised on streptavidin-coated beads. 
 
1. Shake bottle of streptavidin coated sepharose beads to obtain a homogenous 
solution 
2. Prepare binding buffer solution master mix (per sample) 
Beads   2µl 
Binding buffer 38µl 
18.2 mΩ ddH2O 30µl 
3. Add 70µl to PCR plate, shake master mix every few wells so beads don’t settle 
4. Add 10µl PCR product to the binding buffer in plate 
5. Seal plate and shake for at least 5 minutes 
6. Prepare Pyrosequencing plate annealing master mix (per sample) 
Annealing buffer   11.5µl 
Sequencing primer (10pmol/µl) 0.5µl 
7. Add 12µl to the Pyrosequencing plate wells in corresponding locations to those 
on the PCR plate 
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Strand separation 
Switch on the vacuum pump and prime probes by sucking through 18.2 mΩ ddH2O for 
a few seconds. 
1. Remove plate from shaker and immediately apply vacuum prep tool. Make sure 
all sample is taken up. 
2. Place vacuum tool in ethanol trough. Wait for liquid to flow through, then count 
5 seconds. Repeat for denaturation buffer for 5 seconds and wash buffer for 5 
seconds. 
3. Turn off vacuum. Place tool in Pyrosequencing plate to release single stranded 
PCR product into annealing solution. 
4. Place plate on heat block for 2 minutes. Clean vacuum by sucking through 18.2 
mΩ ddH2O. 
5. Remove plate from block and leave to cool for a few minutes. 
 
Pyrosequencing 
Fill reagent cartridge 
1. Switch on the computer. 
2. (If necessary create a new assay, see step 1-4 below) 
3. Go to tools, volume information. It gives the volume for needed for all reagents. 
4. Reconstitute enzyme and substrate mixtures with 18.2 mΩ ddH2O. 
5. Fill Enzyme and substrate tips with appropriate volume for assay. 
6. Fill nucleotide tips with care –air bubbles can interfere with dispensation- flick 
to remove bubbles. 
7. Tips are inserted into cartridge in alphabetical order 
                        E       S 
       A    C    G    T 
 
Creating new assay 
1. Pyro Q CpG → new assay 
2. Type in sequence and generate dispensation order (30-35 nucleotides max) 
3. Tick analyse boxes 
4. Add bisulfite control 
5. Start a Pyrosequencing run 
6. New run. 
7. Instrument parameters MD or HS(A) code 004 NDT 
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8. Use date in plate ID 
9. Load assays into appropriate wells. 
 
Starting a new Pyrosequencing run 
1. Select Pyro Q CpG from the start menu, then select New Run 
2. Select Instrument parameters MD or HS(A) code 004 NDT 
3. Use date in plate ID 
4. In appropriate well, right click and select Load Assay. This will open up files of 
previously save assays. Double click the required assay and it will appear in the 
well 
5. Copy the assay by dragging the bottom corner of the first well to all appropriate 
wells. 
6. Open and close the pyrosequencer using the ‘open process chamber’ and ‘close 
process chamber’ buttons on screen. 
7. To run the assay click the play button 
 
Always test tip dispensing before starting the run – Insert a SEALED 
Pyrosequencing plate into machine and select test dispensation – should observe 6 
dots (one for each tip) 
 
After the assay 
1. Analyse all 
2. Report, analysis reports, all wells, save 
3. Report, programme, all wells, landscape, save 
4. Instrument, shut down instrument. 
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A1.4 Recipe for LB (Lysogeny broth) media and agar with Kanamycin (50μg/ml) 
(1 litre) 
1% tryptone 
0.5% yeast extract 
1% NaCl (Sodium chloride) 
pH 7 
 
10g tryptone 
5g yeast extract 
10g NaCl 
950ml of ddH2O 
Adjust pH to 7 with NaOH (Sodium hydroxide) & increase volume to 1 litre 
Autoclave and allow to cool  
Add 1ml of stock kanamycin (50mg/ml) 
 
If making agar, add 15g prior to autoclaving, cooling and addition of kanamycin 
Pour plates, leave to harden, invert and store at 4ºC. 
 
 
A1.5 QIAprep Spin Miniprep Kit Protocol 
 
After overnight incubation, centrifuge cells at 5000r.p.m. at 4°C for 10 minutes to form 
pellet. Remove media and invert tubes to drain 
 
Add provided RNase A to Buffer P1 then store Buffer P1 at 2-8°C.  
 
Add the provided LyseBlue reagent to Buffer P1 and mix before use. Use one vial 
LyseBlue per bottle of Buffer P1 to achieve a 1:1000 dilution. Shake Buffer P1 
vigorously before use. 
 
All remaining protocol steps carried out at room temperature. 
 
1. Resuspend pelleted bacterial cells in 250 μl Buffer P1 and transfer to a 
microcentrifuge tube. 
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No cell clumps should be visible after resuspension of the pellet; bacteria should be 
resuspended completely by vortexing or pipetting up and down. 
 
2. Add 250μl Buffer P2 and mix thoroughly by inverting the tube 4–6 times. 
Do not vortex, as this will result in shearing of genomic DNA. Do not allow this lysis 
reaction to proceed for more than 5 min. 
Cell suspension will turn blue after addition of Buffer P2. Continue mixing to achieve a 
homogeneously coloured suspension.  
 
3. Add 350μl Buffer N3 and mix immediately and thoroughly by inverting the tube 4–6 
times. 
The suspension should be mixed until all trace of blue has gone and the suspension is 
colourless and cloudy. A homogeneous colourless suspension indicates that the sodium 
dodecyl sulphate (SDS) has been effectively precipitated. 
 
4. Centrifuge for 10 min at 13,000 r.p.m. in a microcentrifuge. A compact white pellet 
will form. 
 
5. Remove the supernatant from step 4 and add to the QIAprep spin column. 
 
6. Centrifuge at 13,000 r.p.m. for 1 minute. Discard the flow-through. 
 
7. Wash the QIAprep spin column by adding 500μl Buffer PB and centrifuging at 
13,000 r.p.m. for 1 minute. Discard the flow-through. 
 
8. Wash QIAprep spin column by adding 500μl Buffer PE and centrifuging at 13,000 
r.p.m. for 1 minute. Discard the flow-through. Centrifuge at 13,000 r.p.m. for another 1 
minute to remove residual wash buffer. 
 
9. Place the QIAprep column in a clean 1.5 ml microcentrifuge tube. To elute DNA, add 
50μl Buffer EB (10 mM Tris·Cl, pH 8.5) to the center of each QIAprep spin column, 
stand for 5 minutes, and centrifuge at 13,000 r.p.m. for 1 minute. 
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A1.6 Recipe for Reagent B (Nucleon) for DNA Extraction, Tris-HCl 1M and NaCl 
1M 
400mM Tris/HCl 
60mM EDTA(Ethylenediaminetetraacetic acid) 
150mM NaCl (Sodium Chloride) 
1% SDS (Sodium dodecyl sulfate) 
pH 8.0 
 
1M Tris-HCl (1 litre) 
121g Tris base 
HCl to pH 8 
Add ddH2O to 1000ml 
 
1M NaCl (1 litre) 
58g NaCl (Sodium Chloride) 
Add ddH2O to 1000ml 
 
A1.7 Recipe for TE (Tris EDTA) Buffer (1x) (1 litre) 
10 mM Tris-HCl, pH 8 
1 mM EDTA 
 
10ml 1 M Tris-HCl 
2ml 0.5M EDTA 
Add ddH2O to 1000ml 
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A1.8 QIAquick PCR Purification Kit/MinElute PCR Purification Kit Protocol 
 
Add 100% ethanol to Buffer PE before use. 
 
All centrifugation steps carried out at 13,000 r.p.m. in a microcentrifuge at room 
temperature. 
 
Add 1:250 volume pH indicator I to Buffer PB (120μl pH indicator I to 30ml Buffer 
PB). The yellow colour of Buffer PB with pH indicator I indicates a pH of 7.5. 
 
1. Add 5 volumes of Buffer PB to 1 volume of the PCR sample and mix. 
 
2. If pH indicator I has been added to Buffer PB, check that the colour of the mixture is 
yellow. 
 
3. Place a QIAquick/MinElute column in a provided 2 ml collection tube. 
 
4. To bind DNA, add the sample to the QIAquick/MinElute column and centrifuge for 1 
minute. 
 
5. Discard flow-through. Place the QIAquick/MinElute column back into the same tube. 
 
6. To wash, add 750μl Buffer PE to the QIAquick/MinElute column and centrifuge for 1 
minute. 
 
7. Discard flow-through and place the QIAquick/MinElute column back in the same 
tube. Centrifuge the column for an additional 1 minute for complete removal of buffers. 
Spin Protocol 
8. Place QIAquick/MinElute column in a clean 1.5 ml microcentrifuge tube. 
 
9. To elute DNA, add an appropriate volume of Buffer EB (10 mM Tris·Cl, pH 8.5) to 
the centre of the QIAquick/MinElute membrane, stand for 1 minute and centrifuge the 
column for 1 min.  
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Appendix 2 – Results Chapter 3  
A2.1 Reproducibility of duplicate Pyrosequencing runs of the same TWIST2 PCR 
product 
Sample Average of 4 CpG sites (%) Difference (%) 
37 7.28  
37 7.19 0.09 
45 10.58  
45 10.17 0.41 
50 4.97  
50 4.45 0.53 
78 7.75  
78 7.55 0.20 
80 3.11  
80 3.42 0.31 
84 9.03  
84 9.00 0.03 
108 4.13  
108 4.19 0.06 
112 5.18  
112 5.07 0.11 
119 8.26  
119 8.54 0.28 
125 3.39  
125 3.46 0.07 
128 9.27  
128 9.37 0.11 
148 4.52  
148 4.52 0.00 
161 7.81  
161 7.53 0.29 
166 12.29  
166 11.78 0.51 
181 11.74  
181 11.76 0.02 
185 19.03  
185 20.08 1.05 
186 4.78  
186 5.70 0.92 
193 7.46  
193 7.31 0.15 
194 5.19  
194 5.06 0.13 
205 11.77  
205 12.49 0.72 
213 14.37  
213 14.90 0.52 
221 6.17  
221 6.23 0.06 
312 5.63  
312 5.48 0.15 
Average difference 
0.29 
between 23 samples 
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For 23 of the 85+ study participants, an aliquot of the same TWIST2 PCR product was 
used for two separate Pyrosequencing runs. For each sample, methylation 
measurements at four consecutive CpG sites was used to calculate the average, and the 
methylation (%) difference between the two repeats is shown. 
 
A2.2 Reproducibility between of Pyrosequencing measurements between two 
duplicate TWIST2 PCR repeats 
 
Sample Average of 4 CpG sites (%) Difference (%) 
37 6.80  
37 7.24 0.44 
45 9.90  
45 10.38 0.48 
50 4.92  
50 4.71 0.21 
78 7.65  
78 7.41 0.24 
80 9.01  
80 10.86 1.85 
84 7.81  
84 9.02 1.21 
108 6.42  
108 4.16 2.26 
112 6.26  
112 5.13 1.13 
119 9.63  
119 8.40 1.23 
125 5.19  
125 3.42 1.77 
128 5.27  
128 9.32 4.05 
148 5.00  
148 4.52 0.47 
161 6.23  
161 7.67 1.45 
166 12.04  
166 9.73 2.31 
181 8.89  
181 11.75 2.87 
185 20.85  
185 19.55 1.30 
186 3.44  
186 5.24 1.80 
193 4.62  
193 5.95 1.32 
194 5.12  
194 5.30 0.18 
 247 
 
Sample Average of 4 CpG sites (%) Difference (%) 
199 6.27  
199 6.84 0.57 
205 12.33  
205 12.13 0.19 
213 17.56  
213 14.63 2.93 
221 4.22  
221 6.20 1.98 
305 5.87  
305 6.42 0.56 
312 9.26  
312 5.55 3.71 
Average difference  
between 25 samples 1.46 
 
For 25 of the 85+ study participants, two distinct TWIST2 PCR amplifications were 
performed and the two products were used for two separate Pyrosequencing runs. For 
each sample, methylation measurements at four consecutive CpG sites were used to 
calculate the average, and the methylation (%) difference between the two PCR repeats 
is shown. 
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Appendix 3 – Results Chapter 4 
 
Figure A3.1: DNA methylation levels of TUSC3, HOXD4, EPHA10 and HAND2 in 
isolated haematopoietic cell populations 
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DNA was isolated from PBLs (lymphocytes, neutrophils, and monocytes), PBMCs 
(lymphocytes and monocytes), B cells and monocytes and methylation levels of the 
TUSC3, HOXD4, EPHA10 and HAND2 promoter measured by Pyrosequencing. 
PBMC-monocytes represent total lymphocytes (T cells, B cells and NK cells). DNA 
methylation levels are lowest in monocytes and highest in B cells. 
 
Table A3.2: Comparison of PBL DNA methylation levels between participants 
with and without history of cardiovascular events in the Newcastle 85+ study 
(initial sample set) 
 
 n TUSC3 TWIST2 HOXD4 HAND2 EPHA10 
Overall 
Mean 
HOXA5 
None 
(%) 
179 10.20 10.56 10.37 10.17 10.47 10.35 63.44 
CVD 
(%) 
91 10.68 11.40 10.76 10.69 10.80 10.87 58.43 
t-test 
p-value 
 
0.142 0.070 0.162 0.113 0.167 0.057 0.013* 
 
Student’s t-test was used to analyse difference in methylation levels between 
participants with a previous history of myocardial infarction, angina, coronary 
angioplasty/stent, coronary artery bypass graft, or none of these. HOXA5 methylation 
levels were significantly different between the two groups *(p < 0.05). 
 
Table A3.3: Comparison of PBL DNA methylation levels between participants 
with and without Type II diabetes in the Newcastle 85+ study (initial sample set) 
 
 n TUSC3 TWIST2 HOXD4 HAND2 EPHA10 
Overall 
Mean 
HOXA5 
None (%) 234 10.41 10.87 10.54 10.36 10.60 10.55 61.99 
T2D (%) 36 10.08 10.71 10.20 10.28 10.45 10.34 60.45 
t-test 
p-value 
 0.300 0.419 0.267 0.447 0.374 0.323 0.326 
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Student’s t-test was used to analyse difference in methylation levels between 
participants with Type II diabetes compared to none. There were no significant 
differences (p < 0.05). 
 
Table A3.4: Comparison of PBL DNA methylation levels between participants 
with and without Dementia in the Newcastle 85+ study (initial sample set) 
 
 n TUSC3 TWIST2 HOXD4 HAND2 EPHA10 
Overall 
Mean 
HOXA5 
None (%) 252 10.36 10.83 10.51 10.35 10.48 10.50 61.24 
Dementia 
(%) 
18 10.41 11.07 10.28 10.34 12.01 10.82 66.54 
t-test 
p-value 
 0.475 0.411 0.390 0.495 0.009* 0.303 0.060 
 
Student’s t-test was used to analyse difference in methylation levels between 
participants with and without Dementia including Alzheimer’s disease. There was 
significantly increased methylation of EPHA10 in participants with dementia *(p<0.05). 
 
 
Table A3.5: Comparison of PBL DNA methylation levels between participants 
with and without stroke in the Newcastle 85+ study (initial sample set) 
 
 n TUSC3 TWIST2 HOXD4 HAND2 EPHA10 
Overall 
Mean 
HOXA5 
None (%) 228 10.34 10.89 10.47 10.22 10.55 10.49 61.30 
Stroke (%) 42 10.46 10.61 10.66 11.07 10.73 10.70 64.44 
t-test 
p-value 
 0.423 0.350 0.358 0.063 0.346 0.309 0.135 
 
 
Student’s t-test was used to analyse difference in methylation levels between 
participants with and without stroke. There were no significant differences (p<0.05). 
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Table A3.6: Comparison of PBL DNA methylation levels between surviving and 
non- surviving (by Phase III) participants of the Newcastle 85+ study (initial 
sample set) 
 
 n TUSC3 TWIST2 HOXD4 HAND2 EPHA10 
Overall 
Mean 
HOXA5 
Survivors 
(%) 
229 10.24 10.89 10.41 10.22 10.51 10.46 61.68 
Non-
survivors 
(%) 
41 11.02 10.58 10.96 11.11 10.97 10.90 62.63 
t-test 
p-value 
 0.09 0.337 0.149 0.060 0.164 0.150 0.373 
 
 
Student’s t-test was used to analyse difference in methylation levels between 
participants who had survived to phase III (36 months later) or not. There were no 
significant differences (p<0.05). 
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Table A3.7: Pair-wise correlations of TWIST2, HOXD4, EPHA10, TUSC3, HAND2 
and HOXA5 DNA methylation levels in 210 validation PBL samples from the 
Newcastle 85+ study participants. 
 
Methylation data for 210 participants was correlated at each pair of loci using Pearson 
test of correlation. The Pearson correlation coefficient (r) and corresponding p values 
are shown. Methylation levels at TWIST2, HOXD4, EPHA10, TUSC3 and HAND2 are 
strongly positively correlated. HOXA5 demonstrates no relationship. 
Black p value = NS, Red p value = significant at <0.003 level after performing 
Bonferroni correction for multiple comparisons. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 TWIST2 HOXD4 EPHA10 TUSC3 HAND2 
TWIST2      
HOXD4 r = 0.72 
p < 1e-16 
    
EPHA10 r = 0.48 
p = 1.3e-13 
r = 0.38 
p = 1.4e-08 
   
TUSC3 r = 0.84 
p < 1e-16 
r = 0.71 
p < 1e-16 
r = 0.54 
p < 1e-16 
  
HAND2 r = 0.52 
p = 1.1e-15 
r = 0.34 
p =  7.4e-07 
r = 0.19 
p = 0.005 
r = 0.48 
p = 1.9e-13 
 
HOXA5 r = -0.018 
p = 0.79 
r = 0.05 
p = 0.51 
r = 0.011 
p = 0.87 
r = -0.047 
p = 0.50 
r = 0.009 
p = 0.89 
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Figure A3.8: Correlation between PBL DNA methylation levels and lymphocyte 
percentage in the peripheral blood of 210 Newcastle 85+ study participants 
(validation sample set). 
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Methylation values of TWIST2, HOXD4, EPHA10, TUSC3, HAND2 and HOXA5 were 
plotted against lymphocyte percentage calculated from full blood counts (Chapter 2.1). 
The linear regression line and r
2
 value indicate a positive relationship for all genes 
except HOXA5, for which there is no association. 
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Table A3.9: Correlation between the DNA methylation levels of TWIST2, HOXD4, 
EPHA10, TUSC3 and HAND2 and the percentage of lymphocytes in the peripheral 
blood of 210 participants in the Newcastle 85+ study (validation sample set) 
 
 TWIST2 HOXD4 TUSC3 EPHA10 HAND2 HOXA5 
Lymphocyte 
(%) 
r = 0.58 
p = 0 
r = 0.48 
p = 5.1e-13 
r = 0.62 
p = 0 
r = 0.41 
p = 6.6e-10 
r = 0.33 
p = 1.6e-06 
r = 0.002 
p = 0.97 
 
Pearson correlation coefficient (r) and corresponding p value is given for each locus. 
Black p value = NS, Red p value = significant at <0.0083 level after performing 
Bonferroni correction for multiple comparisons. 
 
Figure A3.10: Relationship between overall mean DNA methylation and 
percentage of lymphocytes in the peripheral blood of 210 participants from the 
Newcastle 85+ study (validation sample set) 
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Linear regression analysis was performed by plotting the overall mean methylation of 
each sample against the percentage of lymphocytes. A positive relationship is indicated 
by the r
2
 value (0.39). The equation of the regression y = 0.1947x + 4.9659 indicates 
that every 1% increase in lymphocytes (x), is responsible for a 0.1947% increase in 
methylation levels (y). 
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Figure A3.11: The lymphocyte normalisation factor calculated and applied to DNA 
methylation measurements of 210 participants from the Newcastle 85+ study 
(validation sample set) 
 
Sample lymphocytes (%) – Population Mean lymphocytes (29.0%) * Methylation 
increase determined by lymphocytes (0.1947%) 
 
Table A3.12: DNA methylation measurements after correction for the proportion 
of lymphocytes in the peripheral blood of 210 participants from the Newcastle 85+ 
study (validation sample set) 
 
Gene Methylation Range (%) Mean Methylation (%) Standard Deviation (%) 
HOXD4 5-21 10.63 2.2 
TUSC3 4-27 10.63 3.8 
TWIST2 3-36 10.63 4.4 
EPHA10 5-20 10.63 2.8 
HAND2 5-20 10.63 2.5 
 
For each gene, the corrected minimum and maximum methylation levels in the samples 
is shown, alongside the normalised average methylation level calculated as described 
above, and the standard deviation as a measure of variation. 
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Table A3.13: Comparison of PBL DNA methylation levels between individuals 
with and without history of cardiovascular events in 210 participants from the 
Newcastle 85+ study (validation sample set) 
 
 n TUSC3 TWIST2 HOXD4 HAND2 EPHA10 
Overall 
Mean 
HOXA5 
None 
(%) 
142 10.67 10.51 10.68 10.78 10.60 10.65 62.31 
CVD 
(%) 
68 10.55 10.89 10.58 10.40 10.70 10.64 63.79 
t-test 
p-value 
 
0.394 0.243 0.395 0.150 0.391 0.479 0.230 
 
Student’s t-test was used to analyse difference in methylation levels between 
participants with a previous history of myocardial infarction, angina, coronary 
angioplasty/stent, coronary artery bypass graft, or none of these. There were no 
significant associations (p < 0.05). 
 
Table A3.14: Comparison of PBL DNA methylation levels between individuals 
with and without Type II diabetes in 210 participants from the Newcastle 85+ 
study (validation sample set) 
 
 n TUSC3 TWIST2 HOXD4 HAND2 EPHA10 
Overall 
Mean 
HOXA5 
None (%) 71 10.79 11.01 10.59 10.62 10.23 10.65 61.53 
T2D (%) 58 10.93 11.05 10.93 10.72 10.77 10.93 63.92 
t-test 
p-value 
 0.404 0.477 0.226 0.413 0.090 0.240 0.172 
 
Student’s t-test was used to analyse difference in methylation levels between 
participants with Type II diabetes compared to none. There were no significant 
differences (p < 0.05). 
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Table A3.15: Comparison of PBL DNA methylation levels between individuals 
with and without Dementia in 210 participants from the Newcastle 85+ study 
(validation sample set) 
 
 n TUSC3 TWIST2 HOXD4 HAND2 EPHA10 
Overall 
Mean 
HOXA5 
None (%) 70 10.83 11.09 10.60 10.63 10.23 10.68 61.49 
Dementia 
(%) 
36 10.10 10.11 10.27 10.68 11.13 10.46 61.51 
t-test 
p-value 
 0.123 0.087 0.242 0.461 0.043* 0.305 0.497 
 
 
Student’s t-test was used to analyse difference in methylation levels between 
participants with and without Dementia including Alzheimer’s disease. Information 
regarding dementia status was missing for one participant. There was significantly 
increased methylation of EPHA10 in participants with dementia *(p<0.05) 
 
Table A3.16: Comparison of PBL DNA methylation levels between individuals 
with and without stroke in 210 participants from the Newcastle 85+ study 
(validation sample set) 
 
 
 n TUSC3 TWIST2 HOXD4 HAND2 EPHA10 
Overall 
Mean 
HOXA5 
None 
(%) 
186 10.72 10.67 10.70 10.58 10.65 10.67 62.83 
Stroke 
(%) 
24 9.91 10.34 10.29 11.24 10.52 10.46 62.52 
t-test 
p-value 
 0.107 0.342 0.208 0.108 0.413 0.318 0.458 
 
Student’s t-test was used to analyse difference in methylation levels between 
participants with and without stroke. There were no significant differences (p<0.05) 
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Table A3.17: Comparison of PBL DNA methylation levels between surviving and 
non- surviving (by phase III) participants in the Newcastle 85+ study (validation 
sample set) 
 
 n TUSC3 TWIST2 HOXD4 HAND2 EPHA10 
Overall 
Mean 
HOXA5 
Survivors 
(%) 
170 10.63 10.69 10.71 10.59 10.62 10.66 61.88 
Non-
survivors 
(%) 
40 10.63 10.37 10.39 10.96 10.69 10.62 66.66 
t-test 
p-value 
 0.50 0.309 0.215 0.202 0.434 0.456 0.022* 
 
 
Student’s t-test was used to analyse difference in methylation levels between 
participants who had survived to phase III (36 months later) or not. There was a 
significantly higher mean methylation level of HOXA5 in non-survivors *(p<0.05). 
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